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ABSTRACT 
 
 
Type I diabetes mellitus is a metabolic disorder caused by an autoimmune 
destruction of the insulin-producing beta cells in the islets of Langerhans. Despite 
insulin treatment, diabetes results in the development of micro and macro-vascular 
complications that are associated with a high rate of morbidity and mortality. Curing 
diabetes would be the best treatment option for these patients. Pancreas 
transplantation is limited by the shortage of organ donors and by the high risk 
associated with this surgical procedure. Islets transplantation is a more recent non-
invasive technique with a low risk of complications. It is however restricted by the 
shortage of organs and has variable success rates. Additionally, it is well established 
that after infusion of islets, a substantial percentage of them are lost immediately 
post-transplant through the instant blood-mediated inflammatory reaction. A 
promising option would be the use of stem cells as ‘islet equivalents’. These cells 
have the ability to proliferate and the capacity to differentiate into insulin-secreting 
cells leading to islet repair and regeneration of new beta cells. The cell source would 
not be limited and the cells could be transplanted in a non-invasive method. 
 
This work examines the efficacy of two sources of stem cells in restoring 
euglycaemia in a diabetic animal model. It demonstrated the success of pancreas 
derived progenitor cells but not haematopoietic stem cells in reversing this diabetic 
phenotype. This work also examines whether these stem cells expressed tissue 
factor as a trigger for provoking coagulation leading to significant early cell loss. It 
demonstrated that both stem cell types are prothrombotic and that this effect can be 
mitigated by local treatment of these cells with anti-thrombin cytotopic agent. The 
results were however inconclusive whether this procoagulant effect was via TF-
dependent or TF-independent mechanism. 
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Finally, this work includes the completion of a phase I trial demonstrating the safety 
and tolerability of the infusion of autologous expanded progeny of an adult CD34+ 
stem cell subset to patients with type I diabetes mellitus and a successful renal 
transplant. However, there was no convincing evidence to suggest efficacy of these 
cells in reducing insulin requirements in these diabetic patients. 
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1. INTRODUCTION 
 
Insulin dependent diabetes mellitus, also called Type I diabetes mellitus (TIDM) is a 
metabolic disorder characterised by hyperglycaemia due to insulin deficiency. It is 
common and the incidence varies from 8 to 17 per 100,000 population per year in 
Northern Europe and the U.S. with the highest incidence of 35 per 100,000 in 
Scandinavia to the lowest incidence of 1 per 100,000 in Japan and China (Kasper 
2005). 
Type I diabetes causes an estimated 5–10% of all diabetes cases (Daneman 2006) 
or affects 17 - 34 million people worldwide (WHO  2013). The incidence of type I 
diabetes has been increasing by about 3% per year (Aanstoot 2007). Much of the 
data on epidemiology of type I diabetes in young people have been generated by 
large collaborative efforts that were centered on standardised registry data, such as 
the DIAMOND Project worldwide and the EURODIAB Study in Europe (Green  2001; 
Group  2006). The EURODIAB register is an international collaborative effort, which 
encompasses population-based registers of new cases of TIDM in children aged less 
than 15 years from 20 centers, distributed across 17 countries in Europe. In a 
relatively recent Lancet study, Patterson and the EURODIAB Study Group provided 
updated estimates of trends in incidence of Type I diabetes in individuals younger 
than 15 years in Europe from 1989 to 2003. 15-year incidence data collected by 20 
population-based registries in 17 countries were used to estimate rates of increase in 
geographical regions in Europe. Model-based rates of increase were then used to 
predict the number of new cases throughout Europe by 2020. The prediction is that 
between 2005 and 2020, new cases of type I diabetes in European children younger 
than 5 years will double and that the prevalence of cases in those younger than 15 
years will increase by an alarming 70%  (Patterson  2009).  
22 
 
 
  
Type I diabetes mellitus is caused by autoimmune destruction of the insulin-
producing beta cells in the pancreas. Despite insulin treatment, diabetes often results 
in metabolic defects leading to the development and progression of micro and 
macro-vascular complications. Macrovascular disease leads to an increased 
prevalence of cardiovascular disease, while microvascular damage results in diabetic 
retinopathy, nephropathy and neuropathy. These late complications are associated 
with a high rate of morbidity and mortality. It has been shown that these diabetic 
complications are less common and less severe in patients with well-controlled blood 
glucose levels (Nathan 2005).  
Curing diabetes would be the best treatment option for these patients to restore 
euglycaemic state. Replacement of the destroyed insulin-producing tissue, usually by 
whole pancreas transplantation, can cure these metabolic abnormalities but is greatly 
limited by the shortage of deceased organ donors and by the high risk associated 
with this surgical procedure. This means that this curative option is only offered to a 
selective group of patients. Allotransplantation of pancreatic islets is a more recent 
relatively non-invasive technique with a low risk of complications. Although it is a 
more attractive option, it is again restricted by the falling number of organ donors and 
has had a variable success rates in different transplant centres. An ideal and 
promising treatment option to cure TIDM would be to use ‘islet equivalents’ which are 
primarily derived from a stem or progenitor cell population shown to have the ability 
to proliferate extensively and the capacity to either differentiate into insulin-secreting 
cells in sufficient numbers or promote islet repair by the regeneration of new beta 
cells. The source of these cells would hence not be limited and they could be 
transplanted in a similar non-invasive method to pancreatic islets with a low risk of 
complications.  
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1.1 Pancreas development and anatomy  
1.1.1 Embryological development 
The pancreas forms from the embryonic foregut and is therefore of endodermal 
origin. Pancreatic development begins with the formation of ventral and dorsal 
anlage or buds. The ventral pancreatic bud becomes the head and uncinate process, 
and comes from the hepatic diverticulum. The ventral system also gives rise to the 
hepatobiliary system. At approximately the eighth intrauterine week of life, differential 
rotation and fusion of the ventral and dorsal pancreatic buds results in the formation 
of the definitive pancreas. As the duodenum rotates to the right, it carries with it the 
ventral pancreatic bud and common bile duct. After reaching its final destination, the 
ventral pancreatic bud fuses with the much larger dorsal pancreatic bud. At this point 
of fusion, the main ducts of the ventral and dorsal pancreatic buds fuse, forming the 
duct of Wirsung, the main pancreatic duct (Carlsson 2004; Kozu 1995). Figure 1 
illustrates the stages of embryological development of the pancreas. 
Differentiation of cells of the pancreas proceeds through two different pathways, 
corresponding to the dual endocrine and exocrine functions of the pancreas. In 
progenitor cells of the exocrine pancreas, important molecules that induce 
differentiation include follistatin, fibroblast growth factors, and activation of the Notch 
receptor system. Development of the exocrine acini takes place through three 
successive different stages. These include the predifferentiated, protodifferentiated, 
and differentiated stages, which correspond to undetectable, low, and high levels of 
digestive enzyme activity, respectively. 
Progenitor cells of the endocrine pancreas arise from cells of the protodifferentiated 
stage of the exocrine pancreas. Under tight control of several pancreas-specific 
transcription factors, these cells differentiate to form two lines of committed 
endocrine precursor cells. Among these factors are pancreatic and duodenal 
24 
 
homeobox 1 (Pdx1), neurogenin-3 (NGN-3) and Insulin gene enhancer protein ISL-1.  
The first line of committed cells, under the direction of PAX-6 forms alpha-(α) and 
gamma-(γ) cells, which produce glucagon and pancreatic polypeptides respectively. 
The second line, influenced by PAX-4, produces beta-(β) and delta-(δ) cells, which 
secrete insulin and somatostatin respectively. Insulin and glucagon can be detected 
in the human fetal circulation by the fourth or fifth month of fetal development 
(Carlson 2004). 
 
 
 
Figure 1: Anatomy and embryology of the pancreas. Adapted with permission from: Fogel E, Sherman 
S. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2013. Copyright © 2013 UpToDate, Inc. 
 
 
1.1.2 Anatomy and physiology 
The pancreas is a composite gland of both exocrine and endocrine components. 
Pancreatic beta cells are found in the islets of Langerhans, which are of various sizes 
and contain a few hundred to a few thousand endocrine cells. Islets are anatomically 
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and functionally separate from pancreatic exocrine tissue. Exocrine cells secrete 
pancreatic enzymes and fluid directly into ducts that drain into the duodenum. 
Normal subjects have about one million islets that in total weigh 1 to 2 grams and 
constitute only 1 to 2% of the mass or parenchyma of the pancreas (Bray 1994).  
Islets vary in size from 50 to 300μm in diameter. They are composed of several types 
of cells. At least 70% are beta cells, which are localized in the core of the islet and 
secrete insulin. These beta cells are surrounded by alpha cells that secrete 
glucagon, smaller numbers of delta cells that secrete somatostatin and pp cells or 
gamma cells that secrete pancreatic polypeptide as shown in figure 2. All of the cells 
communicate with each other through extracellular spaces and through gap 
junctions. This arrangement allows cellular products secreted from one cell type to 
influence the function of downstream cells. As an example, insulin secreted from 
beta cells suppresses glucagon secreted from alpha cells (Constanzo 2011).  
A neurovascular bundle containing arterioles and sympathetic and parasympathetic 
nerves enters each islet through the central core of beta cells. The arterioles branch 
to form capillaries that pass between the cells to the periphery of the islet and then 
enter the portal venous circulation. 
After birth, the maintenance of beta cell mass is the result of a dynamic process 
consisting of neogenesis, proliferation and apoptosis (Bonner-Weiss 2002). This is a 
physiological process whose objective is to guarantee the preservation of glucose 
homeostasis in the presence of different challenges such as obesity and other states 
of insulin resistance (Fernandes 1997; Swenne 1992). One study by Bonner-Weir 
and colleagues demonstrated that there was 27% recovery of pancreas weight and 
42% of the endocrine pancreas 8 weeks after near-total pancreatectomy in young 
rats (Bonner-Weir 1983). The same group estimated the beta cell turnover in adult 
rat islets to be as high as 3% per day (Finegood 1995). In normal or even in diabetic 
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animal models, chronic high-dose glucose infusion protocols showed increased beta 
cell mass, beta cell function, neogenesis and indices of beta cell replication (Bonner-
Weir 1989; Sako 1990; Topp 2004). 
 
 
Figure 2: Schematic representation of the anatomic relationship in an islet of Langerhans. The insulin -
secreting beta cells  (in blue) are in the centre closest to the blood supply and are surrounded by the 
glucagon-producing alpha cells (in orange). On the outside are the delta cells (in yellow), which make 
somatostatin, and the PP cells (in green), which make pancreatic polypeptide. Adapted with permission 
from: Robertson RP. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2013. Copyright © 2013 
UpToDate, Inc. 
 
1.2 Type I diabetes mellitus 
TIDM is characterised by the permanent destruction of insulin-secreting β-cells within 
the pancreatic islets of Langerhans (Atkinson 1994). This process occurs in 
genetically susceptible subjects, is probably triggered by one or more environmental 
factors, and usually progresses over many months or years during which the subject 
is asymptomatic and euglycemic. This long latent period is a reflection of the large 
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number of functioning beta cells that must be lost before hyperglycemia occurs 
(McCulloch 1991). 
Symptomatic patients typically have lost more than 70% of their beta-cell population, 
resulting in essentially no insulin production and an inability to regulate plasma 
glucose levels properly. The beta-cell destruction seen in type I diabetes is most 
often caused by an autoimmune mechanism. The immune system in such patients 
loses the immunologic tolerance against beta cell antigens, resulting in an immune 
response against the islets. This process involves both CD8+ and CD4+ cells and 
results in insulitis, an inflammatory process, which causes the destruction of 
pancreatic beta cells (Gepts 1965; Notkins 2001).  
There are a number of auto-antigens within the pancreatic beta cells that may play 
important roles in the initiation or progression of autoimmune islet injury including 
glutamic acid decarboxylase (GAD), insulin, insulinoma-associated protein 2 (IA-2), 
and zinc transporter ZnT8 (Boitard 1992).  
In the latter stage of the natural history of the disease, there is little insulin secretion 
as manifested by low or undetectable serum C-peptide levels. C-peptide is co-
secreted with insulin by the beta cells as a by-product of the enzymatic cleavage of 
pro-insulin to insulin. Thus measurement of C-peptide provides a validated means of 
quantifying endogenous insulin secretion being closely related to the amount of 
functioning beta cell mass (Palmer 2004). The natural history of diabetes is illustrated 
in figure 3. 
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Figure 3: Time course of the development of type I diabetes. Adapted with permission from: Pietropaolo 
M. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2013. Copyright © 2013 UpToDate, Inc. 
 
 
Although the natural history of diabetes has been described in the literature, there 
are no published data on the actual rates of transient or complete remission in 
patients with new diagnosis of type I diabetes. There are some studies that 
investigated the residual insulin secretion at the time of diagnosis for type I diabetes. 
It has been widely accepted that insulin secretion is profoundly impaired at the time 
of diagnosis of type I diabetes. However, recent studies suggest that on the whole, 
insulin production may be more substantial at diagnosis than had been previously 
appreciated and that residual insulin production may persist in a subgroup of patients 
with autoimmune diabetes (Sherry  2005). Steel et al. studied insulin secretory 
responses to a mixed-meal tolerance test (MMTT) patients with new-onset type I 
diabetes. They found the average response to be 52% of the response of normal 
control subjects but with maximal stimulation, the impairment in response was more 
profound at 30% of normal response. In same study, they also found that insulin 
secretion in response to MMTT declined gradually to a level at 2 years that was 28 ± 
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8.4% of the response at diagnosis (Steele  2004). By 24 months, 47% of patients had 
C-peptide levels that were below the lower limit of detection. 
 
1.3 Vascular complications in type I diabetes mellitus 
Diabetes results in metabolic defects leading to both microvascular and 
macrovascular disease. These complications are associated with significant 
morbidity and mortality as has been shown in many studies (Barzilay 1992; Krolewski 
1988). Microvascular complications include diabetic retinopathy, nephropathy and 
neuropathy while macrovascular disease leads to coronary artery disease, peripheral 
vascular disease and cerebrovascular complications. Mechanisms for vascular 
disease in diabetes include the pathologic effects of advanced glycation end product 
accumulation, impaired vasodilatory response attributable to nitric oxide inhibition, 
smooth muscle cell dysfunction, overproduction of endothelial growth factors, chronic 
inflammation, hemodynamic dysregulation, hypercoagulability, and enhanced platelet 
aggregation (Vinik  2002). Hyperglycaemia induces the glycation of mitochondrial 
proteins resulting in the generation of superoxide anions. The latter are key in the 
pathogenesis of microvascular diabetic complications via activation of the polyol 
pathway, the hexosamine pathway, formation of advanced glycation end products 
(AGE), activation of protein kinase C and nuclear factor F-kB (NFκB) in endothelial 
cells. Some of these processes may persist even after correction of hyperglycaemia, 
providing a molecular explanation for the concept of ‘glycaemic memory’ (Vella  
2010). In the pathogenesis of macrovascular disease, free fatty acids (FFA) may 
have similar effects on mitochondrial oxidative stress pathways, particularly in states 
of insulin resistance (Vella  2010).  
Common risk factors for vascular disease in patients with diabetes include 
hyperglycaemia, dyslipidaemia, hypertension, smoking, and obesity. The association 
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of hyperglycaemia with vascular complications was confirmed in the prospective 
Diabetes Control and Complications Trial (DCCT). This trial demonstrated that 
intensive insulin therapy, aiming for lower glucose levels, resulted in lower rate of 
microvascular complications (DCCT 1995; DCCT 2006). At best, tight diabetic control 
by intensive insulin therapy reduces the risk of microvascular complications by 35-
90% when compared to conventional therapy (DCCT 2002).  In addition, the 
observational Epidemiology of Diabetes Interventions and Complications (EDIC) 
follow-up study to the DCCT, reported extended benefit of risk reduction of 
retinopathy and nephropathy over the next 10 years in the intensive insulin therapy 
compared to conventional therapy, despite the absence of a difference in glycaemic 
control between the 2 groups during the post-DCCT trial period. The same EDIC 
study also demonstrated that tight glycaemic control in type I diabetes decreased 
fatal and nonfatal cardiovascular events (Nathan 2005). 
 
1.4 Current therapies for type I diabetes mellitus 
1.4.1 Insulin 
Exogenous insulin replacement has been the primary therapeutic option for 
controlling plasma glucose levels. However, even modern insulin regimens 
consisting of short-, medium- and long-acting, genetically synthesised insulin fail to 
match the sensitivity of nutrient-induced, endogenous insulin production, potentially 
resulting in undesirable patient outcomes. While intensive management of diet and 
insulin therapy is desirable as it has been shown to reduce complications, patients 
with type I diabetes are susceptible to hypoglycaemia, which remains a limiting and 
potentially life-threatening side effect. This risk of hypoglycaemia is increased with 
intensive insulin therapy and is particularly problematic in patients with brittle type-I 
diabetic disease and in those who suffer hypoglycaemic unawareness, a 
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manifestation of autonomic neuropathy (DCCT 1995; DCCT 2006). These 
complications and side effects make insulin administration a suboptimal treatment 
option for this group of patients. 
 
1.4.2 Beta cell - based treatment 
The ideal treatment for type I diabetic patients is restoration of euglycaemia by 
replenishing the pancreatic islets through either repair or regeneration or both. In 
view of evidence for regenerative potential of the pancreas (section 1.1.2), some 
researchers attempted the use of effective and safe immunoregulatory strategies in 
an attempt to block the autoimmune process causing diabetes and ultimately 
preserve beta-cell mass by facilitating endogenous mechanisms of beta cell 
regeneration. Such immunomodulatory approach should be done shortly after or 
even before the clinical presentation of type I diabetes since larger beta cells mass 
would be preserved. Studies with chronic use of immunosuppressive agents such as 
steroids, azathioprine, or combination of both or cyclosporine demonstrated a slower 
decline or even some improvement in serum C-peptide levels in patients with new 
diagnosis of type I diabetes (Assan 1990; Cook 1989; Elliott 1981). Other studies 
used immunomodulatory therapies such as humanized anti-CD3 or rabbit polyclonal 
anti-T cell globulin. However, this strategy was not effective as only minority of 
patients experienced short-term insulin independence despite increased C-peptide 
levels. Treated patients did show better beta cell function and lower insulin 
requirement up to 1 year post therapy when compared to placebo group but this 
effect was not long lasting (Keymeulen 2005; Saudek 2004).  
For long term type I diabetes, immunointervention regimens alone would not be 
successful as most of the beta cell mass would have been destroyed already 
(section 1.2) by the time patients are diagnosed. For these patients, the strategy 
32 
 
should combine immunointervention to prevent ongoing autoimmunity with beta cell 
replacement. Because type I diabetes is caused by loss of function of a single cell 
type, cell-based treatment focusing on replacing lost beta (β)-cell populations is 
possible. These therapies include whole pancreas organ transplantation, islet 
allograft transplantation and islet “equivalent” cell therapy based on stem cells. 
These potential strategies are summarised in figure 4.  
 
 
 
Figure 4: Potential strategies for treatment of recent onset and long term type I diabetes adapted from 
(Couri 2008a) 
 
 
1.5 Pancreas transplantation 
Whole pancreas transplantation remains the current gold standard of cell-based 
therapies for type I diabetes mellitus. It can offer a sustained normoglycaemic state 
by restoring glucose-regulated endogenous insulin secretion in these patients. This 
in turn improves the quality of life, reduces the long-term risk of vascular damage and 
eliminates the risk of hypoglycaemia (Vardanyan 2010). This surgery was first 
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performed in Minnesota in 1966, and by 2008 over 30,000 pancreas transplants had 
been performed worldwide; 22,000 in the US and 8,000 elsewhere (Gruessner 2008; 
Kelly 1967). The majority of these transplants (60-70%) were simultaneous kidney 
pancreas transplants (SKPT), less frequently pancreas after kidney (PAK) in patients 
with end stage renal failure due to diabetic nephropathy. Fewer than 4% of cases 
were pancreas combined with heart, liver, or intestine. Pancreas transplant alone 
(PTA) represented only 7% of the 2008 total pancreas transplants but this has 
increased to 25% in 2012 (United Network for Organ Sharing 2012).  
 
1.5.1 Pancreas transplant outcomes 
The mortality, morbidity and results of pancreas transplantation have improved over 
the years but vary with surgical experience, patient and donor selection. Patient 
survival rates range from 95-98% at one year, 90-92% at 3 years and 85-88% at 5 
years. (Arbor Research Collaborative for Health; Gruessner 2011; United Network for 
Organ Sharing 2012). 
Graft survival is defined as sustained exogenous insulin independence evidenced by 
normal fasting glucose concentrations and normal glycosylated haemoglobin (Hba1c) 
values. Long-term graft function remains highest in patients receiving an SKPT 
followed by PAK and PTA. Graft survival varied between 86-92% at 1 year and 60-
76% at 5 years in SKPT recipients. This compares to graft survival rates of 78-88% 
at 1 year and 45-55% at 3 years for pancreas transplants alone (Arbor Research 
Collaborative for Health; Gruessner 2011; United Network for Organ Sharing 2012). 
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1.5.2 Benefits of pancreas transplantation  
Successful pancreas transplantation restores euglycaemia almost immediately post 
transplantation. Recipients experience normal fasting and post-prandial glucose 
levels and Hba1c returns to normal levels. It results in independence from 
exogenous insulin as a consequence of restoring pancreatic islet function. The 
impact of successful pancreas transplantation on the secondary complications of 
diabetes have been mainly studied and reported in SKPT recipients. Morbidity and 
mortality have decreased markedly during the past several decades after pancreas 
transplantation. Recipients who become insulin independent report better quality of 
life despite the need for immunosuppression (Becker  2001; Landgraf  1996). The 
best patient survival was observed in recipients of SKPT with prolonged pancreas 
graft function (Reddy  2003; Smets  1999; Weiss  2009). Figure 5 shows patient 
survival in diabetic patients receiving SKPT transplant compared to those receiving a 
kidney transplant alone. Patient survival of those who were transplanted with a SKPT 
has also been reported to be superior to patient survival observed with waitlisted 
patients who remain on dialysis (Witczak 2007). In addition, stabilization or 
improvements in microvascular complications, such as diabetic retinopathy, 
nephropathy and neuropathy, have been reported after successful pancreas 
transplantation (Fioretto 1998; Navarro 1997). Positive impact on macrovascular 
disease progression after SKPT has also been demonstrated (Jukema 2002; 
Sutherland 2001). Hypoglycaemia and hypoglycaemic unawareness are rare post 
pancreas transplant. Pancreas transplantation results in improvement of glucose 
counter-regulation after hypoglycaemia so that symptom recognition of 
hypoglycaemia is restored and occurs at higher blood glucose concentrations.  
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Figure 5: Long-term patient survival following simultaneous kidney-pancreas transplantation (SKPT) 
versus kidney transplantation alone whether from a live donor (LD) or deceased donor (CAD) in patients 
with type I diabetes mellitus and renal failure (Reddy 2003) 
 
 
1.5.3 Limitations to pancreas transplantation 
Although pancreas transplantation has a high success rate, it is a major surgical 
procedure with associated mortality rates between 1 and 3%. The technical failure 
rate in the United States is around 8%. Common complications encountered early 
after pancreas transplantation includes increased cardiac morbidity as well as 
hospitalisation and systemic infection. Beyond the first year, complications are 
usually related to long-term immununosuppression (White 2009). Accordingly, it is 
currently recommended only for patients with type I diabetes who do not respond to 
conventional, insulin-based treatment and who are deemed fit to undergo this 
surgical risk. An unavoidable and major restriction of whole-pancreas transplantation 
is the limited availability of organ donors in general and of donor pancreata 
specifically that are suitable for transplantation.  
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Donor selection in pancreas transplantation significantly impacts on outcome 
(Sutherland  2001). An ideal donor would be defined as a donation after brain death, 
between 10 and 40 years of age, with a BMI less than 28kg/m2 and cause of death 
other than cerebrovascular disease (Fridell  2010). Hence there is reluctance to 
accept higher-risk organs resulting in higher non-recovery or discard rates compared 
to other abdominal donor organs (Gruessner  2011; Muthusamy  2012).  
The combination of donor and recipient selection, organ shortage and the high risk of 
complications associated with pancreas transplantation makes this treatment option 
suitable only for a minority of diabetic patients. 
 
1.6 Islet transplantation 
Given the complications of whole pancreas transplantation, newer research efforts 
have explored transplanting only pancreatic islet cells. Islet transplantation has the 
potential to restore homeostatic insulin secretion and hence normoglycaemia in 
patients with type I diabetes. Importantly, it is less invasive than whole pancreas 
transplant. The process of islet transplantation is summarised in figure 6. A mixture 
of highly purified specialized enzymes (Collagenase) is used to isolate islets from the 
pancreas of a deceased donor. Collagenase solution is injected into the pancreatic 
duct that runs through the head, body and tail of the pancreas. Delivered this way, 
the enzyme solution causes distension of the pancreas, which is subsequently cut 
into small chunks and transferred into so-called Ricordi's chamber, where digestion 
takes place until the islets are liberated and removed from the solution. Isolated islets 
are then separated from the exocrine tissue and debris in a process called 
purification. A radiologist usually performs the transplant where the islets are infused 
slowly through an intravenous catheter into the portal vein of the liver of the recipient. 
Blood flow within the vein carries the islets into the liver tributaries where they lodge 
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within the sinusoids and establish vascular connections. Possible risks of the 
procedure include bleeding and thrombosis. 
Because the islets are fragile, the process of islet preparation and purification is 
difficult and results in significant proportion of islets damaged or lost. Typically a 
patient receives at least 10,000 islet "equivalents" per kilogram of body weight, 
extracted usually from two donor pancreata. Patients often require two or three islet 
infusions to achieve insulin independence. Some transplants have used fewer islet 
equivalents taken from a single donated pancreas. 
 
     
 
Figure 6: The process of clinical islet transplantation for the treatment of diabetes mellitus 
 (Naftanel  2004) 
 
 
 
1.6.1 Islet transplant outcomes 
Although it is theoretically advantageous procedure, it has not yielded the tangible 
success seen with whole-pancreas transplants. Insulin independence was first 
achieved with this method in 1989, but it required significant immunosuppression to 
maintain graft survival (Scharp 1990). Over the following decade, developments of 
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more effective and less toxic immunosuppressive regimens as well as improved 
harvesting techniques have significantly increased the success rate of islet 
transplantation. In 2000, the novel Edmonton protocol, a steroid-free 
immunosuppressive regimen, enabled seven patients to remain insulin-independent 
for an average of one-year post procedure (Shapiro 2000). Figure 7 shows that in 
2000 islet graft survival of the Edmonton protocol became comparable to pancreas 
transplant graft survival of the mid 1980’s. However these results have been difficult 
to reproduce and 9-year islet graft survival rates even among the original Edmonton 
patients remain below 10% (Robertson 2004a). Initially successful islet transplant 
had an uncertain long-term islet survival, with the majority of patients requiring 
multiple islet infusions to achieve normoglycaemia.  
The Collaborative Islet Transplant Registry (CITR) data, collected across 
international clinical islet programmes showed that between 1999 and 2009, 571 
allogeneic islet transplant recipients received 1,072 infusions from 1,187 donors. The 
United States contributed 66% of these transplants and the remaining 34% were 
preformed in Europe and Australia. 31% of transplant recipients received a single 
islet infusion, 47% received two infusions, 20% received three and 2% received 4-6 
infusions (CITR 2012). CITR data also reported that 60% of patients, including 
patients with multiple infusions, achieve insulin independence with the first year, but 
by the third year, the percentage that remain euglycaemic is closer to 35%. As 
described in section 1.6, a significant proportion of the islet equivalent will be lost in 
the purification process in addition to further islet mass loss early post transplantation 
into the liver. Up to 50% of islets can be lost during the isolation process and hence 
the frequent need for 2-3 pancreata to prepare sufficient islets for a single recipient 
(Leitao 2008).  The mechanism of the additional early graft loss following 
transplantation is by a process termed the instant blood-mediated inflammatory 
reaction (IBMIR). This process is explained in detail later in section 1.10.6. 
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Figure 7: Comparison of rates of progress of allogeneic islet transplantation versus pancreas 
transplantation as therapy for type I diabetes. The first allogeneic islet transplant to be reported as 
successful appeared in 1980, 20 years earlier than the Edmonton series was reported. The first 
pancreas transplant to be reported as successful appeared in 1966, 18 years earlier than the 1984–
1987 series was reported. At 15 months post-transplant, the Edmonton series of allogeneic islet 
transplants for the years 2000–2005 compared favourably with the success rate of pancreas transplants 
for the years 1984–1987 (Robertson  2010) 
 
 
 
1.6.2 Benefits of islet transplantation 
Allotransplantation of pancreatic islets is a relatively recent non-invasive technique, 
which has had variable success rates in different transplant centres. It is less efficient 
in reversing diabetes but is associated with a lower risk of immediate post-procedure 
complications and lower morbidity rate when compared to whole pancreas 
transplantation. Although long-term insulin independence is rarely achieved in the 
vast majority of patients, there are important benefits by partial function. The 
occurrence of severe hypoglycaemic events decreases and hypoglycaemic 
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unawareness abates. Improvements in HbA1c levels are seen and patients exhibit 
persistent C-peptide function (Bromberg 2006; Ryan 2005).  
There are published data that report stabilization of diabetic retinopathy and 
neuropathy following islet transplantation (Thompson 2008; Warnock 2008). Fiorina 
et al. demonstrated improvement in diabetic microvascular and macrovascular 
complications as well as improved patient and graft survival rates in patients with 
islet after kidney transplant when compared with recipients of kidney transplant alone 
(Fiorina 2003; Fiorina 2005).  
 
1.6.3 Limitations to islet transplantation 
Although islet transplantation is relatively non-invasive, at least 50% of islet 
recipients experience at least one adverse event, which are either related to 
immunosuppression or complications associated with the infusion procedure (CITR 
2012). These adverse events remain less serious that the complications following 
pancreas transplantation. Islet transplantation is more restricted than pancreas 
transplantation by the limited number of deceased donors particularly given that very 
often at least two pancreata are required to isolate an adequate number of islets per 
recipient. This is due to the complex and difficult processes required to isolate and 
purify the islet transplant as well as early loss post transplantation in the hepatic 
portal vein. Another potential consequence of islet transplantation is a high rate of 
sensitization. Olack et al. and others showed that sensitization occurred in early 
diabetic patients who had been treated with multiple islet preparations from multiple 
donors, leading to the development of anti-human leucocyte antigen (anti-HLA) 
antibodies (Mohanakumar 2006; Olack 1997; Rickels 2006). This antibody formation 
and in turn sensitization may preclude the ability to undergo future transplantation 
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whether it is islet, pancreas or kidney due to decreased probability of finding a 
compatible graft. 
The body of literature that supports the benefits of islet transplantation or secondary 
complications is small as the number of studies is limited. Khan and Harlan 
concluded that there is no enough evidence to advocate the use of allogeneic islet 
transplantation over conventional diabetes therapy. The current results cannot 
outweigh the risks or consequences of islet transplantation (Khan 2009). 
In summary, islet transplantation still faces major challenges; especially those related 
to cell loss during the process of islet isolation and the losses related to the graft site, 
apoptosis, rejection, autoimmunity and immunosuppression. The main strategies to 
optimize islet transplantation should aim at improving the processes of isolation, 
purification and implantation of the islets as well as avoiding alloimmune injury. This 
will lead to better islet outcomes, reduction in the need for multiple infusions and 
decreasing allosensitisation risks but there is a lot to be done before reaching that 
goal. 
 
1.7 Islet xenotransplantation and its limitations 
As a solution for organ shortage and the availability of suitable donor pancreata, 
xenotransplantation has been investigated as a new source of islets for 
transplantation. Xenotransplantation refers to the transplantation of tissues or organs 
from one species to another. Since the early 1990’s, there have been few published 
cases of clinical islet xenotransplantation (Elliott  2011; Groth  1994; Valdes-
Gonzalez  2005). More recently over the last decade, significant progress has been 
made, with pig islets providing sustained normoglycaemia in a small number of non-
human primates in which diabetes has been induced (Cardona  2006; Cardona  
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2007; Hecht  2009; Sun  1996). These results were encouraging and indicated that 
pig islet xenotransplantation may offer clinically viable treatment option for diabetes 
in the long-term. However, it also raised many novel medical, logistic, safety and 
ethical issues. Disease transmission and permanent alteration to the genetic code of 
the animals used have also been causes for concern. 
Successful clinical application of islet xenotransplantation currently is inhibited by a 
number of immunological and non-immunological barriers. To date no 
xenotransplantation trials have been entirely successful due to the events arising 
from the response of the recipient’s immune system. This response, which is 
generally more extreme than in allotransplantation, ultimately results in the loss and 
rejection of the xenograft after transplantation. Following transplantation into the 
portal vein, similar to early islet allotransplant loss, islet xenotransplants face 
immediate destruction by the non-specific instant blood-mediated inflammatory 
reaction. In addition and dependening on the source of the islets, preformed 
xenoreactive natural antibodies may contribute to IBMIR which is then followed by a 
largely T-cell mediated acute rejection. This immune process leads to further loss of 
the surviving islets (Van der Windt  2012). The mechanism of these processes is 
described in section 1.10.4. 
There are also several technical and logistical obstacles for xenotransplantation. 
These challenges include the difficulty in isolation and preparation of pig islets which 
are significantly influenced by the donor age. Deriving islets from pigs of different 
ages has different advantages and disadvantages. For example, islets from neonatal 
pigs are smaller in size compared to adult pigs and hence they harder to isolate and 
purify. On the other hand, neonatal islets have high resistance to hypoxia and 
maintain a proliferative capacity after transplantation. This may result in a functional 
islet mass after transplanting a smaller number of islets (Emamaullee  2006; Korbutt  
1996). The optimum age of donor pigs is the subject of ongoing investigation. 
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There have been several strategies used to attempt to overcome some of these 
hurdles for islet xenotransplantation. These include genetic engineering of pigs to 
avoid the effects of the IBMIR, more targeted and efficacious immunosuppressive 
regimes, investigating alternative anatomical sites for islet xenotransplantation and 
immunomodulation by co-transplantation of mesenchymal stem cells of either donor 
or recipient origin (Van der Windt  2012).  
Finally, safety of clinical islet xenotransplantation remains a concern mainly the 
potential for the transfer of pig microorganisms and viruses to the islet recipient such 
as porcine cytomegalovirus. There have been guidelines issued by the US regulatory 
authorities that address this problem (Emamaullee  2006).  
In view of these many hurdles, there is still some way to go before islet 
xenotransplantation becomes an achievable therapeutic option for type I diabetes. 
 
1.8 Stem cells for beta-cell substitution 
The number of islet and pancreas transplants, as currently practiced, has an 
extremely limited impact on the type I diabetes burden. Ultimately, alternate sources 
of transplantable cells are needed because the current donor pool of 2000 pancreata 
annually is minor compared to the need (United Network for Organ Sharing 2012). In 
addition, both transplants are associated with the development of serious 
complications. Stem cell therapy can offer the greatest potential of producing an 
unlimited source of cells and if adequately differentiated, they can become fully 
mature and functional beta cells. If autologous, stem cells could minimize the need 
for immunosuppression. However, targeted immunosuppression may be required to 
prevent the autoimmune destruction of the new beta cells (McCall 2009).  
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Stem cells have the unique function of asymmetric division (Wagers 2004). They 
have 3 general properties; first, they are capable of long-term self-renewal; second, 
they are undifferentiated; and third, they can give rise to specialised cell types. These 
important characteristics distinguish them from other cell types. Stem cells possess 
the ability of producing undifferentiated daughter cells or generating progenitor 
tissue-specific or organ-specific specialised cells when given appropriate 
physiological signals or experimental conditions. A stem cell is pluripotent when it 
has the ability to differentiate into any of the three germ layers (endoderm, 
mesoderm and ectoderm) and to give rise to any fetal or adult cell type. This 
compares to a multipotent stem cell that can give rise to cells of multiple but limited 
cell types (Alison 2009). Stem cell can be classified as either embryonic stem cells, 
which are pluripotent or adult stem cells, which are multipotent.  
For stem cell therapy to work in type I diabetes, scientists need to recreate ex-vivo in 
cell culture what happens in the embryo. The stem cell must first be induced to make 
definitive endoderm, then differentiate into pancreatic endoderm or PDX1- 
expressing and finally reach a stage in which it secretes insulin in response to high 
glucose concentrations. The molecular details of this differentiation pathway are still 
not completely identified. Detailed understanding of the sequence of events, the 
signaling pathways and quantitative pattern of gene expression during differentiation 
is essential for designing and producing fully functional insulin-producing cells as 
shown in figure 8 (Mayhew 2010). 
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Figure 8: Beta cell differentiation and potential source of stem cell therapy (Mayhew 2010) 
 
To achieve the promise of novel stem cell-based therapies, scientists must be able to 
easily and reproducibly manipulate the cells so that they possess the necessary 
characteristics for successful differentiation, transplantation and engraftment. To be 
useful for transplant purposes, stem cell must be reproducibly made to: 
 Proliferate extensively and generate sufficient quantities of tissue, which is 
often a technical hurdle. 
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 Produce progeny that can differentiate into the desired cell type(s) 
 Survive in the recipient after transplant 
 Integrate into the surrounding tissue after transplant and improve the function 
of the damaged tissue. 
 Function appropriately for long duration 
 Avoid harming the recipient in any way 
 Avoid the problem of immune rejection 
 
 
1.8.1 Embryonic stem cells 
Embryonic stem cells (ESC) are undifferentiated cells derived from the inner cell 
mass of a blastocyst, usually harvested 4-5 days after fertilization. First isolated in 
humans in 1998, these cells express high levels of telomerase activity and are 
capable of differentiating into all three embryonic germ layers, ectoderm, mesoderm 
and endoderm. Pluripotency is the main characteristic that distinguishes ESC from 
adult stem cells. Because of their pluripotency and potentially unlimited capacity for 
self-renewal, ESC therapies have been proposed for regenerative medicine and 
tissue replacement. They can produce limitless numbers of themselves for continued 
research or clinical use. However, isolating the embryoblast or inner cell mass results 
in the destruction of the fertilized human embryo, which raises ethical issues. The 
other major concern with the possible transplantation of ESC into patients as 
treatment is their ability to form tumours including teratomas (Hussain 2004).  
Murine and human embryonic stem cells can be differentiated into insulin-producing 
cells by manipulating culture conditions. In vitro differentiation of ESC can generate 
embryoid bodies, which, after selection for nestin-expressing ESC, were stimulated 
to differentiate towards a beta-cell-like phenotype (Lumesky 2001; Segev 2004). With 
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manipulation of culture conditions and the use of transcription factors associated with 
beta-cell lineage resulted in higher yield of cells with properties of functional beta 
cells (Blyszczuk 2003; Kahan 2003). Transplantation of ESC-derived insulin-
producing cells reversed diabetes in rodents, indicating that these cells do synthesise 
and release insulin (Blyszczuk 2003; Hori 2002). ESC lines are not assumed to be 
identical and problems in control of differentiation and teratoma formation remain 
issues to be overcome. It has been shown that animals develop tumours when they 
are transplanted with ESC-derived insulin-producing cells (Fujikawa 2005).  
Ethical and safety concerns of ESC remain extra hurdles for their use in practice. 
These issues need to be addressed and resolved before these cells can become 
readily available option for use as clinical therapies. 
 
1.8.2 Adult or tissue Stem cells 
Adult stem cells (ASC) are multipotent undifferentiated cells found among 
differentiated cells in a tissue or an organ. The primary role of adult stem cells is to 
maintain and repair the tissue in which they are found. Adult stem cells typically 
generate the cell types of the tissue in which they reside. However, many 
experiments over the years have shown that stem cells from one tissue may exhibit 
the ability to give rise to specialised cell types of other tissue, a phenomenon known 
as plasticity (Lakshmipathy 2005). ASCs have been identified in many organs and 
tissues including the brain, bone marrow, skin, liver, heart and the pancreas. They 
exist in very small number and are thought to reside in a specific area of each tissue 
where they remain quiescent for many years until they are activated by tissue injury 
(Walker 2009).  
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If these adult stem cells can be grown in cell culture and manipulated to generate 
specific cell types then they can be used to treat injury or disease such as developing 
insulin-producing cells as therapy for type-I diabetes. A potential advantage of using 
ASCs is that they can be autologous. In that case, patient’s own adult stem cells 
could be expanded in culture and then reintroduced into the patient. This would avoid 
the need for immunosuppression to prevent rejection, which may be needed in 
allogeneic ASC or ESC. This has not yet been determined in human studies.  
Different sources of adult stem cells have been proposed for the production of beta- 
cells. There have been studies that reported the generation of insulin-producing cells 
from induced pluripotent stem cells, haematopoietic stem cells, stem cells derived 
from the pancreas and non-pancreatic organ-bound stem cells. 
 
1.9 Sources of adult stem cells for beta cells 
1.9.1 Induced pluripotent stem cells 
Induced pluripotent stem cells (iPSC) are pluripotent stem cells that are artificially 
derived from adult somatic cells that have been reprogrammed into ESC-like state. 
Somatic cells are modified by inducing the expression of certain stem cell genes and 
proteins (Yu  2007). Two studies reported the successful generation of mature 
insulin-producing cells from murine and human iPSC (Jeon 2012; Zhang 2009). iPSC 
would be an ideal source for cell replacement therapy because it has been shown 
that they can be derived from patients including those with diabetes (Maehr 2009). 
These cells can be used to generate autologous beta cells for transplantation 
avoiding the controversial use of ESC and the need for long-term 
immunosuppression. Despite these advantages, reprogramming of adult somatic 
cells to obtain iPSCs can pose significant risks that could limit their use in humans. If 
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viruses are used to genomically alter the cells, the expression of oncogenes may 
potentially be triggered and hence their propensity to form tumours (Yu 2007). 
However, with rapid advances in iPSC technology, many subsequent studies have 
already reported iPSC generation using non-integrating methods of gene delivery 
(Mayhew 2010). At present, tumourgenicity of iPSC cell remains a serious concern 
making them unsuitable candidates for cell-based therapy until future studies prove 
their safety. 
 
1.9.2 Bone marrow derived stem cells 
Bone marrow derived stem cells (BMSC) have been studied for many years and are 
therefore the best-characterised type of stem cells. They are multipotent, capable of 
self-renewal and well known as a source of stem cells for blood cells. They have also 
been shown to have the ability under control of local factors in certain 
microenvironments to differentiate into other cell types after migration to the site of 
damage in several tissues (Herzog 2003; Korbling 2002). 
Three distinct populations of stem cells are thought to reside in the bone marrow: the 
haematopoietic stem cells (HSC), the mesenchymal stem cells (MSC) and 
endothelial progenitor cells (EPC). Haematopoeitic stem cells express CD34 and 
CD133 on their cell surface and give rise to all lineages of blood cell differentiation 
while mesenchymal stem cells give rise to the stromal cells of the bone marrow, 
including the ostogenic, chondrogenic and adipogenic lineages (Gangaram-Panday 
2007).  
HSCs are rare cells, with a frequency of 1 in 104 to 1 in 105 amongst bone marrow 
cells. Human HSCs can be isolated by selection based on expression of the cell 
surface sialomucin CD34 (Nielson 2008). Stem cells in hematopoietic tissue have 
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been used for haematological reconstitution for many years. MSCs have a significant 
immunosuppressant property and are able to differentiate into several tissues. EPCs 
are capable of angiogenesis and are widely used in regenerative therapy. All three 
types of stem cells have been used in cell-therapy and are candidates for the 
treatment of diabetes  (Couri 2008b).  
Many experiments over the last decade demonstrated the plasticity of BMSCs in vitro 
and their role in pancreatic endocrine regeneration post injury in vivo. Early work by 
Ianus et al. suggested that grafted bone marrow stem cells could differentiate into 
functional pancreatic beta cells in diabetic mouse model. BMSC tagged with green 
fluorescent protein (GFP) were injected into irradiated mice. After 6 weeks, GFP 
positive cells were found within the pancreatic islets of the recipient mouse 
accounting to only 1-3%. These cells were shown to express insulin and other 
transcription factors associated with beta cells. They also responded to glucose 
stimulation by secreting insulin. So the researchers concluded that these cells have 
effectively differentiated into pancreatic beta cells although there were low levels of 
engraftment. However, all subsequent in vivo studies have failed to replicate these 
results but did demonstrate that BMSC are able to stimulate beta-cell regeneration in 
damaged pancreatic tissue by a variety of mechanisms (Ianus 2003). 
In the same year, another group injected irradiated mice with GFP positive BMSC 
followed by streptozotocin to induce pancreatic islet damage. At the end of the study, 
these cells were found in the pancreatic islets but they did not produce any insulin, 
glucagon or Pdx-1. However, there was an increase of insulin-secreting 
bromodeoxyuridine (BrdU) positive cells within islets. BrdU is an analogue of 
thymidine and is commonly used in the detection of proliferating cells in living 
tissues. Additionally, treated mice had near-normal glucose levels 5 weeks post 
streptozotocin injection. The authors concluded that while BMSC did not seem to 
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differentiate into pancreatic beta cells, they still have the potential for being host cells 
in beta-cell replacement therapy (Choi 2003). 
Hess et al. repeated a similar experiment but reversing the steps by injecting 
irradiated mice with streptozotocin causing pancreatic injury first followed by GFP 
positive BMSC transplantation. Similar to Choi et al., they found that GFP positive 
BMSCs preferentially engraft to the damaged pancreatic tissue and most of them did 
not secret insulin. However, they did demonstrate that a small proportion of these 
cells in the islets did produce insulin showing that BMSC can differentiate into insulin-
producing phenotype. However, they noted that this small population was too few in 
number to explain the reversal of hyperglycaemia and the increased levels of 
systemic insulin. This effect was observed prior to the detection of GFP positive 
insulin-producing cells and did not occur in control animals. These findings led to the 
conclusion that the reduction in hyperglycaemia was attributable to a rapid rise in 
endogenous insulin stimulated by BMSC transplantation rather than differentiation of 
the BMSC into beta cells (Hess 2003). 
The ability of BMSC to transdifferentiate into insulin-producing cells by culture in high 
glucose conditions and exposure to beta-cell stimulating factors was also 
demonstrated by Tang et al. These differentiated cells expressed multiple pancreatic 
genes including insulin, GLUT2 and Pdx-1 and were sensitive to glucose stimulation 
by secreting insulin in response. Moreover, they resulted in normoglycaemia 1-week 
post transplantation into streptozotocin induced diabetic mice confirming their effect 
in vivo (Tang 2004). 
Hasegawa et al. confirmed previous data that acute pancreatic injury was necessary 
to get improvements in hyperglycaemia and islet regeneration. They also found that 
pancreata with regenerated islets were surrounded by BMSC-derived haemopoietic 
cells. Most of the BrdU-positive cells were found within close vicinity of these 
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hematopoietic cells, suggesting that they were involved in the proliferation and 
differentiation of pancreatic progenitor cells. Finally, they also concluded that 
mobilization of BMSC-derived endothelial and hematopoietic progenitor cells was 
critical for beta-cell regeneration. Endothelial progenitor cells are important in 
neovascularisation, which is an important process of tissue regeneration (Hasegawa 
2006). 
The relationship between BMSC-derived endothelial progenitor cells and beta-cell 
regeneration, in response to pancreatic injury was examined in another study. 
Mathews et al. found an increase in BMSC-derived and endogenous endothelial cells 
along with an increase in the total number of blood vessels in the animal with time 
after streptozotocin injection, irradiation and GFP positive BMSC transplantation. 
These researchers concluded that these endothelial progenitor cells were recruited 
to the pancreas in response to beta-cell injury (Mathews 2004). 
MSC have also been shown to home to and promote repair of pancreatic beta cells 
in rodents  (Lee 2006). The question of possible contribution of immunosuppressive 
qualities of MSCs to beta cell regeneration was addressed in a more recent study. 
Hyperglycaemia in streptozotocin-induced irradiated mice was reversed by 
concomitantly administration of bone marrow cells and syngeneic or allogeneic 
MSCs. Neither bone marrow cell nor MSC transplantation was effective alone. 
Successful treatment of diabetic animals was not due to the reconstitution of the 
damaged islet cells from the transplant, since no donor-derived beta cells were found 
in the recovered animals, indicating a graft-initiated endogenous repair process. In 
addition, MSCs were shown to have significantly suppressed beta cell specific T-cell 
proliferation in the pancreas protecting newly formed beta cells from destruction by 
T-lymphocytes (Urban 2008).  
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In summary, this evidence suggests that BMSCs can be manipulated to differentiate 
into beta cells in vitro but they do not differentiate into insulin-producing cells in vivo. 
Despite this, published data have established that all 3 populations of BMSCs (HSC, 
MSC and EPC) are able to stimulate beta-cell regeneration and support pancreatic 
growth in vivo by different mechanisms making the bone marrow an attractive option 
for cell-therapy of type I diabetes.  
 
1.9.3 Pancreas derived stem cells 
The most logical place to search for a means to regenerating new beta cells would 
be in the pancreas itself. It is known that beta-cell mass increases markedly during 
development and that it can fluctuate with physiological changes such as obesity and 
pregnancy (Bonner-Weir 2000). The exact origins and nature of cells required in vivo 
to repair pancreatic damage remains a complex and controversial problem. It has 
been shown that significant regeneration of pancreatic tissue, including beta-cell 
mass, occurs in adult rats after a 90% pancreatectomy (Bonner-Weir 1993).  Dor et 
al. used genetic tracing studies to demonstrate that existing beta cells are the 
primary source of new beta cells in vivo (Dor 2004). However, many other studies 
have found evidence of the involvement of pluripotent stem cells. Various different 
candidate populations of pancreatic resident progenitor stem cell have been 
described in the literature including pancreatic-duct epithelial cells, islet derived 
progenitor cells, and exocrine tissue, all of which appear capable, to a variable 
degree, of differentiating into insulin-producing cells in vitro.  
Wang et al. used pancreatic duct ligation to instigate a regenerative response in rats 
and discovered that there was considerable islet cell hyperplasia composed mostly of 
beta-like cells. A beta-like cell is similar to an actual beta cell but did not definitively 
express all markers at the exact same levels of normal beta cells. Using 
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bromodeoxyuridine labelling, the investigators demonstrated that this hyperplasia 
could not entirely be accounted for by proliferation of existing beta cells alone. The 
study suggested that these new beta cells were derived from progenitor stem cells. 
He proposed that exocrine duct cells differentiated and proliferated to form new beta 
cells (Wang 1995). Subsequently, further studies described the role of ductal cells in 
islet regeneration. Bonner-Weir et al. also demonstrated that pancreatic ductal 
epithelial cells could dedifferentiate into progenitor cells capable of proliferating and 
forming new beta cells and acini (Bonner-Weir 2004). One study by Gao et al. 
addressed the factors that affect transdifferentiation of pancreatic ductal cells and 
they established that these endocrine cells could be derived from cytokeratin 19 
positive ductal cells and that this differentiation could be inhibited by serum-
contained factors, although these specific growth factors were not identified (Gao 
2003).   
The second potential group of stem cells is islet-derived stem cells. The evidence for 
this group of stem cells came from studies that showed a population of insulin-
containing cells reappearing in the islets after total destruction of the beta cell mass 
with streptozotocin (Guz 2001). Nestin-positive cells have been proposed to 
represent a population of islet-derived stem cells (Zulewski 2001). However, later 
evidence suggests that although nestin is a functional protein expressed in beta-cell 
precursors, it might also be present in other different populations in the pancreas and 
hence is not a specific marker for endocrine stem cells but important functional 
protein in a variety of stem cell sources (Wang 2005). Xu et al. reported that beta cell 
replacement post pancreatic injury in a mouse model involved Ngn3 positive 
endocrine progenitor cells in the ductal lining. These cells were found to be 
pluripotent and were capable of differentiating into all four pancreatic endocrine cell 
subtypes (Xu  2008). 
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One interesting study described the generation of beta-like cells by reprogramming 
differentiated exocrine pancreas cells in vivo using a combination of transcription 
factors. These beta-like cells did not aggregate in vivo to form islet-like clusters but 
were similar to beta cells in morphology and function. They were able to mitigate 
hyperglycaemia by secreting insulin (Zhou 2008).  
Based on currently published data, it is generally accepted that the pancreas in the 
adult has a small population of cells that are capable of continuous self-renewal and 
can differentiate into cells of the pancreas. These cells would hold several 
advantages over other sources of stem cells. They combine the ability for prolong 
proliferation with an already partial differentiation towards endocrine phenotype. This 
might facilitate a more readily and less complicated differentiation strategy towards 
islet cells than that of other sources. 
 
1.9.4 Hepatic and other non-pancreatic stem cells 
Extra-pancreatic organ-bound stem cells can differentiate into islet cells. 
Hepatocytes, human adipose tissue-derived mesenchymal stem cells and 
splenocytes have been shown to have this ability (Gangaram-Panday 2007). As the 
liver and the pancreas are both endodermally-derived, it is thought that the liver 
would be a potential source of pancreatic stem cells. It is easily accessible and has 
substantial regenerative ability making it ideal tissue for autologous grafting and 
trans-differentiation cells. 
Rodent-liver stem cells and human fetal-liver cells have been differentiated in vitro 
into insulin-secreting cells by culture methods and/or introduction of beta cell-specific 
genes. When transplanted, these cells reverse diabetes in rodents (Zalzman 2003; 
Zalzman 2005). Cells within liver that can differentiate into insulin-secreting cells after 
56 
 
introduction of beta-cell-specific genes have also been seen in vivo after adenoviral 
gene-delivery into rodents that have been rescued from diabetes for long periods 
(Ber 2003; Yang 2006). Table 1 summarises the advantages and disadvantages 
associated with different types of beta cell replacement including stem cells. 
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 Source of    
 Cells 
Advantages Disadvantages Autologo
us 
source 
Insulin 
produced 
in vitro 
Insulin 
produced in 
vivo 
Comment 
 Whole   
 pancreas   
 transplant 
Curative with 
immediate clinical 
efficacy  
[insulin 
independence 
medium –long 
term] 
Limited donors 
 
Risk of major surgery 
 
Long-term 
immunosuppression 
No Not 
applicable 
Yes [in 
humans] 
Gold standard 
therapy 
 Islet cell  
 transplant 
Less invasive 
procedure 
 
 
Limited donors 
Risk of sensitisation 
[need for several 
infusions] 
 
Variable results 
[short-term insulin 
independence] 
 
Long-term 
immunosuppression 
No Not 
applicable 
Yes Improved 
isolation and 
delivery 
methods 
 Embryonic  
 stem cells 
 [ESC] 
Unlimited supply 
Pluripotent 
Ethical controversy 
Risk of teratoma 
No long term studies 
No Yes Yes  
 Induced   
 pluripotent   
 stem cells   
 [iPSC] 
Unlimited supply 
without ethical 
concerns of ESC 
Viral and genomic 
integration with the 
risk of tumour 
formation and 
infections 
Yes Yes Yes New derivation 
methods 
avoiding 
integration 
 Bone  
 marrow   
 stem cells  
 [BMSC] 
Easy accessibility 
 
Established 
harvest and 
delivery protocols 
 
Immunoprotective 
properties 
 
Stimulate beta cell 
regeneration in 
damaged pancreas 
Difficulty in achieving 
sufficient cell number 
in vitro for in vivo 
effect 
Yes Yes Yes Multiple 
mechanisms for 
increasing 
insulin 
production in 
damaged 
pancreas 
 Pancreatic   
 stem cells 
Already partially 
differentiated 
towards beta cells 
Difficulty in isolating 
cells and 
transdifferentiation 
factors 
Yes Yes No Unclear on 
origin, role and 
location 
 Hepatic  
 cells 
Easy accessibility 
 
Regenerative 
tissue 
 
Endodermal origin 
Difficulty in achieving 
sufficient cell number 
in vitro for in vivo 
effect 
Yes No Yes Transdifferentia
tion into beta-
like cells 
 
 
Table 1: Summary of different types of beta cell replacement, advantages and disadvantages Adapted 
from (Godfrey 2012) 
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1.10 Clinical trials in stem cell therapy for type I diabetes 
Stem cells in hematopoietic tissue have been used for haematological reconstitution 
for many years. These bone marrow cells are already routinely collected for current 
medical procedures such as various autoimmune disorders and haematological 
malignancy treatments. They have the advantage of being easily accessible. 
Harvesting BMSC in the form of aspirate bone marrow or mobilised stem cells 
isolated by apheresis has been standard clinical practice for decades. Thus, the 
bone marrow could potentially serve as an autologous source for cells and in turn 
minimise immunosuppression and rejection problems. These factors make the bone 
marrow an attractive source for potential type I diabetes stem cell therapy.  
There have been several phases I/II clinical studies of BMSC therapy in type I 
diabetes over the last 20 years. One of the earliest studies by Elliott et al. was 
published without complete outcome data in the Lancet in 1981 (Elliott 1981). The 
researchers obtained a bone marrow biopsy from the diabetic patient and infused 
BMSC including both MSC and HSC directly into the patient’s pancreas by arterial 
catheterization. This trial included 52 patients that had either type I or type II 
diabetes.  
The largest prospective phase I/II study with the longest follow-up comes from the 
Bone Marrow Transplantation Unit in Ribeirao, Brazil. These researchers based their 
cell-therapy for type I diabetes on the concept of “immunologic resetting” to stop the 
islets from being destroyed by the autoimmune response early within 6 weeks of 
disease presentation. Their 3-stage protocol aims to use an immunomodulatory 
strategy during the initial phase of the disease when the patient still has an important 
beta-cell reserve in an attempt to preserve and protect it. It starts with mobilisation of 
HSC from the bone marrow with low dose cyclophosphamide and granulocyte colony 
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stimulating factor (G-CSF). These HSC are collected and frozen. This is followed by 
a conditioning regimen, which includes high dose cyclophosphamide and rabbit anti-
thymocyte globulin (rATG), to destroy most of the patient’s lymphocyte clones, which 
include both autoreactive and non-autoreactive. Finally, the previously collected HSC 
are re-infused into the patient to regenerate or recover an immune system that will no 
attack the pancreatic beta cells (Couri 2009a; Voltarelli 2007). There was no control 
group in this study. 
Up to December 2008, 23 patients have been enrolled in the study. During a mean 
follow up of 29.8 months, 20 patients became insulin independent for some time. 
12/23 (52.3%) patients remained free from insulin for a mean of 31 months, 8/23 
(37.8%) patients were transiently insulin-free for a mean of 17.7 months post HSC 
infusion then relapsed. 3 patients were maintained on daily insulin doses. Patients, 
who experienced an insulin-free period, had improvement in their glycoslated 
haemoglobin Hba1c, increased mean peak C-peptide levels for prolonged time, up to 
4 years after treatment. The severe adverse effects included bilateral pneumonia in 2 
patients, 2 cases of autoimmune disease (Graves, hypothyroidism), and a case of 
transient hypogonadism as well as 9 cases of post-transplant hypospermia. None of 
the patients developed primary infection or reactivation of cytomegalovirus Epstein-
Barr virus. There was no mortality (Couri 2009b).  
As there was no control arm in the study by Couri et al, the best comparable would 
be the control untreated patients in several previous immunomodulatory trials for 
type I diabetes. One example of such trial is the Canadian-European Cyclosporine 
trial where it was reported that in the control untreated group only 27 and 10% of 
patients were in a non–insulin-requiring remission at 3 and 12 months, respectively, 
after diagnosis (Group  1988; Martin  1992). Similarly, a randomized trial by the 
IMDIAB Study group compared nicotinamide (NCT) and nicotinamide plus 
cyclosporine (NCT+CyA) in recent onset insulin-dependent diabetes. This trial 
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reported remission of 4/27(14.8%), 3/27(11.1%), 0/28 in NCT group, NCT+CyA 
group and placebo group respectively at one year after diagnosis (Pozzilli  1994) 
Another trial published by Harrison et al. in 1985 demonstrated an increased 
remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. 
In this study, there was a controlled arm with diabetic untreated patients of similar 
demographics to those that were treated. They reported that at 12 months 7/8 
(87.5%) patients in the treated group were in remission compared to 1/11 (0.09%) in 
the untreated group. Remission was not sustained in the treated group after 1-2 
years after treatment (Harrison  1985). If the results of the untreated control group 
can be used as the rate of remission during the natural course of type I diabetes then 
it can extrapolated that study by Couri et al. does demonstrate some benefit to these 
patients. 
Based on the Brazilian autologous nonmyeloablative HSC treatment protocol, few 
further studies in type I diabetes have occurred worldwide. The first study included 
16 patients in China. 5 out of 6 patients, that had type I diabetes for less than 3 
months, became insulin independent and one patient had 50% insulin dose 
reduction. All other 11 patients that were diagnosed for more than 3 months before 
treatment remained on insulin (Couri 2009b). Secondly, the use of autologous 
umbilical cord stem cells in children with type I diabetes resulted in no significant 
differences in daily insulin doses and in a decline in C-peptide levels after 1 year of 
follow-up. This study was conducted at the University of Florida  (Voltarelli 2009). 
Similar to Brazil, there is a research group in cell-therapy in Argentina that has 
undertaken human studies looking at the effect of endovascular implantation of 
autologous adult mononuclear CD34+ CD38- cells into patients with type I and type II 
diabetes. They reported their outcome data for both studies in an abstract form only 
at the 4th International Society of Stem Cell Research (ISSCR) annual meeting in 
2006. They stated that there was an increase in C-peptide levels and a reduction in 
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the daily insulin requirement in 23 type I diabetic patients enrolled in the study. None 
of the patients became insulin-independent but based on higher C-peptide levels; 
they concluded that these cells improved pancreatic function in these patients 
(Feranndez Vina 2006). 
Finally, a collaborative multi-centre randomised research project between Chicago 
and the Brazilian group in Sao-Paulo was planned to start in 2010. No published 
report of this study is available so far (Couri 2009b).  
 
1.11 Coagulation and beta-cell therapy 
1.11.1 The Coagulation cascade 
Coagulation is the transformation of flowing blood into a stable gel, and the 
transformation is the result of complex enzymatic mechanisms that are initiated when 
blood comes in contact with extravascular surfaces. This process is accomplished 
when soluble fibrinogen molecules undergo enzymatic cleavage and assemble into 
insoluble fibrin fibers.  Figure 9 shows the classical model of the coagulation cascade 
involving a regulated series of zymogen activation reaction. At each stage a 
precursor protein or zymogen is converted to an active protease by cleavage of one 
or more peptide bonds in the precursor molecule. Other components involved are a 
non-enzymatic protein co-factor, calcium ions and an organizing surface provided by 
a phospholipid emulsion in vitro or by platelets in vivo. The final protease generated 
is thrombin that converts the soluble protein fibrinogen into an insoluble fibrin matrix. 
This is strengthened further by covalent cross-linking catalyzed by factor XIIIa to form 
a clot (Adams  2009).  
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Figure 9: The coagulation cascade showing the intrinsic, extrinsic and the common pathways involved 
(bigtomato.org/drugs/bigcoagcascade.php) 
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There are two separate initiation mechanisms for the enzymatic coagulation 
cascade, both leading to the same end-point, which is fibrin network formation. The 
two initiation pathways are termed the intrinsic or contact activation pathway and the 
extrinsic pathway. The terms are derived from the fact that all functional components 
of the intrinsic pathway are intravascular, whereas triggering component of the 
extrinsic pathway, tissue factor (TF), is not found in blood, but in extravascular tissue. 
Although there are major differences in the activation mechanism and the 
subsequent enzymatic steps, both the intrinsic and extrinsic pathways converge into 
the common pathway, ultimately leading to fibrin formation (Adams  2009; Ruseva  
2011). 
TF, also known as thromboplastin, platelet tissue factor, factor III, thromboplastin, or 
CD142 is a protein present in subendothelial tissue and leukocytes necessary for the 
initiation of thrombin formation from the zymogen prothrombin. It is a non-enzymatic 
glycoprotein constitutively expressed on the surface of cells that are not normally in 
contact with plasma such as macrophages and fibroblasts. Exposure of plasma to 
these cells initiates the coagulation to repair a damaged blood vessel. Endothelial 
cells also express TF when stimulated by inflammatory stimuli and cytokines such as 
endotoxin, tumour necrosis factor or interleukin-6 and probably involved in thrombus 
formation under pathologic conditions (Ruseva  2011).  
The contemporary accepted cell-based model of in vivo coagulation describes a 
stepwise and overlapping pattern of activation highlighting three distinct phases of 
the cascade. A simplified version of the 3-phase coagulation cascade is shown in 
figure 10. The initiation phase of coagulation, by TF, which binds small amounts of 
circulating factor VIIa, activates factor X to factor Xa and this can then convert trace 
amounts of prothrombin to thrombin (i.e the extrinsic system). It also activates factor 
IX and thus linking the intrinsic and extrinsic pathway. The minor amount of thrombin 
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produced through the extrinsic factor tenase complex pathway is insufficient for 
complete fibrin formation but is enough to activate platelets through the protease 
activated receptors (PAR) as well as converting factors V and VIII in the intrinsic 
pathway to their active forms. This feedback activation of intrinsic system factors by 
these small amounts of thrombin constitutes the initial amplification phase where 
there is conversion from extrinsic to intrinsic thrombin generation. This is followed by 
the propagation phase, which involves the conventional activated tenase (VIIIa:IXa) 
and prothrombinase (Va:Xa) complexes, and leads to the generation of large 
amounts of thrombin capable of cleaving fibrinogen. This phase takes place on 
negatively charged phospholipid surfaces, which in vivo are provided by platelet 
membranes. The platelet is probably the only cell type on which the propagation 
phase can occur effectively. When enough thrombin is generated at a sufficient 
speed to result in a critical mass of fibrin, these soluble fibrin molecules will 
polymerize into strands and result eventually in an insoluble fibrin matrix (Adams  
2009; Ruseva  2011).  
  
65 
 
 
 
 
Figure 10: Simplified modern clotting cascade pathways. Coagulation is initiated by extrinsic tenase, 
which forms when factor VIIa binds to tissue factor. Extrinsic tenase activates factors IX and X. In the 
presence of calcium, factor IXa binds to negatively charged phospholipid surfaces where it interacts with 
factor VIIIa to form intrinsic tenase, a complex that efficiently activates factor X. Factor Xa binds to factor 
Va on negatively charged phospholipid surfaces to form prothrombinase, the complex that activates 
prothrombin to thrombin. Thrombin then converts fibrinogen to fibrin. Activated platelets or monocytes 
provide negatively charged phospholipid surfaces on which these clotting reactions occur (Bates 2005). 
 
 
 
1.11.2 Regulation of coagulation and anticoagulants 
Regulation of the pathway occurs at each level, with each phase associated with 
inhibitory factors, either by enzymatic inhibition or modulation of cofactor activity. The 
main inhibitory regulatory proteins are tissue factor pathway inhibitor (TFPI), 
antithrombin, protein C and heparin cofactor II. The serine protease TFPI is the main 
TF regulator. It neutralizes activated factor Xa and inhibits the TF and activated 
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factor VIIa complex. It is predominantly produced by endothelium, bound to heparin 
sulphate as well as other cells including platelets. It is also found in a circulating form 
bound to low-density lipoprotein (LDL). The administration of heparin or low 
molecular weight heparin (LMWH) results in the endothelial form of TFPI being 
released into the circulation leading to systemic anticoagulation. Antithrombin is a 
serine protease inhibitor exerting its actions preferentially on free enzymes and to a 
lesser extent on bound serine proteases. The action of antithrombin is greatly 
enhanced by the administration of heparin or heparin-like molecules expressed on 
endothelium. Thrombin-binding to constitutively expressed endothelial 
thrombomodulin activates protein C, which with protein S as a cofactor inactivates 
factors Va and VIIIa. Heparin cofactor II expressed on liver cells inactivates thrombin 
in the presence of heparin or heparin-like molecules (Adams  2009).  
Heparin is the first anticoagulant drug to be identified. It has high affinity for 
antithrombin and inactivates serine proteases including factors II, VII, IX and X. At 
higher doses, heparin cofactor II is activated which results in thrombin inactivation 
(Kovacs  2003). Hirudin is a polypeptide that was first isolated from the medicinal 
leech. It binds thrombin at the active site and fibrin binding site forming an 
irreversible hirudin:thrombin complex (Chang  1989). Both heparin and hirudin cause 
non-selective systemic anticoagulation. 
 
1.11.3 Coagulation in vitro 
The pathways of the coagulation cascade model are reflected in the laboratory 
analysis of clotting in vitro. When blood is placed in a glass test tube, it clots fairly 
quickly. Calcium ions are required for this process. Addition of 
Ethylenediaminetetraacetic acid (EDTA) or citrate prevents clotting by binding 
calcium. Clotting can be initiated in vitro at a later time by adding back an excess of 
67 
 
calcium ions. Recalcified plasma will clot in 2-4 minutes. Coagulation can be initiated 
via the “intrinsic” pathway in vitro when factor XII, prekallikrein and high-molecular 
weight kininogen (HMWK) bind to kaolin, glass, or another artificial surface. Once 
bound, reciprocal activation of XII and prekallikrein occurs as shown in figure 7. 
Factor XIIa triggers clotting via the sequential activation of factors XI, IX, X and 
prothrombin. Hence the clotting time after recalcification can be shortened by the 
addition of emulsion of negatively charged phospholipids with or without by 
preincubation of the plasma with kaolin (insoluble aluminium silicate). This would be 
a measure of the intrinsic coagulation pathway. The clotting time is also shortened by 
the addition of thromboplastin, which contains tissue factor, and hence this would 
reflect and would be a measure of the extrinsic coagulation pathway (Adams  2009; 
Tollefsen 2013).  
 
1.11.4 Coagulation and inflammation 
Homeostasis is a defense mechanism to prevent haemorrhage and disseminated 
thrombosis. Activated by vessel wall injury, it consists of intertwined activation of 
platelets and the coagulation cascade, tightly controlled by natural anticoagulants 
and the fibrinolytic system (Levi 2004). Inflammation aims to restore the integrity of 
damaged tissues, most frequently because of injury or infectious pathogens. The 
coagulation system and the innate inflammatory response share a common ancestry 
and are coupled via common activation pathways and feedback regulation systems 
(Delvaeye 2009). The two-way relationship between both has persisted throughout 
evolution: coagulation triggers inflammation and inflammation triggers the activation 
of the coagulation system. Extensive interaction between inflammation and 
coagulation involves cell receptor-mediated signaling, cellular interactions and the 
production of cell-derived microvesicles by endothelial cells, leucocytes and platelets 
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in addition to enzymes and soluble or cell-expressed regulators that work on both the 
coagulation and inflammation pathways.   
Platelets, tissue factor and thrombin in inflammation are a good illustration of this 
two-way relationship. After adhering to the injured vessel wall, activated platelets 
release cytokines, growth factors, and numerous proinflammatory mediators. 
Inflammatory cytokines induce TF expression in leucocytes and in endothelial cells. 
The formation of a complex between TF and the coagulation FVIIa or Xa is 
instrumental in initiating coagulation on negatively charged cell membranes, whereas 
membrane-bound TF is also capable of signal transduction directly mediating 
inflammatory reaction (Schouten 2008). Blocking TF activity completely abrogates 
inflammation-induced coagulation activation in models of experimental endotoxaemia 
or bacteraemia (Levi 1994). A series of feedback and amplification steps lead to the 
generation of large amount of thrombin, which results in the generation of fibrin 
polymers and fibrinogen deposition.  In addition, the major coagulation enzyme 
thrombin has many functions beyond haemostasis. It is a key regulator of cell 
activation by protease activated receptors present on platelets but also on 
endothelial cells, thus triggering inflammatory pathways (Shrivastava 2007).  
Failure of the complex balance between pro- and anticoagulation, or between pro- 
and anti-inflammatory reactions because of genetic or acquired disturbances may 
result in disease. Inflammation shifts endothelial cells towards a more prothombotic 
state, downregulating anticoagulant defence mechanism and leading to expression 
and synthesis of thrombogenic molecules such as von Willbrand factor and TF. 
Thrombotic vascular occlusion can occur in several multisystem disorders, may 
complicate local procedures such as angioplasty and vascular surgery, and features 
prominently in the pathology of hyperacute rejection of allografts or xenografts, 
where it leads to irreversible infarction of the transplanted organ. In this setting, the 
procoagulant state within the graft develops from the simultaneous effects of 
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complement activation, dependent on the deposition of anti-graft endothelial cell (EC) 
antibody, subendothelial tissue factor exposure, loss of proteoglycan linked 
anticoagulant molecules such as antithrombin III and TFPI from endothelial cell 
surfaces, downregulation of thrombomodulin, which is internalized after EC activation 
and widespread platelet activation (Platt 1990). All of which leads to thrombosis and 
consequently infarction.  
 
1.11.5 Coagulation and Islet transplantation 
It is established that islet loss experienced during the isolation, implantation and 
engraftment period is high. An estimated 50% of the final preparation infused into the 
patient is lost during engraftment period (Leitao 2008). The large number of islets 
needed to establish insulin-independence in a diabetic receiving islet transplant is 
thought to be due to the early loss of a significant proportion of these injected islet 
cells through both non-immune and immune processes.  
The association between coagulation and inflammation plays a major role in the field 
of islet transplantation. It is well established that after infusion of islets into the portal 
vein, a substantial percentage of them are damaged in the immediate post-transplant 
period through an inflammatory response termed the “instant blood-mediated 
inflammatory reaction” (Bennet 2000a; Bennet 2000b). IBMIR manifest by activation 
and consumption of platelets, activation of neutrophils and monocytes, and activation 
of the coagulation and complement systems (Bennet 1999; Titus 2003). IBMIR is 
potentially triggered by molecules expressed on the cell surface of islets such as 
tissue factor and collagen residues that are normally not in direct contact with the 
blood (Moberg 2002). Islet transplant also results in activation of both humoral and 
cellular responses and the innate immune system may be involved in IBMIR and in 
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turn contribute to the further loss of a significant fraction of transplanted islets 
(Bottino 1998; Chandra 2007; Nagata 1990). 
Moberg et al. provided evidence for the production of TF by the islet cells as a trigger 
of the detrimental thrombotic reactions observed in clinical islet transplantation. 
Coagulation activation and subsequent release of insulin were found consistently 
after clinical islet transplantation in 4 patients even in the absence of signs of 
intraportal thrombosis. The endocrine cells were found to synthesise and secrete 
active TF demonstrated by higher expression of TF in the islet preparations and 
higher activity of TF when assessed in vitro. Additionally, they successfully abrogated 
the clotting reaction triggered by the islets in vitro by blocking the active site of TF 
with specific antibodies or site inactivated factor VIIa making this agent a candidate 
drug for inhibition of TF in vivo (Moberg 2002).  
The same group in a follow up experiment confirmed that islets intended for clinical 
transplantation produced TF in both membrane-bound form and the alternative 
spliced form and that factor VIIa inhibitor blocked both forms of TF in vitro. They also 
demonstrated correlation between initial Thrombin-antithrombin complex (TAT) and 
FVIIa-antithrombin complex (FVIIa-AT) levels, which increase with the activity of 
IBMIR, and C-peptide levels 7 days post islet infusion. Patients with initially strong 
IBMIR showed no increase in insulin synthesis highlighting the important role of TF in 
this process (Johansson 2005). However, these researchers reported considerable 
variation in the amount of TF expression in islets from different donors, and in turn 
suggested that TF expression may be induced. They went on later to suggest that TF 
expression is probably only one feature in an array of pro-inflammatory events, 
including the expression of Monocyte chemotactic protein 1 (MCP-1) and IL-8 that 
are triggered in the islets by the chain of events prior to transplantation (Korsgren 
2005).  
71 
 
If early graft loss after intra-portal islet transplant is to be reduced, interventions 
should be directed against various components of IBMIR or, ideally, against all 
components by a single agent. The preventive strategies for IBMIR that have been 
investigated so far include systemic treatment of recipient with heparin but this 
harbours the risk of systemic complications, especially that of bleeding.  
Other strategies included pre-conditioning of the isolated islets before transplant with 
anticoagulation or anti-inflammation agents and the genetic alteration of the islets. 
The prior administration of soluble complement receptor-1 reduces this rapid islet 
destruction both in vitro and in vivo (Bennet 2000a). Rood et al. showed that pre-
transplantation complement depletion or anticoagulation with dextran sulphate 
reduces porcine islet xenograft loss significantly but neither alone sufficient to 
prevent IBMIR (Rood 2007). Similarly, Titus et al. demonstrated that inhibition of 
coagulation or inhibition of platelet aggregation by the incubation of islets in 
allogeneic blood with heparin or Reopro (monoclonal anti-GpIIbIIIa) respectively did 
not make a substantial improvement in the destruction of the islets in terms of 
histology or proinsulin release (Titus 2003). Johansson et al. reported successful a 
dose-dependent inhibition of IBMIR by low molecular weight dextran sulphate in vitro 
and in vivo in a nonhuman primate model suggesting it use as part of a tentative 
protocol in clinical islet transplantation (Johansson 2006). On the other hand, the 
Swedish group encapsulated the islet surface with continuous heparin coating 
rendering it blood biocompatible in vitro and in a vivo mouse model. They concluded 
that this novel pre-treatment procedure efficiently inhibited the IBMIR without 
increasing the risk of bleeding and without inducing acute or chronic toxicity in the 
islets and hence should be considered for clinical use (Cabric 2007). More recently, 
pre-conditioning human islets with recombinant human activated protein C (rhAPC) 
alone or Tirofiban alone or in combination was examined by Akima et al. They found 
that Tirofiban monotherapy was ineffective, whereas rhAPC monotherapy prevented 
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IBMIR in a dose-dependent manner preserving islet integrity in vitro. The 
combination of pre-treatment with both agents worked synergistically to preserve 
islets suggesting that co-inhibition of the platelet and coagulation pathways id 
required for the optimal anti IBMIR effect. (Akima 2009). 
As mentioned earlier, having identified TF as a trigger for IBMIR post islet 
transplantation, several groups investigated the effects of blocking TF by various 
agents as a potential target therapy for elimination of IBMIR (Moberg 2002). Moberg 
et al. used low molecular mass factor VIIa inhibitor and demonstrated its efficacy in 
vitro (Johansson 2005; Moberg 2002). The same group investigated the effect of L-
arginine, cyclospine A, enalapril and nicotinamide, which all have been previously 
shown to affect TF and MCP-1 expression in monocytes and endothelial cells, on 
human islet cells in vitro. Their results led to the conclusion that adding nicotinamide 
to the culture medium can reduce TF and MCP-1 expression in human islets and in 
turn can diminish the IBMIR in clinical islet transplantation without the systemic effect 
of antithrombotic drugs (Moberg 2003).  Another group reported the protection of 
islets from IBMIR by pre-treatment of islets and the recipient with a humanised 
monoclonal anti-TF antibody (CNTO859) in a nonhuman primate marginal mass 
model. Although intervention with the antibody did not lead to insulin independence, 
compared to their matched controls, treated animals had decreased post transplant 
markers of coagulation, higher fasting C-peptide levels and prolonged graft function. 
They concluded that this study should be used as a foundation on which to build on a 
more effective peritransplant strategy to minimize islet loss and maximize islet 
function (Berman 2007). 
In current practice, in most transplant centres, islets are transplanted in heparinised 
medium to prevent coagulation at the time of infusion followed by systemic 
coagulation with either intravenous heparin or subcutaneous low molecular weight 
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heparin for 5-7 days post transplant. None of the trials report adverse effects such as 
bleeding (Goss 2003; Hering 2005; Shapiro 2000). 
 
1.11.6 Coagulation and islet xenotransplantation 
Successful clinical application of islet xenotransplantation is currently not achievable 
due to a number of immunological and non-immunological barriers. The xenograft 
islets transplanted into the portal vein are lost very early post transplantation due to 
IBMIR similar to that observed in islet allotransplantation where TF plays an 
important trigger to this process. Incompatibilities between the human and pig 
coagulation-anticoagulation systems makes IBMIR even more problematic in 
xenotransplantation (Ji  2011; Johansson  2005). Inhibition of TF expression or 
thrombin formation prevented islet damage in vitro but in vivo anticoagulation does 
not fully prevent IBMIR suggesting another component to this response. (Ji  2011; 
Moberg  2002; Ozmen  2002) 
Dissimilar to islet allotransplant, in addition to tissue factor triggering inflammation 
and coagulation, the human complement system is also activated due to preformed 
xenoreactive natural antibodies, known as XNAs. This results in endothelial damage, 
inflammation, thrombosis and necrosis of the transplant (Ji  2011; Johansson  2005; 
Van der Windt  2012). The vascular endothelium of pigs express galactose-α1, 3-
galactose (GAL) oligosaccharide against which humans have natural anti-GAL 
antibodies (Good  1992). The binding of antibodies to GAL antigen after islet 
xenograft infusion results in almost immediate complement activation leading to the 
destruction of the graft. Adult pig islets have lower expression of GAL compared to 
neonatal pig islets but still undergo IBMIR when transplanted (Rayat  2003). In 
addition neonatal islets from pigs that do not express GAL are less susceptible but 
does not obliterate the IBMIR (Thompson  2011). This suggested than antibody 
74 
 
binding to other non-GAL antigens may be an initiating factor in complement 
activation (Van der Windt  2012). Figure 11 shows the mechanisms involved in 
IBMIR post islet xenotransplantation. 
 
 
 
Figure 11: Schematic overview of the instant blood-mediated inflammatory reaction. Tissue factor 
expression and antibody binding to non-Gal antigens, as well as to Gal on neonatal pig islets, activate 
coagulation and complement cascades, leading to clotting, direct cellular membrane damage through 
the membrane attack complex (MAC), and recruitment of macrophages and monocytes through the 
chemoattractants C3a and C5a (Van der Windt  2012)  
 
 
1.11.7 Coagulation and stem cell therapy 
Although there is ample precedence in islet allo- and xenotransplantation literature 
demonstrating the important role of anticoagulation, there is very little published at 
present to support the idea of intravenous, intraportal or intrarterial delivery of stem 
cell transplants in humans is associated with increased risk of thrombosis. Most of 
the stem cell transplant data available comes from the field of HSC transplant in 
haematological settings, which are different to the use of stem cell-based therapy in 
diseases such as diabetes. All the evidence published for potential causes of 
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coagulopathy comes from HSC transplant (HSCT) for haematological diseases 
where there is association with the abnormal bone marrow and the extent of pre-
conditioning regime. In the absence of haematological disease, diabetic patients or 
patient with degenerative disorders responsive to stem cell therapy should in theory 
have a relatively normal bone marrow and in most of these disorders, pre-
conditioning immnunosuppressive regime would not be required prior to the stem cell 
transplant.  However, there have been no studies that investigated the state of the 
bone marrow in these patients prior to stem cell infusion and in turn no evidence to 
support this assumption.  
There is evidence however that suggests three typical haemostatic complications in 
HSCT, namely veno-occlusive disease (VOD), thrombotic microangiopathy (TMA) 
and diffuse alveolar haemorrhage (DAH) may be manifestations of thrombosis in the 
microcirculation. These thrombotic complications are observed following allogeneic 
or autologous HSCT at slightly different rates and are a major cause of morbidity and 
mortality. Proliferation of bone marrow endothelial progenitor cells, which is a source 
of endothelial cell repair is attenuated under the effect of HSCT conditioning regimen, 
rendering the vascular bed vulnerable (Nadir 2012). These haemostatic impairments 
are found to be related to administration of chemotherapy, and growth factors, use of 
intravenous catheters, and graft-versus-host reaction (Nadir 2004; Piguet 1989). 
Hepatic VOD develops in 1-22% of patients after HSCT wit onset typically within the 
first month post stem cell infusion. It ranges in severity from mild, reversible disease 
to severe form associated with multi-organ failure and death (Richardson 1999). 
Several endothelial injury markers are upregulated in patients with VOD, including P- 
and E- selectins, TFPI, soluble TF and endothelial PAI-1 (Nurnberger 1998). The role 
of prophylactic heparin anticoagulation, alone or in combination with other agents, in 
VOD has been assessed in only one randomised controlled study, which reported 
beneficial effect of low-dose heparin infusion (Attal 1992). There is no approved 
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therapy for established hepatic VOD. Current strategies focus on supportive 
management and anticoagulant or fibrinolytic drugs (Nadir 2012). Defibrotide, a 
single stranded polydeoxyribonucleotide that exerts anti-thrombotic activity by 
binding to vascular endothelium, without significant effect on systemic coagulation, 
has shown encouraging results in VOD management (Chopra 2000). 
The incidence of TMA following stem cell transplantation is between 0.1% and 15%. 
It is significantly lower after autologous HSCT compared to allogeneic transplant 
(Iacopino 1999). Elevated von Willebrand factor (VWF) antigen levels found in 
patients with TMA are more likely the results of diffuse endothelial injury and not due 
to severe VWF-cleaving protease deficiency (Elliott 2003). The optimal management 
of transplantation-related TMA has not been established. The suspected offending 
drug is usually discontinued and plasma exchange has been used as a part of 
treatment because of clinical similarity to idiopathic thrombotic thrombocytopenic 
purpura (TTP) but with limited efficacy. Other therapies attempted include defibrotide 
and immunoglobulin G with variable success (Nadir 2012). 
Although endothelial cell injury is a common feature of the pathogenesis of HSCT- 
associated thrombotic complications and the intravascular thrombosis observed with 
pancreas and islet transplantation, it is unclear if non-HSCT or HSCT for non-
haematological diseases share that phenomenon. 
 
1.12 Site of beta- cell delivery 
At present, islet or cell-based transplantation, whether allogeneic, autologous or 
xenogeneic most commonly involves the intravenous delivery of the islets or cells 
into the portal vein of the liver. The liver was established as the site of choice for islet 
transplantation in clinical practice following the publication of the first few cases of 
77 
 
successful islet infusion into the liver in 1980s and subsequently in 1990 (Najaran  
1980; Scharp  1990; Sutherland  2001). However, it has become increasingly 
recognised that the liver does not provide the ideal microenvironment for islets due to 
immunological, anatomical and physiological factors that contribute to the loss of islet 
mass early after infusion. In both islet allo and xenotransplantation, this method and 
site of delivery results in a large number of islets lost early post transplant thorough 
the non-specific IBMIR and rejection as described in section 1.10.5 and 1.10.6 
respectively. IBMIR results in fibrin capsule formation surrounding the islets and 
leads to infiltration of leucocytes mainly polymorphonuclear cells. After activation, 
these cells secrete reactive oxygen species that cause rapid and direct damage to 
the islets that are extremely susceptible to oxidative stress. Intraliver infusion is also 
associated with thrombosis and hepatic tissue ischaemia caused by islet entrapment 
in to liver sinusoids that leads to endothelial cell activation and functional impairment 
(Cantarelli  2011).  
Revascularization of transplanted islets is essential for proper glucose homeostasis. 
In view of intra-islet endothelial cells loss during the isolation process, islets are more 
susceptible to post-transplant stresses and damage as the revascularisation of the 
intraliver islets is not immediate and often takes several days. Complete circulation is 
only re-established within 10-14 days post infusion (Carlsson  2002). Additionally, 
islets placed into hepatic-portal circulation are exposed to higher levels of 
immunosuppressive drugs that are thought to be largely toxic for islet function 
(Shapiro  2005). Intra-liver islets are not exposed to arterial concentrations of 
glucose. Intra-portally transplanted islets are exposed to intermittent hyperglycaemia 
of a greater magnitude than seen in normal physiology, an effect that can be toxic to 
the islets, or, at the very least, challenges the beta cells that have not encountered 
this environment in the native pancreas (Gray 1989; Juang 1994; Makhlouf 2003; 
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Yumiba 1992). However, there is little evidence to suggest that this exposure 
composes a major hurdle for islet survival post transplantation. 
In view of the negative consequences of the intravenous islet graft delivery into the 
liver, there have been attempts to address these barriers by investigating alternative 
transplantation sites to improve graft survival and engraftment.  An ideal islet 
transplant site would have multiple desirable properties that provide the conditions 
favouring optimum islet survival. The transplant site should result in minimal early 
inflammatory reactions and protect islets from cellular immune responses. It should 
be a well-vascularised microenvironment with good access to nutrients, suitable 
oxygen tension at physiological pH and free from toxic metabolites and oxygen-free 
radicals. Additionally, it should be easily accessible technically via minimally invasive 
approach.  
Table 2 reports the various alternative islet transplant sites that have tested in 
experimental models. Most of these studies have been investigating alternative sites 
in small animal models. Only a few of these have been transferred to large animal 
models and finally in clinical practice in humans. The table reveals the advantages 
and disadvantages for each of the alternative transplant sites in terms of the desired 
immunological, anatomical, physiological and surgical properties. Adapted from 
(Cantarelli  2011; Merani  2008). For example extravascular implantation sites such 
as muscle and kidney capsule provide the benefit of IBMIR avoidance but they do 
not mimic physiological insulin release. On the other hand, while the pancreas 
provides the most suitable physiological site for islet transplantation, it poses a 
challenge in terms of technical accessibility and high risk of acute complications post 
transplantation. The thymus, testis, anterior eye chamber and brain may confer 
protection in allotransplantation. They are thought to be immunoprivileged sites and 
may offer complete or partial protection from allorejection or xenorejection without 
the need for concurrent immunosuppression. There are specific barriers to each of 
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these immunoprivileged sites in the clinical context. The thymic site is the most 
developed with large animal investigations (Cantarelli  2011; Merani  2008).  
Although many transplantation sites have been proposed, few have found their way 
into the clinical setting. Additionally, there have been several studies evaluating the 
immunological benefit of prevascularised subcutaneous chamber devices and the 
technology of encapsulation for the transplantation of xenogeneic porcine islets 
(Pilleggi  2006; Siebers  1997; Sykes  2007). Finally, There are currently few ongoing 
clinical phase I/II studies testing the safety, feasibility and efficacy of alternative sites 
for autologous and allogeneic islet transplantation and their results are awaited. 
While the ideal site for islet implantation in humans is yet to be identified, the liver 
remains the site for islet transplantation in clinical practice at present. 
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Transplant site Minimal 
IBMIR 
Immune- 
protection 
Well 
vascularised 
Physiological 
insulin release 
Easy access 
 Liver - _ ++ + + 
 Pancreas - _ + + _ 
 Muscle + _ + _ ++ 
 Omentum + + ? + _ 
 Bone marrow ++ _ ++ _ ++ 
 Gastric       
 submucosa 
? _ + + + 
 Genitourinary  
 tract 
? _ _ _ + 
 Kidney capsule ++ _ + _ + 
 Anterior eye                           
 chamber 
? + + _ + 
 Testis ? + + _ + 
 Thymus ? + ? _ _ 
 
Table 2: Evaluation of immunological, anatomical, physiological and surgical properties of alternative 
experimental islet transplant sites. Adapted from (Cantarelli  2011; Merani  2008) 
 
 
In HSCT, the cells are infused peripherally and the thrombotic complications are 
described in section 1.10.7 and do not occur immediately post administration which 
suggests no direct association to the site or method of infusion. There is no evidence 
to suggest that a similar response to IBMIR occurs in this setting. In the few stem cell 
trials or studies published as treatment for diabetes, none report the exact infusion 
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method or site so it is unclear whether the cells are administered peripherally or intra-
portally. There were no reported adverse events related to thrombosis at any site. It 
is hence unknown what is the ideal site for stem cell transplant in patients with 
diabetes. 
 
1.13 Potential strategies for anticoagulation therapy  
At present, there is no feasible and safe alternative site for islet transplantation to 
intra-liver delivery. Whilst this remains the only option in clinical practical, there have 
been attempts to address the main cause of early islet graft loss post intra-portal vein 
placement. Several strategies has been investigated which aim to minimize the 
IBMIR thereby enhancing islet engraftment and survival. 
The treatment options described so far for the prothrombotic state found after 
intravenous intra-portal islet transplantation have been either systemic 
anticoagulation or pre-conditioning of the islet graft pre-transplantation with a variety 
of therapeutic agents. Systemic anticoagulation has been documented as being of 
preventive benefit. However, systemic treatment can be complicated by bleeding, 
involving sites remote from the primary pathology, which at times may be life 
threatening.  Pre-conditioning regimes have mainly been applied to islet 
transplantation in experimental models and only heparin in reality is used in the 
clinical setting. An alternative approach is to either the use genetic strategy to target 
expression of anticoagulant molecules in xenotransplantation or more promising the 
use of antithrombotic cytotopic constructs directed to the graft cells and can act 
locally to prevent coagulation without the undesirable systemic complications. 
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1.13.1 Genetic constructs or engineering 
This work was directed towards the potential use of a genetic strategy for 
xenotransplantation, where transgenic pigs might be useful as a source of islets. In 
xenotransplantation, this option might involve pre-transplant perfusion of xenografts 
with genetic material, or genetic alteration of the islets. 
Riesbeck et al. at Imperial College engineered two genetic constructs encoding novel 
membrane-tethered anticoagulant fusion proteins based on soluble human tissue 
factor pathway inhibitor (hTFPI) and the leech anticoagulant hirudin. Hirudin is the 
most potent natural inhibitor of thrombin. Unlike antithrombin III, hirudin binds to and 
inhibits only the activity of thrombin, with a specific activity on fibrinogen. Both sets of 
constructs have been expressed in rodent cells and have been shown to bind 
appropriate coagulation factors (Riesbeck  1997; Riesbeck  1998). When expressed 
constitutively on the surface of porcine endothelial cells (PEC), anchored by the 
transmembrane/cytoplasmic tail of human CD4, hTFPI bound to and inhibited factors 
Xa, VIIa, and porcine tissue factor (pTF), and hirudin retained potent thrombin-
binding activity. Hirudin expression significantly modified the procoagulant phenotype 
of PEC in human plasma, leading to prolongation of clotting time (Riesbeck 1998). 
Chen et al. demonstrated that expression of hTFPI-CD4 on PEC effectively 
prevented pTF-dependent clotting, whereas expression of hirudin-CD4 construct 
inhibited both pTF-dependent and -independent fibrin generation. When both 
constructs were co-expressed in the same cell, the potent procoagulant properties of 
in vitro cultured, IL-1a-activated PEC were almost completely abolished this 
experimental system. The scientists concluded that these results support the 
hypothesis that the hTFPI-CD4 and hirudin-DC4 constructs may be useful agents for 
clinical applications as a safer and more effective way to inhibit thrombosis. Genetic 
manipulation will allow for targeted expression for local anticoagulant in situations in 
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which thrombotic complications are anticipated such as islet xenotransplantation 
avoiding the undesirable effects of systemic anticoagulation (Chen 1999a; Chen 
1999b). 
Chen et al. further developed the work with the anticoagulant fusion proteins by 
applying it to heart transplantation in rodent model to demonstrate their effect in an in 
vivo setting. Because intravascular thrombosis and systemic coagulopathy are 
prominent features of acute humoral xenograft rejection, they hypothesized that 
expression of anticoagulants on xenogeneic vascular endothelium might inhibit the 
process. Hearts from novel transgenic mice strains, expressing hTFPI construct and 
hirudin respectively, were transplanted into rats. In contrast to control non-transgenic 
mouse hearts, which were all rejected within 3 days, 100% of the organs from both 
strains of transgenic mice were completely resistant to humoral rejection and 
survived for more than 100 days when T-cell-mediated rejection was inhibited by 
administration of cyclosporine A. The anticoagulant constructs achieved effective 
inhibition of thrombosis in transplanted cardiac xenografts and offered complete 
protection against humoral rejection. These results demonstrated the critical role of 
coagulation in the pathophysiology of acute humoral rejection and the potential for 
inhibiting rejection by targeting the expression of anticoagulants to graft endothelial 
cells (Chen 2004).  
In summary, the genetic strategy of the expression of anticoagulant fusion protein 
constructs to target localised thrombosis has been successfully demonstrated in vitro 
and in vivo. The animal work by Chan et al. covered a spectrum of mouse models 
including humoral rejection in xenogeneic transplantation. These results are 
encouraging where it’s envisaged that transgenic pigs might be useful for islet 
xenotransplantation. However, in practice, the use of this strategy is limited because 
xenografts remains in the experimental pre-clinical phase and because the gene 
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therapy approaches have suffered from poor delivery of the genetic material and 
from side effects related to viral delivery systems. 
 
1.13.2 Anti-thrombotic cytotopic agents 
As a clinical strategy for xenografts, gene therapy is limited in its utility and a more 
practical and promising approach is the use of cytotopic agents developed in the 
MRC Centre for Transplantation at Kings College in London. Cytotopic agents are 
engineered protein and peptide agents made to function at the Cell Surface. 
Cytotopic proteins made by Richard Smith of the MRC Centre have been modified to 
behave like intrinsic membrane proteins while retaining pharmaceutically acceptable 
physical properties. The primary modification is based on a natural mechanism used 
by proteins such as Src and Ras, the myristoyl-electrostatic switch. The anti-
coagulant cytotopic agent is a soluble compound comprising an antithrombotic agent 
and a membrane-binding element, where the antithrombotic agent has a weight of 
less than about 5,000 daltons. It can bind to the cell membrane of cells, tissues and 
organs to prevent or reduce the formation of blood clots. ‘Thrombalexin’ (TLN) is one 
such compound, based on hirulog peptide, the active moiety in the leech 
anticoagulant hirudin, which binds thrombin irreversibly. TLN contains a synthetic 
structurally minimized and chemically reactive form of a myristoyl-electrostatic 
switch. In laboratory testing, TLN has been shown to retain potent antithrombin 
activity when bound to cell membranes and can inhibit fibrin clot formation in a re-
calcified plasma assay. In these assays, cell-bound hirulog inhibits only clotting that 
is initiated by the cells, in contrast to when soluble hirulog is added, when all clotting 
is inhibited, including that induced by the glass tubes, a situation that is analogous to 
the systemic anticoagulant effect seen in vivo when soluble therapeutics are used. 
The compound is relatively small in size which means that it is generally less 
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immunogenic than large agents, especially if it originates from an exogenous source. 
Another advantage is that it is easy to manufacture and importantly can be 
manufactured synthetically. Finally, since the compound can bind to cell membranes, 
it can be administered locally so that the compound has an effect at a specific 
location rather than having a systemic effect. The compound can be used in the 
short-term manipulation of organs in transplantation. It can also be used in cell 
therapies in which it is desirable to confer resistance to coagulation. TLN is currently 
undergoing pre-clinical development in a £1.3M project funded by a Wellcome Trust 
Translation Award, with the aim of generating pharmaceutical grade reagent for a 
Phase I Clinical Trial by 2015 (Dorling  2013; Smith  2001; Smith  2012). 
In translational terms, one potential clinical use of such cytotopic constructs has been 
in prostate cancer therapy. The membrane localizing anti-coagulant hirudin cytotopic 
analog PTL004 were shown to have comparable anti-migratory and anti-proliferative 
properties to hirudin, and liposomes bearing this compound are even more effective 
at inhibition of proliferation of PC3 prostate cancer cells. These results demonstrate 
the potential of a cytotopic approach using tailed anticoagulants in localized prostate 
cancer therapy (Galustian  2011). 
Another compound (Mirococept), based on applying similar modifications to human 
complement receptor type 1 is at an advanced stage of development. Mirococept has 
potent biological activity (including against C5) in multiple pre-clinical models and has 
undergone Phase 1 and pilot Phase II clinical studies in human renal transplant 
patients. A large Phase II study in kidney transplantation is funded by the MRC and 
will start recruiting in 2013 (Dorling  2013; Smith  2001).  
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1.14 Summary and hypothesis 
At present, organ shortage remains a major limiting factor for pancreas 
transplantation, which is the gold standard therapy for type I diabetes. In addition to 
limited organ supply for donation, islet transplantation has several hurdles before it 
becomes a treatment of choice for this disease. Although limited supply is not an 
issue in xenotransplantation, it has a different set of barriers that need to be resolved 
before it can be used in clinical practice. Insulin secreting stem cells provide a 
solution to organ shortage and so may be a novel and promising treatment for type I 
diabetes. However, based on the evidence available for the IBMIR following 
intravenous transplantation of islet allo and xeno-transplanation into the liver, it can 
be postulated that intravenous administration of ‘islet equivalent’ stem cells will 
provoke a similar immediate inflammatory response and thrombosis trigged by tissue 
factor. This will lead to significant early loss of the cells infused.  
The current study investigates the following hypothesis and attempts to find a 
therapy to reverse it. 
I) Stem or progenitor cells capable of insulin secretion ‘islet equivalent’ are capable 
of successfully reversing diabetic phenotype in a mouse model and in a phase I 
human trial. 
II) The insulin secreting cells express tissue factor on their cell surface. Following 
transplantation, this TF expression can initiate the coagulation cascade and cause 
thrombosis leading to early cell loss following treating diabetic mice with these cells. 
III) Treatment of ‘islet equivalent’ cells with anti-thrombotic cytotopic agent, based on 
hirulog peptide, prior to transplantation reverses this coagulation cascade partially or 
completely in vitro. This potentially can be used in vivo as a mechanism to improve 
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stem cell survival in the diabetic mouse model and reduces the number of cells 
required to achieve normoglycaemia. 
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2. MATERIALS AND METHODS 
2.1 “islet equivalent” stem cells sources  
2.1.1 Pancreatic-Derived Pathfinder cells 
The Shiels’ laboratory, part of the Division of Cancer Sciences and Molecular 
Pathology, in Glasgow have isolated and characterised a novel population of cells 
from adult rat pancreatic ducts. These cells were found to exhibit the potential to 
differentiate into both pancreatic and hepatic cells types. They termed this cell 
population pancreas derived progenitor cells (PDPCs) and published their findings in 
2009. The exact methods for the isolation of PDPCs and the rest of the in vitro 
characterisation work are described in the paper by Stevenson et al. (Stevensen, 
2009). 
Two subpopulations of PDPC were selected in vitro culture and characterised. These 
were CD90 or Thy1.1 positive (CD90+) and CD90 negative (CD90-) cells. CD90, also 
known in rodents as rat and mouse Thy1 and Thy1.1 respectively, is cell-surface 
protein which is expressed on a variety of cell types including thymocytes, fetal liver 
cells, umbilical cord and mesenchymal stem cells in humans, mice and rats. CD90 is 
now considered a surrogate marker for various kinds of stem cells such as HSC, 
usually in combination with other markers. The function of CD90 has not been fully 
elucidated or understood. It has speculated roles in cell-cell and cell-matrix 
interactions. There is evidence suggesting that it is involved in cell recognition, 
adhesion and signal transduction (Gerhengorn 2004, Hasegawa 2007, Lee 2006, 
Munoz 2005, Zhou 2008). Several studies proposed that the expression of CD90 in 
the adult liver rat oval stem cell population facilitated them to recognize and adhere 
to stromal tissue as potentially repair cells after injury (Colman, 2004,Hasegawa, 
2007,Thorel, 2010,Yagi, 2010). 
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Both PDPC subpopulations expressed pancreatic and duodenal homeobox-1 (Pdx-
1). Pdx-1, also known as insulin promotor factor 1 (IPF1) in humans, is a 
transcription factor necessary for pancreatic development and beta- cell maturation. 
The protein encoded by this gene is an activator of several genes, including insulin, 
somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. 
The encoded nuclear protein is involved in the early development of the pancreas 
and plays a major role in glucose-dependent regulation of insulin gene expression. 
Defects in this gene are a cause of pancreatic agenesis, which can lead to early-
onset insulin-dependent diabetes mellitus, as well as maturity onset diabetes of the 
young (MODY). The detection of Pdx-1 transcriptional expression indicated the 
potential of these PDPC subpopulations to become insulin-producing cells 
(Stevensen, 2009).  
These two subpopulations were distinct when characterised. CD90+ sub-population 
could be induced to differentiate into hepatic cell types expressing albumin and 
storing glycogen typical of mature hepatocytes. These differentiated cells showed 
both morphological and gene expression consistent with hepatic lineage. The same 
population could be induced into pancreatic lineage forming a 3D islet-like structures. 
On the other hand, CD90- subpopulation in pancreatic differentiation medium could 
also be induced into pancreatic lineage but they did not have the same morphology 
observed with CD90+ cells (Stevensen, 2009).  
In pancreatic nicotinamide-containing differentiation media, PDPC subpopulations 
exhibited different morphology. The fibroblast-like CD90+ developed into islet-like 
clusters by 28 days which eventually detached from the parent cell layer while the 
small epithelial-like CD90- cells remained unchanged in morphology at day 28. 
Reverse transcription polymerase chain reaction (RT-PCR) analysis of 
undifferentiated cells demonstrated positive pdx-1 expression but no expression of 
insulin or glucagon in both CD 90+ and CD90- populations. However, differentiated 
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CD90+ cell clusters were positive for the transcriptional markers of all these three 
markers compared to only Pdx-1 and insulin in differentiated CD90- cells (Stevensen, 
2009).  
The isolation of these novel PDPCs into two morphologically distinct subpopulations, 
which in vitro, can both potentially differentiate into insulin-secreting cells led to the 
desire to examine in vivo effects of these sorted cells. In addition, the same group in 
Glasgow was able to isolate and identify similar PDPCs from human pancreatic 
biopsies. In this study, I investigated the in vivo effect of both rat and human PDPCs 
isolated in Glasgow on a diabetic mouse model and examined their coagulation 
properties. 
 
2.1.2 Haematopoeitic stem cells “Omnicytes”  
Habib’s group at Imperial College isolated a subpopulation of CD34+ cells as a 
separate putative stem cell source. These cells have small lymphocyte-like 
morphology, of approximately 7 to 15µm in diameter, adhere to tissue culture plastic 
and in culture produce a population of cells exhibiting diverse morphologies and 
expressing genes corresponding to multiple tissue types. This CD34+ subpopulation 
of cells with these distinct properties was termed “Omnicytes”. CD34+ cells were 
harvest by leukapheresis of G-CSF mobilised peripheral blood progenitor cells from 
donors. Typical yield from this process was 5-10x1010 most of which are 
mononuclear cells and around 1% are CD34+ (5-8x108). These CD34+ cells are 
separated and cultured. The adherent fraction usually constitute about 1% of the total 
CD34+ population. So a typical process would provide 5-10x106 putative stem 
progenitor cells. These cells are then cultured in vitro where 3-4 log expansion in 
number is achievable within 1-2 weeks. This would provide 5-10x109 for clinical 
91 
 
applications. The cell expansion was highly reliable and reproducible in their 
experiments (Gordon, 2006). 
The researchers demonstrated that before and after culture, the adherent CD34+ 
cells and their progeny express an array of gene products as revealed by reverse 
transcription- polymerase chain reaction analysis, flow cytometry and gel 
electrophoresis consistent with various tissue lineages. RT-PCR results indicated 
that adherent CD34+ cells differentiate into cells expressing markers associated with 
liver, pancreas, cardiovascular, muscle and nerve cell tissue as well as 
haematopoiesis. They express Pdx-1, NGN-3 and insulin consistent with pancreatic 
differentiation. It is worth noting that these adherent CD34+ cells express CD38, 
CD33 and HLA-DR. The expression of HLA antigens potentially can make these cells 
susceptible to rejection if used as allogeneic rather than autologous transplant. 
Gordon et al. described the exact methods for the isolation and culture of Omnicytes 
as well as the rest of the in vitro work in the paper published in 2006 (Gordon, 2006).  
In this study, Omicytes were the source of stem cells for in vitro and in vivo work. I 
investigated their vivo effect in a diabetic mouse model and examined their 
coagulation properties. Autologous infusion of insulin-secreting Omnicyte progeny 
was the source of stem cells in the phase I clinical trial described later 3.5. 
 
2.2 In vivo effects of stem cells on streptozotocin-induced diabetes 
The pancreatic beta cells are terminally differentiated and can be ablated by the toxin 
streptozotocin (STZ). Cell-based therapy that might enable or cause a terminally 
non-functional tissue to reinitiate repair process and reform a functional organ would 
be very attractive.  
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The in vivo effect of these PDP cells and Omicytes in a diabetic mouse model was 
investigated at Imperial College under supervision of Professor Anthony Dorling. The 
experiments I performed were based on the hypothesis that these cells could 
contribute to islet formation in vivo as mediators of pancreatic tissue regeneration 
and in turn could potentially be a direct cellular therapy for diabetes.  
 
2.2.1 Isolation and maintenance of PDPCs and Omnicytes 
As described in Stevenson et al. paper, the isolation of rat and human PDPCs was 
performed in Glasgow. Pancreatic ductal tissue was isolated from 12-month old 
Albino Swiss (Glasgow) rats, and from undiseased female human pancreatic biopsy. 
In both instances, tissue was microdissected and minced, prior to seeding in CMRL 
medium (Invitrogen, Paisley, UK). The PDPCs form a confluent monolayer after 
approximately 5 weeks in culture. These were then harvested and washed in 
phosphate-buffered saline (PBS). PDPC were maintained in culture in 20ml of CMRL 
1066 medium supplemented with 10% fetal bovine serum (FBS; Sigma, Poole, UK), 
2mM glutamate, 1.25mg/mL amphotericin B, and 100U/ml Penicillin, 100 mcg/ml 
streptomycin (all Invitrogen, Paisley, UK) in T75 flasks with 0.2μm filter caps 
(Corning,UK) at 37°C in a 5% CO2 atmosphere (Stevensen, 2009).  
Gordon et al. described the method of Omicyte isolation in their paper and performed 
in their lab at Imperial College (Gordon 2006). All blood samples containing the 
CD34+ cells were diluted at 1:4 in Hanks’ buffered saline solution (HBSS; Gibco, 
Paisley, UK) before the mononuclear cells (MNCs) were separated by centrifugation 
over a Lymphoprep (Axis-Shield, Kimbolton, Cambridgeshire, UK) density gradient at 
1,800 rpm for 30 minutes (Heraeus, Hanau, Germany). The MNC fraction was 
collected and washed first in HBSS, then with MACS (magnetic cell sorting) buffer 
(PBS supplemented with 0.5% bovine serum albumin (FBS) and 5mM EDTA). 
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CD34+ cells were isolated from MNCs, using the CD34+ positive cell selection kit 
(MiniMacs; Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated CD34+ cells 
were plated on 35-mm2 Petri dishes in α-minimal essential medium (α-MEM) 
supplemented with 15% fetal bovine serum and incubated for 2 hours at 37°C and 
5% CO2. After 2 hours, the non-adherent cell fraction was removed by washing the 
plates three times. Adherent CD34+ cells were cultured in α-MEM supplemented with 
30% FBS and cytokines (20 ng/ml stem cell factor (SCF), 1ng/ml GM-SCF, 5 ng/ml 
IL-3, and 100 ng/ml G-CSF) at 37°C in 5% CO2 in air (Gordon, 2006). 
Both these cell populations PDPCs and Omnicytes once isolated and cultured, were 
delivered to our laboratory in Imperial College to be used in the work performed in 
this study. 
 
2.2.2 Mouse strain and streptozocin treatment   
I performed these experiments at Imperial College. All animal procedures were 
conducted under the terms of the project licence issued by the United Kingdom 
Home Office under the Animals (Scientific Procedures) Act 1986.  
5 groups of female C57Bl/6 mice (4 animals in each group for the PDPCs 
experiments and 5 animals in each group for the Omnicytes experiments) were made 
diabetic by intraperitoneal injection of streptozocin (Sigma, Aldrich) at a dose of 
250mg/kg on day 0 of the experiment. Streptozotocin, a glucosamine-nitrosourea, is 
a DNA alkylating agent that enters cells exclusively via the GLUT2 glucose transport 
protein. It is a toxic glucose analogue that preferentially accumulates in pancreatic 
beta cells via the GLUT2 glucose transporter. High doses of STZ selectively destruct 
the insulin - producing beta cells and induce rapid and permanent hyperglycaemia in 
mice. This usually takes 3-4 days in mice and 7 days in rats. In contrast, the injection 
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of multiple low doses of STZ generates Hydrogen peroxide and induces the 
expression of GAD autoantigens. This causes the development of delayed and 
progressive hyperglycaemia which may take up to 20-30 days. Chemical induction of 
diabetes with STZ is the most widely used animal mouse model of diabetes mellitus. 
Genetic and surgical models are rarely used because they require highly technical 
skills and the percentage of animals sacrified during the procedures are usually 
higher compared to chemical induction models (Van Belle 2009). The high dose STZ 
diabetic animal model was chosen in all the experiments of this study as it is well 
established, relatively well understood, and it is the most widely used model 
(Colman, 2004,Mansford, 1968,Van Belle, 2009). It is technically simple and results 
in rapid and irreversible hyperglycaemia of the mice which is what was required in 
the study to accurately assess any effect of insulin-secreting “islet-equivalent” on 
glucose levels and beta cell damage.  
STZ was prepared in 20mM citrate buffer (pH 4.5) and used immediately for 
intraperitoneal delivery. This high dose was used to ensure the destruction and 
obliteration of beta cells, to the extent that the untreated control mice would not 
survive long enough to regenerate sufficient pancreatic tissue to alleviate the effects 
of STZ treatment. In this protocol, diabetes is defined as serial non-fasting glucose 
levels, 3 days post-STZ administration of ≥20 mM/L. Severe progressive 
hyperglycaemia under the Home Office licensed and proved protocol is defined as 
progressive rise in serum glucose to ≥ 30mM/L or clinical signs of hyperglycaemia. 
Hence, animals with glucose ≥ 30mM/L or a body weight loss of ≥20% were sacrified. 
 
2.2.3 stem cell infusion  
1.5x106 cells were injected into the tail vein of the animals on day 3 after STZ 
administration. The cells administered were one of the following types unsorted male 
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rat cells, CD90+ male rat cells, CD90- male rat cells, female human PDPCs or day 7 
human adherent CD34+ Omnicytes. In the PDPCs experiments, this infusion was 
repeated on day 10 after STZ administration. All animals receiving Omnicytes had a 
single intravenous infusion of cells but in the initial experiment performed by Dr Daxin 
Chen, a scientist in our laboratory at Imperial College, one of treated animal groups 
were injected with the same number of day 7 human adherent CD34+ Omnicytes 
directly into the pancreas of the animal instead of intravenously into the tail vein. 
Control animals were injected with equal volumes of conditioned culture medium into 
the tail vein at the same time points. Blood glucose was monitored every 3 days for 
the first 4 weeks then weekly until end of the follow up period. Animals were 
weighted weekly throughout the experiment duration. Under the Home Office 
approved protocol, animals were followed up for a maximum of 100 days. 
In the PDPCs experiments, the use of xenogeneic model in which male albino swiss 
rat or human PDP cells were injected into female C57Bl/6 mice facilitated the 
tracking of the transplanted cells and in turn allowed us to address whether the PDP 
cells differentiated in vivo to repair damage, stimulated the host tissue to repair 
damage, or both. 
 
2.2.4 Blood glucose measurement 
In all experiments, two glucose values were determined from a blood sample 
obtained from the tail vein of the animal, and measured using the Ascensia® 
AutodiscTM Blood Glucose Test Sensors (Bayer Healthcare, Berks, UK) following 
the manufacturer’s recommendations. The mean of the two measurements was 
recorded. Blood glucose was monitored every three days for the first four weeks then 
weekly until end of the follow-up period. Animals were weighed weekly throughout 
the experiment duration. 
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2.2.5 Immunosuppression 
The expression of HLA antigens by Omnicytes made them potentially immunogenic 
and possibly susceptible to rejection after transplantation. Hence, Cyclosporine 
(NEORAL® Oral Solution, Novartis), which is a potent immunosuppressive drug, was 
administrated to all animals involved in the Omnicytes studies whether they were 
treated with cells or were control animals. Cyclosporine (CyA) binds with the 
cytosolic protein cyclophilin of lymphocytes especially T-cells. This complex of 
cyclosporine and cyclophilin inhibits calcinuerin, which is responsible for activating 
the transcription of interleukin 2 (IL-2) and in turn interfering with the activity and 
proliferation of T-cells. CyA was diluted in normal saline to 15mg/ml and was injected 
at a dose of 20mg/kg intraperitoneally into all animals daily for 7 days starting on day 
of cellular therapy or control infusion.  
On the other hand, CyA was not used in any of the experiments using rat or human 
PDPCs, as these cells were not believed to be immunogenic. Earlier preliminary 
work in our laboratory, by Dr Daxin Chen, demonstrated that these PDPCs are not 
immunogenic. Administration of cyclosporine at a dose of 20mg/kg as an 
immunosuppressant had no effect on the efficacy of PDPCs in reducing blood 
glucose levels in this animal model of diabetes (Data unpublished). Hence, since 
PDPC are thought to be immunologically null, no immunosuppression was given to 
the animals in any of these experiments. 
 
2.2.6 Tissue harvest and further analysis 
At the end of the experiment follow-up time of 90 days, animals were scarified. Solid 
organs including pancreata from PDPC transplanted and control mice were removed 
and snap-frozen in liquid nitrogen, then embedded in Tissuetek OCT compound (RA 
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Lamb). These were sent to Glasgow for further tissue analysis. Shiels laboratory in 
Glasgow performed immunohistochemistry and fluorescence in situ hybridisation 
experiments. The materials and methods for these examinations were described in 
our paper (Stevensen, 2011).  
Similarly, at end of the experiment follow-up time of 35 days, Omnicyte-treated or 
control animals were sacrificed. Pancreata from CD34+ cell transplant and control 
mice were removed and snap-frozen in liquid nitrogen, then embedded in Tissuetek 
OCT compound (RA Lamb). These were delivered to Prof Habib’s group at Imperial 
College for further tissue analysis (Data analysis not completed). 
 
2.3 In vitro assessment of coagulation properties of stem cells  
Similar to islets, we postulated that following intravenous infusion, stem cells capable 
of insulin secretion i.e. ‘islet equivalent’ (PDPCs or Omnicytes) will provoke an 
inflammatory response and thrombosis, which will lead to significant loss of cell. The 
second hypothesis tested in this study is that these stem cells expressed tissue 
factor on their cell surface that can initiate the coagulation cascade. It has already 
been demonstrated that TF plays an important role in the mechanism of thrombosis 
in islet allo and xenotransplantation (Chapter 1.10.5 and 1.10.6). It follows that 
treatment of TF positive cells prior to transplantation into the diabetic mice with anti-
thrombotic proteins, such as hirudin, may reduce the degree of early cell destruction 
observed due to thrombosis. This can be used as a way to improve the survival of 
these cells post transplantation and optimise their performance. 
To investigate these hypotheses, coagulation or plasma recalcification assays were 
performed to establish if the cells caused in vitro clotting and attempts were made to 
identify the potential mechanism by examining tissue factor expression structurally 
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and functionally as one possible pathway. Pre-conditioning of these insulin-secreting 
cells with anti-thrombotic cytotopic agents was preformed to assess if this treatment 
reverses this procoagulant effect and results in reduced thrombosis and cell loss. 
 
2.3.1 Antibodies 
The primary and secondary antibodies used in plasma recalcification assays (PRA) 
and, immunocytochemistry (ICC), together with appropriate isotype controls, are 
listed in table 3.   
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Antibodies Fluorochrome Concentration 
mg/ml 
Investigations Company 
Rabbit anti-
mouse tissue 
factor IgG 
- 1 PRA and ICC America 
diagnostica inc. 
Polyclonal 
sheep anti-
human tissue 
factor IgG 
- 10 PRA and ICC Affinity 
Biologicals 
Sheep IgG - 0.4 PRA Affinity 
Biologicals 
Rabbit IgG  - 0.4 PRA Santa Cruz 
biotechnology 
Goat anti-rabbit 
IgG 
FITC 0.4 ICC Santa Cruz 
biotechnology 
Donkey anti-
sheep IgG  
FITC 0.4 ICC Sigma-Aldrich 
Table 3: Primary, secondary and isotype control antibodies used in PRA and ICC 
 
 
2.3.2 Hirulog-like cytotopic peptide construct 
The anti-thrombotic cytotopic agent was developed by Richard Smith in the MRC 
Centre for Transplantation at Kings College. It was kindly donated to our group to 
perform these experiments and assess its effect and efficacy in the setting of stem 
cell use in diabetes. The agent used in my experiments is registered as HLL peptide 
(PTL006; with patents/US2012232014) with a molecular weight of 5272 Daltons. It is 
a derivative of hirulog prepared by solid phase synthesis disulphide linked to a 
polyethylene glycol conjugate of phosphatidyl ethanolamine (PEGTAIL-1). It acts as 
an irreversible thrombin inhibitor with membrane-localising properties.  It was 
prepared as a colourless solution at 50μM concentration and stored at -20° . In 
laboratory testing, the peptide was shown to retain potent antithrombin activity when 
bound to cell membranes and can inhibit fibrin clot formation in a re-calcified plasma 
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assay. In these assays, cell-bound hirulog-like peptide inhibits only clotting that is 
initiated by the cells, in contrast to when the soluble peptide is added, when all 
clotting is inhibited, including that induced by the glass tube (section 1.12.1). 
 
2.3.3 Plasma recalcification assay 
1.5 x105 cells were suspended in 50μL tris-buffered saline and mixed with 100μL of 
plasma composed of 90% fresh human plasma and 10% mouse plasma (ICR mouse 
plasma in sodium citrate; Harlan UK Ltd) and 100% fresh human plasma for rat 
PDPC and human Omnicytes respectively in a glass tube (Corning, Corning, NY). 
100μL of 25 mM Calcium chloride CaCl2 in tris-buffered saline was added, and the 
tube was incubated at 37°C in a water bath; the time for fibrin clot to form was 
determined in triplicate, during which the tubes were continuously agitated by tilting. 
The mean and standard error of the triplicate clotting time was calculated for each of 
the re-calcified plasma assay. P-values were calculated using Student’s t-test. 
Rodent TF binds poorly to human factor VII. To measure rat or mouse TF activity, a 
mixture of 10% rat plasma and 90% human plasma is used in this assay. The 10% 
rat plasma provides sufficient rodent factor VII (Morrissey Lab, University of Illinois at 
Urbana-Champaign, Urbana, IL 61801 http://tf7.org/mlabprotocols.htm). 
To test for TF functional expression on the surface of the cells and the effect of the 
cytotopic agent, in some of the clotting assays, cells were treated with one of these 
options; 2.5μl of rabbit anti-mouse Tissue factor (100μl/ml), sheep anti-human TF 
antibody  (1mg/ml), 2.5μl of isotype control for 30 min at 4°C or 250 μl of 50mM anti-
thrombotic cytotopic agent (described in section 2.3.2) for 10 min at 4°C before 
determining clotting times. This last option allows the antibody to bind to the cell 
surface or the cytotopic agent to tether into the cell surface respectively. To test the 
effect of soluble rather than localised anti-thrombotic cytotopic peptide, 167μl of 
101 
 
50μM of this agent was added to the PBS solution in which the cells were suspended 
prior to immediately determining the clotting time. This did not allow time for the 
peptide to tether into the cell surface.  Finally, in some assays, TF- dependent 
thrombin generation requires the participation of FVIIa, and therefore, FVII-deficient 
plasma (Diagnostic Reagents) was used in a separate assay to determine whether 
clotting was TF-dependent.  
The Plasma recalcification assay used in this study is a technically simple and cheap 
test. It is a well-established assay, widely used in experimental work and does not 
require any complex equipment. However, the clotting time does rely on the human 
eye to detect the formation of a fibrin clot. This factor has the potential to introduce a 
higher degree of inaccuracy compared to other complex methods. I attempted to 
minimise this error by taking several steps. There was only one operator for all the 
assays as I performed all the experiments alone. Additionally, each specific test was 
performed  in triplicate and the mean of all 3 clotting times was calculated and finally 
the plasma recalcification assay was repeated at least twice on each type of cells 
assessed.  
 
2.4 Immunocytochemical staining 
200μl of fresh cells at a concentration of 2.5x106 cells/ml were suspended in each 
well of a 96 well tray. The trays were centrifuged at 1800 min-1 for 2 minutes at 4οC. 
Medium was removed by flick/blotting and the pellet resuspended in 200μl of 1% 
bovine serum albumin (BSA). 50μl of these cells were pipetted, mixed with BSA and 
suspended into a well.  Another 50μl of 1% BSA were added to make up 100μl in 
each well. 1-2μl of the primary antibody or control isotype was added to each well 
then the tray was placed on ice for 30 minutes. PBS was used to wash the cells twice 
then the tray was centrifuged again as above for 2 minutes. The medium was 
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removed and 100μl of 1% BSA was added to the remaining pellet in each well. 1-2 μl 
of the secondary antibody was added and the tray was left on ice for 30 minutes. The 
cells were washed again twice with PBS as previously described. Cells in each well 
were diluted with 60μl of PBS. 5μl of this diluted solution was dropped onto a slide 
and allowed to dry completely. Once the cells were dry, they were fixed with 30μl of 
cold 4% paraformaldehyde for 15-20 minutes at room temperature. For immune 
staining, the nuclei were visualized with a mounting medium with DAPI (4,6 diamino-
2-phenylindole; Vecta Shield) was added and then slides were viewed under a 
fluorescence deconvolution microscope (Zeiss Axiovert S100-TV, Zeiss, Germany). 
 
2.5 In vivo assessment of the coagulation properties of stem cells 
2.5.1 Mouse strain and stem cell infusion 
3 groups of female C57Bl/6 mice (3 animals in each group) were made diabetic by 
intraperitoneal injection of streptozocin as described earlier in section 2.2.2. On day 3 
post injection post STZ, 1.5x106 day 7 human adherent CD34+ Omnicytes were 
injected into the tail vein of the first group. The second group of animals received day 
7 human adherent CD34+ Omnicytes that had been treated with the hirulog-like 
peptide (section 2.3.2) by incubation for 10 minutes at 4° prior to infusion. The third 
group was a control group where the animals were injected with equal volumes of 
conditioned culture medium. 30 minutes after intravenous cell infusion, all animals 
were sacrified. Immediate collection of mouse blood was performed via intra-cardiac 
aspiration. This blood was used to obtain plasma and evaluate platelet consumption 
as indirect evidence for coagulation. 
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2.5.2 Evaluation of platelet count 
Platelet-rich mouse plasma was obtained from blood by centrifugation at 80g for 10 
min at 4°C, followed by dilution at 1:20 with 1% ammonium oxalate and 2.5 mM Gly-
Pro-Arg-Pro peptide (Sigma, St Louis, MO). Samples were placed in a counting 
chamber in a moist petri-dish, and the platelets in 1mm2 were counted (N). The 
number of platelets per liter of blood equaled 2Nx109. Mice usually have 3-4 times 
number of platelets when compared to humans. 
 
2.6 Stem cell product for phase I clinical trial 
The isolation and culture of the stem cell product used in the clinical trial entitled 
“Phase I Safety and tolerability study following the infusion of autologous Expanded 
progeny of an adult CD34+ stem cell subset (Insulincytes) to patients with type I 
diabetes mellitus and a successful renal transplant” was performed under GMP 
conditions at the Imperial College Stem Cell Laboratory and John Goldman Centre 
for Cellular Therapy, Hammersmith Hospital.  
Manufacture of the expanded adherent CD34+ stem cells concentrate took place in 
three stages; bone marrow mobilisation and leukapheresis, followed by 
immunoselection and adherence selection of the CD34+ stem cells, and finally 
involves the expansion and differentiation of the immunoselected adherent CD34+ 
stem cells in cell factories with the addition of cell growth media supplemented with 
cell growth cytokines. 
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2.6.1 Registration and ethics for phase I clinical trial 
The trial was registered with ClinicalTrials.gov with identifier NCT00788827 and 
registered with EudraCT 2006-002328-40. Imperial College, London (Protocol Code 
HHSC/005) was the trial’s sponsor. Medicines and Healthcare Products Regulatory 
Agency (MHRA) and Local Research Ethical Committee approval was formally 
granted prior to starting trial. Informed consent was obtained for every patient 
screened for the trial.  
 
2.6.2 Mobilisation of bone marrow   
We know from previous work at Imperial College that “Omnicytes” are 
haematopoietic stem cells that are small and nucleated and bear the heavily 
glycosylated mucin-like surface antigen CD34. So they are early non-differentiated 
haematopoietic cells that are extractable from the peripheral blood circulation of 
individual donors as described in section 2.1.2. 
Granulocyte colony-stimulating factor is commonly used at a dose of 10 mg/kg/day 
subcutaneously to mobilize peripheral blood stem cells (PBSC) from healthy donors. 
Mobilisation of cells expressing CD34 antigen peaks in the peripheral blood between 
days 4 and 5 of G-CSF dosing. Thus, leukapheresis is typically commenced on day 4 
or 5 of G-CSF treatment and is repeated until a target number of CD34+ cells are 
collected (usually ≥4×106/kg). Compared with the graft composition of bone marrow 
harvests, G-CSF mobilized products contain three to fourfold higher CD34+ doses 
(Cashen, 2007). 
Based on these haematological protocols, patients enrolled in the study received a 
daily subcutaneous injection of G-CSF filgrastim (NEUPOGEN® is the Amgen Inc.) 
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at 10µg/kg of for five days to mobilise bone marrow progenitor cells and increase 
numbers of peripherally circulating CD34+ stem cells.  
 
2.6.3 Leukapheresis 
After completion of bone marrow mobilisation, the study participant undergoes 
leukapheresis in the haematology day unit to obtain autologous lymphocytes and 
monocytes containing the CD34+ stem cells fraction needed for the study. Apheresis 
is a laboratory procedure for separating out one particular constituent of blood and 
returning the remainder to the circulation. Leukapheresis is apheresis of white blood 
cells. It is a standard procedure for the isolation of stem cells from the peripheral 
circulation via a central or femoral line. It has been routinely used in patients with 
haematological malignancies requiring HSCT.  
At the end of the first leukapheresis, the total CD34+ cell count isolated was 
measured. If this was found to be below that necessary to obtain sufficient cells for 
expansion and differentiation (less than 1x107 /10mL), the patient will undergo a 
second leukapheresis. In this case, G-CSF treatment was continued for further 24 
hours prior to the second leukapheresis on the following day. Following the 
collection, the labelled leukapheresis product was then transported to the GMP 
manufacturing site for further processing.  
 
2.6.4 Immunoselection and expansion of adherent CD34+ cells 
Immuno-magnetic purification of the CD34+ stem cell subset population was carried 
out in the stem cell laboratory. The collected lymphocytes and monocytes was first 
washed in PBS/EDTA/HAS followed by the addition of a set volume of specific cell 
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type reagent composed of CD34+ antigen coated magnetic beads and following 
mixing, the bag is aseptically connected to the CliniMACS machine. An automated 
process applies the cells to the separation column, performs a series of washes 
depending on the programme selected and finally elutes the purified CD34+ cells. 
The key components of the CliniMACS instrument are an integrated computer, the 
magnetic separation unit, a peristaltic pump and various pinch valves.  The 
integrated computer controls all components of the instrument and directs the system 
to perform procedures in a standard sequence.  The magnetic separation unit 
includes a movable permanent magnet and a holder for the selection column.  The 
peristaltic pump controls the flow rate through the tubing set and 11 pinch valves 
ensure controlled flow of buffer and cell suspension.  Once connected, the system 
works within a closed environment, protecting the product at all stages. 
Adherence selection is achieved by incubating the CD34+ cells in tissue grade 
plastic “cell factories” followed by three washes with more than 100ml saline solution 
to remove the non-adherent CD34+ cells. Following removal of non-adherent cells, 
the cells are resuspended in Alpha medium supplemented with 30% human AB 
serum containing specific concentrations of cell growth cytokines Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF), interleukin-3 (IL-3), SCF, and G-
CSF and human male blood group AB serum.  The cells are then incubated at 37oC 
in 5% CO2 in air for seven days. 
 
2.6.5 Differentiation into “Insulincytes” 
At the end of the 7-day expansion, the progeny of the immunoselected adherent 
CD34+ stem cell were differentiated into insulin and C-peptide expressing cells by 
the sequential addition of the various reagents and growth factors. Glucose was 
added on day 7 (2.5mM final concentration) followed by fibroblast growth factor on 
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day 8 (10ng/mL). Dimethyl Sulfoxide (DMSO, 1% final concentration), butylated 
hydroxyanisole [100M final concentration] and exendin-4 (10ng/mL) were all added 
on day 9. On day 10, glucose (11.1mM final concentration), sodium pyruvate (1mM 
final concentration), fibroblast growth factor (20ng/mL), epidermal growth factor 
(20ng/mL) and exendin-4 (10ng/mL) were also added. Finally, the process ends with 
the addition of glucose (2.5mM final concentration), nicotinamide (10mM final 
concentration), hepatocyte growth factor (100pg/mL), exendin-4 (10ng/mL) and 
activin A (2nM final concentration) on day 14. On day 21, the expanded and 
differentiated cells termed ‘Insulincytes’ were aseptically aspirated from the ‘cell 
factory’ and following a final wash in saline and samples are taken for sterility, total 
nucleated cell count and viability. The aspirated cell culture was volume reduced and 
then packaged for release and use in the study.  At this stage, the Insulincytes are 
sampled for total nucleated cell count and viability, sterility and freedom from 
mycoplasma contamination. 
Figure 12 is a flow chart summarising the manufacturing process from collection of 
autologous leukapheresis product to harvesting of expanded and differentiated 
CD34+ stem cell progeny (Insulincytes).  
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Figure 12: Summary of the manufacturing process of expanded and differentiated CD34+ stem cell 
progeny ‘Insulincytes’ 
 
 
2.6.6 Insulincyte infusion 
On day 21, the autologous expanded progeny of adult CD34+ stem cell subset 
‘Insulincytes’ were injected into either the body or tail of the pancreas of the 
participant.  This procedure was performed by selective catherisation of the splenic 
artery under fluorescent guidance by an experienced radiologist. Prophylactic 
anticoagulation therapy was administered for five days post stem cell infusion to 
avoid cell thrombosis in the form of 20mg subcutaneous enoxaparin (Clexane 
prefilled syringes, Sanofi). Figure 13 reveals intra-arterial digital subtraction 
angiography images of the stem cell product infusion into the pancreas of one of the 
study patients. 
  
Differentiation into Insulincytes 
Volume adjustment and packaging  
Quality Control testing and release for 
autologus infusion 
Immunoselection of  CD34+ cells using the CliniMacs apparatus                       
Selection of Omnicytes (by adhesion to 
plastic) 
Expansion of Omnicytes in a cell factory 
plus growth factors 
Leukapheresis product  
Wash and volume adjustment Mouse anti-human micro-beads added 
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Figure 13: Intra-arterial digital subtraction angiography (IADSA) images of the stem cell product infusion 
into the pancreas of one of the study patients 
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2.7 Statistical analysis 
Significant differences were tested by Student’s t-test between the groups. P value of 
<0.05 was considered significant. All data were presented as the mean ± standard 
error (SE) or standard deviation (SD).                                       
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3. RESULTS 
 3.1 Hypothesis I 
Stem or progenitor cells capable of insulin secretion ‘islet equivalent’ are able to 
reverse diabetic phenotype in a mouse model.  
 
3.1.1 In vivo examination of whether rat and human PDPC treatment 
normalises blood glucose and reverses the diabetic phenotype in a mouse 
model 
To investigate whether PDPCs reversed diabetes, 20 animals were made diabetic by 
the administration of STZ as described in 2.2.1. STZ injection resulted in progressive 
hyperglycaemia with blood glucose levels above 20 mmol/L by day 3 in all animals, 
which met the definition of diabetes in the protocol of the study described in 2.2.1. 
There were 5 groups and each group was composed of 4 animals. The 4 treated 
animal groups were administered one of four cell treatment options intravenously 3 
days post STZ as described in 2.2.2. These cell treatment options were blinded to 
me at the time of the experiment and were marked as cells A, B, C, D. 
Retrospectively, these corresponded to the cell treatment options of mixed 
population of unsorted rat PDPCs (CD90+ and CD90- cells), CD90+ rat PDPCs, 
CD90- rat PDPCs, and mixed population of unsorted human PDPCs (CD90+ and 
CD90- cells) respectively. The subpopulations of rat PDPCs based on CD90 
expression were studied here to determine if they have the same in vivo effect 
despite their distinct morphological differences, gene expression and differentiation 
capabilities (Stevensen  2009). A second infusion of the same cell therapy for each 
group was administered to the animals on day 10 after STZ injection. Mice in the 
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control group were injected with conditioned culture medium into the tail vein at the 
same time points as the treated animal groups. 
All treated animals had gradual reduction in blood glucose after receiving intravenous 
cellular therapy while blood glucose levels continued to rise in animals of the control 
group. Prior to reaching 12 days after STZ induction, these control animals had to be 
sacrificed as glucose measurements reached above 30mmol/L and they became 
profoundly diabetic. On day 9 post STZ injection, all treated animals had significantly 
lower blood glucose than the control group. The results of the experiment are shown 
in figures 14 and 15. Student’s t-test p-value was <0.005 for all treated groups 
compared to the control group as shown in table 4. Cell-treated animals became 
euglycaemic with time. They remained diabetes-free until the end of the experiment 
at 90 days when all the animals were scarified in keeping with the home-office 
licensing conditions.  
Both unsorted rat and human PDPC treated groups demonstrated reduction of blood 
glucose to eventually normal levels similar to pre-STZ treatment. However, this effect 
may have been less pronounced in the earlier stage of the experiment in the mixed 
rat PDPC compared to unsorted human PDPC, CD90+ and CD90- PDPC treated 
animals as shown in figure 15. By day 39, treated animals all had similar 
measurements and maintained this effect until the end of the experiment. The 
explanation for this is unclear but maybe related to the small number of animals or 
the differences in cellular sub-fractions or batch variation. 
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Figure 14: Both unsorted human and rat PDPCs are equally efficacious in successfully reversing 
hyperglycaemia in STZ induced diabetic animals. Mean blood glucose levels in millimoles/L (mmol/L) ± 
SD are shown versus time in days following STZ treatment (day 0) and post PDPCs infusion (day 3 and 
day 10) 
 
 
 
 
  
 
 
Figure 15: Equivalent efficacy of CD90+ and CD90- rat PDPCs in reversing the diabetic phenotype of 
STZ-treated mice. Mean blood glucose levels in mmol/L ± SD are shown versus time in days following 
STZ administration (day 0) and post PDPCs treatment (day 3 and day 10) 
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 Mean glucose level on day 
9 post STZ (mmol/L ± SD) 
Student’s t-test p-value 
Control  36.6 ± 5.0 - 
Unsorted rat PDPCs 22.6 ± 3.5 0.00187 
CD90+ rat PDPCs 16.3 ± 3.2 0.00023 
CD90- rat PDPCs 15.7 ± 2.9 0.00018 
Unsorted human PDPCs 18.5 ± 1.5 0.00022 
 
Table 4:  Mean glucose level for each animal group in mmol/L ± SD on day 9 and Student’s t-test results 
for blood glucose measurements of each of the treated groups compared to the control group 
 
 
A second important observation and consistent with the normalisation of blood 
glucose was that all PDPC-treated animals recovered from an initial loss of body 
mass and then reached a body weight consistent with their age. The appropriate 
animal weight was maintained until the end of the experiment as shown in figure 16. 
This contrasted with the ongoing body weight loss throughout the experiment in the 
control group with their profound hyperglycaemia until they were sacrificed. 
 
 
 
 
Figure 16: Gain of body weight following the infusion of PDPCs into STZ- treated diabetic mice. Mean 
body weight in grams ± SD are shown versus time in days following STZ administration (day 0) and post 
treatment with PDPCs (day 3 and day 10) 
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In summary, xenotransplanted rat and human pancreas-derived pathfinder cells 
delivered intravenously completely reversed the diabetic phenotype of STZ-treated 
mice. All treated animals had normalised glucose measurements irrespective of 
which cellular therapy option they received. So unsorted rat, unsorted human, CD90+ 
and CD90- all resulted in the same outcome of normoglycaemia and reversal of 
weight loss pattern. These data indicate significant insulin secretion has been 
achieved in all treated animals and in turn would be consistent with ongoing 
pancreatic tissue regeneration.  
 
3.1.2 In vivo examination of whether day 7 human adherent CD34+ Omnicytes 
treatment normalises blood glucose and reverses the diabetic phenotype in a 
mouse model 
Preliminary work by Dr Daxin Chen was performed in our laboratory prior to starting 
this study. He used the same method described in 2.2.3 to induce diabetes in 3 
groups of animals with STZ. 3 days after STZ administration, one animal group was 
injected with day 7 human adherent CD34+ Omnicytes (Omnicytes) directly into the 
pancreas of each animal, one group was injected with a similar number of these cells 
intravenously into the tail vein of the animal and the third group acted as a control 
group. All animals received cyclosporine injections as described in 2.2.5. Glucose 
measurements in all groups were monitored for 33 days.  
As demonstrated in figure 17 below, the cellular therapy whether administered into 
the pancreas or intravenously resulted in stabilisation of the glucose levels while 
measured glucose levels continued to increase in the control animals. They became 
progressively and increasingly hyperglycaemic until the end of the experiment (Data 
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not published but copied with permission from Anthony Dorling and Daxin Chen). At 
the end of the experiment follow-up time of 35 days, Omnicyte-treated and control 
animals were sacrificed.  
 
 
  
 
Figure 17: Equal efficacy of intravenous and intra-pancreatic day-7 adherent CD34+ Omnicytes 
treatment of STZ induced diabetic animals in successfully stabilising glucose measurements compared 
to control animals. Mean blood glucose levels in mmol/L are shown versus time in days following STZ 
treatment (day 0) and post cell infusion (day 3). (Unpublished data; permission from A Dorling). 
 
 
Although the diabetic phenotype was not completely reversed in the treated animals 
(i.e. normoglycaemia was not induced), the treatment did halt the progression to 
overt hyperglycaemia. In addition, there was no significant difference on the effect of 
these cells on the animals between the two cell-delivery modalities. Hence, further 
experiments were carried out using the simpler approach of intravenous 
administration of the cellular therapy into the tail of the animals. 
To confirm whether treatment with day 7 human adherent CD34+ Omnicytes has the 
ability to reverse diabetes and to assess whether the earlier findings of Dr Chen can 
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be replicated, 10 animals were made diabetic by the administration of STZ that 
resulted in progressive hyperglycaemia with blood glucose levels above 20 mmol/L 
by day 3 in all mice. On day 3 post STZ, 5 animals were infused with Omnicytes as 
described in 2.2.2 and 5 animals were infused with equal volumes of conditioned 
culture medium at the same time and acted as the control group. Both treated and 
control animals had increasing glucose levels with time at a similar rate. All animals 
had to be sacrificed between 9 and 12 days post STZ injection due to significant 
hyperglycaemia and/or weight loss. The results of this experiment are shown in 
figure 18. Both groups of animals had significant body mass loss by day 6 as 
demonstrated in figure 19. The observed mean weight of animals in both groups 
appears to have increased between day 6 and the end of the experiment on day 12. 
This can be explained by the sacrifice of animals that had ≥20% body weight loss in 
keeping with the home-office licensing conditions during that period leaving only 
animals with higher body mass. 
 
 
 
 
Figure 18:  Day-7 human CD34+ Omnicyte treatment of STZ induced diabetic animals did not reverse 
hyperglycaemia. Mean blood glucose levels in mmol/L ± SD are shown versus time in days following 
STZ treatment (day 0) and post cell infusion (day 3) 
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Figure 19: body weight loss following the infusion of day-7 human CD34+ Omnicytes into STZ- treated 
diabetic mice. Mean body weight in grams ± SD are shown versus time in days following STZ 
administration (day 0) and post treatment with cells or control media (day 3) 
 
 
 
 
Although I repeated this experiment several times, I was unable to show that 
Omnicyte treatment resulted in normalising glucose levels in this diabetic animal 
mode. Additionally, I was unable to reproduce similar results to those demonstrated 
by Dr Chan where therapy with these cells led to glucose level stabilisation and 
partial mitigation of STZ diabetic effect. A possible explanation to this lack of 
reproducibility maybe related to the variability of the cells and the batches.   
In summary, although day 7 human adherent CD34+ Omnicytes under certain culture 
conditions in vitro are able to differentiate into insulin-secreting cells (Gordon 2006), 
the intravenous administration of these cells did not reverse hyperglycaemia in STZ-
induced diabetic animal model. At best, this cellular therapy stabilised glucose levels 
in vivo on one occasion. This effect was not consistent or easily reproducible in vivo. 
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3.1.3 Conclusion of in vivo efficacy of ‘islet equivalents’ 
The results of in vivo work using PDPCs as cellular therapy demonstrated the 
complete reversal of the diabetic phenotype of STZ-treated mice. The outcome was 
similar and sustained for CD90 sorted and unsorted rat PDPCs as well as human 
PDPCs. Data from this experiment indicate significant insulin secretion has been 
achieved in all treated animals and would be consistent with pancreatic tissue 
regeneration by all progenitor cell types.  
The Glasgow group took this work further forward in order to identify the mechanism 
by which PDPCs reversed diabetes in this animal model. Organs and tissues from 
my experimental mice were sent to Glasgow as described in 2.2.6. Members of Paul 
Shiel’s group in Glasgow performed further analysis on this tissue. They reported 3 
salient findings. Firstly, Immunohistochemical examination was supportive of the 
hypothesis that observed normoglycaemia in PDPC-treated animals was the result of 
sufficient insulin production caused by pancreatic beta cells regeneration in these 
animals. They demonstrated that therapy with rat or human PDPCs was associated 
with regeneration of beta cell islets that expressed insulin, glucagon and C-peptide in 
a pattern similar to normal mice at 90 days post therapy (Stevenson 2011). 
Furthermore, using fluorescence in situ hybridization (FISH), the same group showed 
that the majority of the new islet tissue was mouse in origin. Only 0.05-0.018% of the 
signal detected was rat or human in origin.  Xeno- signals from human or rat PDPCs 
were found to be scattered throughout the pancreatic sections indicating that these 
cells were not forming islet-like structures in vivo in comparison to the in vitro findings 
(Stevenson 2009). However, they remained unclear if these xeno-signals came from 
surviving original infused cells or their progeny. Finally, RT-PCR analysis of 
pancreatic tissue in treated animals detected insulin gene (Ins II) transcripts that 
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were both rat and mouse in origin. The majority of the transcripts were mouse- 
derived. The number of rat PDPCs isolated in the pancreatic tissue is sufficient to 
explain the small proportion of observed rat Ins II mRNA. Significantly, Ins I gene 
transcript that is normally only produced during embryonic development in the 
mouse, was also detected in treated animals by RT-PCR studies (Stevenson 2011). 
The conclusion of this work was that the presence of small number of rat and human 
PDPCs in the tissue of treated animals as well as rat gene Ins II transcript indicated 
that these progenitor cells do home towards damaged tissue and differentiate into 
insulin-secreting cells without forming islet-like clusters themselves. However, their 
small number can only have minor contribution to the total insulin made by the 
regenerative pancreas and so could not account for the normoglycaemic recovery 
observed in these animals. The presence of Ins I gene transcript in regenerated 
pancreas was indicative of endogenous repair processes taking place and involved 
developmental reprogramming within the pancreas. (Stevenson 2011). 
Based on these findings, the Glasgow group went on to propose that these adult 
progenitor cells work by stimulating the process of repair in the damaged pancreas of 
the animal probably by activating other host cell types to form new islets. However, 
the exact mechanism of this activation and the nature of host cells involved remain 
unclear. This suggestions would also explain similar in vivo efficacy of both CD90+ 
and CD90- rat PDPCs despite their differences in differentiation capability and 
morphology in vitro. As it was not possible to determine if the injected PDPCs had 
undergone division or not, it is hence unclear whether this regenerative effect was 
due to a subpopulation progeny common to both CD90+ and CD90- cells or applies 
to all parent PDPCs. This proposal is consistent with other published data 
demonstrating initiation of pancreatic endogenous tissue regeneration in vivo by 
bone - marrow derived mouse stem cells (Hasegawa, 2007, Hess, 2003, Lee 2006). 
These host cells are incapable of independent regeneration under these 
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experimental conditions and require the presence of PDPC to be stimulated directly 
or indirectly by paracrine effect for repair. Possible candidates for cell types include 
functionally analogous murine PDPC, islet-derived adult stem cells, Embryonic Stem-
like cells surviving from embryonic development, activated NGN-3+ve facultative 
progenitors and other endocrine or exocrine cells of the pancreas (Zhou 2008, 
Stevenson 2011). 
The in vivo work using the second source of stem cells, Omnicytes, had a different 
outcome in this diabetic mouse model. The intravenous administration of these cells 
did not reverse hyperglycaemia but did stabilise glucose levels in one experiment, an 
effect that was not replicated. Pancreata from Omnicyte-transplanted and control 
mice were removed respectively and were delivered to the Habib’s group at Imperial 
College for further tissue analysis. However, this investigation remains incomplete 
and therefore it is not possible to comment on the engraftment location of the infused 
cells in treated animals or on the presence or absence of any differences in the 
pancreatic tissue and in turn islet architecture between treated and control animals. It 
is also difficult to speculate on the mechanism by which Omnicytes led to glucose 
stabilisation in the treated mice in one of the experiments. 
Several potential explanations can be proposed for the inconsistent effect of 
Omnicytes in this diabetic animal model. Firstly, these cells came from consented 
individuals who underwent bone marrow mobilisation and apheresis either as normal 
volunteers or in most cases due to underlying different haematological disorders or 
malignancies. So although all of the cells were isolated and cultured in a similar 
manner in vitro, the cell batches were very heterogeneous in origin. This may have 
resulted in having a slightly different end product in each of the batches used in 
these experiments.  
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Secondly, Gordon et al. did report that the yield of in vitro differentiation of day-7 
Omnicyte into insulin-secreting cells was very variable and at best was 40% of total 
cells (unpublished data). In my experiments, day-7 human adherent CD34+ 
Omnicytes rather than insulin-secreting differentiated progeny were used to treat this 
diabetic mouse model. So it can proposed that in vivo these cells failed to 
differentiate into insulin-secreting cells or that the number of differentiated insulin-
secreting cells was insufficient to have an effect directly or indirectly on the damaged 
pancreatic tissue of the animals in most of the experiments. The apparent 
dissimilarity between in vitro and in vivo behaviour of these cells could be due to the 
incorrect conditions of the engraftment niche for differentiation into insulin-producing 
cells.  
Thirdly, similar to islet allo and xenotransplantation, it is possible that the intravenous 
delivery of these cells resulted in a significant early cell loss either due to thrombosis, 
as suggested in the hypotheses of this study, or due to acute rejection. It is known 
from earlier characterisation studies that Omnicytes do express HLA antigens 
(Gordon 2006) making them immunogenic and hence susceptible to alloimmune 
injury. Cyclosporine was used as an immunosuppressive therapy and was 
administered regularly in the experiments but may have not protected these cells 
sufficiently to avoid loss caused by rejection. All these 3 potential explanations are 
plausible and maybe all contributing to the observed variable outcome of these 
experiments. 
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3.2 Hypotheses II and III 
II) The insulin secreting cells express tissue factor on their cell surface. Following 
transplantation, this TF expression can initiate the coagulation cascade and cause 
thrombosis leading to early cell loss following treatment of diabetic mice with these 
cells. 
III) Treatment of ‘islet equivalent’ cells with anti-thrombotic cytotopic agent, based on 
hirulog peptide, prior to transplantation reverses this coagulation cascade partially or 
completely in vitro. This potentially can be used in vivo as a mechanism to improve 
stem cell survival in the diabetic mouse model and reduces the number of cells 
required to achieve normoglycaemia. 
 
3.2.1 Assessment of coagulation and tissue factor expression 
In order to test the second hypothesis, I assessed the physical and functional 
expression of TF on the cell surface of “islet equivalents” using plasma recalcification 
assays and immunocytochemistry studies respectively.  
To test the third hypothesis, PTL006 was used as the cytotopic agent in this study. It 
is a hirulog analogue peptide and targets thrombin by binding irreversibly to it.  
Thrombin is a logical and a good target because of its multiple roles in coagulation. It 
converts fibrinogen to fibrin, the final step in the coagulation cascade; it amplifies its 
own generation by feedback activation of FV and FVIII, key co-factors for the 
prothrombinase and intrinsic tenase complex respectively; and it coordinates platelet 
activation and aggregation with coagulation. The inhibition of thrombin not only 
blocks fibrin formation but also attenuates thrombin generation and platelet activation 
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as described in section 1.10. Hence inhibiting thrombin would result in reversing 
thrombosis whether it is due to TF-dependent or TF-independent mechanism. 
Another advantage to using this agent in this setting is that PTL006 has already been 
shown to retain potent anti-thrombin activity when bound to cell membranes and can 
inhibit fibrin clot formation in recalcified plasma assay similar to the assay used in 
these experiments (Dorling 2013; Smith 2012).  
 
3.2.2 Assessment of contact activation clotting time for human and rodent 
plasma 
It is worth mentioning that in assessing coagulation in rodent stem cells and to 
measure rodent TF activity with plasma recalcification assays, a mixture of 10% 
mouse plasma and 90% human plasma was used in the study. We know that rodent 
TF binds poorly to human factor VII so the 10% mouse plasma provides sufficient 
rodent factor VII (Morrissey Lab). In addition, in the absence of any cells, using 100% 
mouse plasma in this recalcification assay to measure the spontaneous contact 
activation clotting time results in less than half of the clotting time observed with 
100% human plasma. This makes it difficult to detect any small significant changes in 
the time measurements especially in assays that result in shortening of the clotting 
time.  
In a titration assay that I performed, the mean spontaneous contact activation clotting 
time for 100% mouse plasma (MP) was 62.7 seconds compared to 153.1 seconds 
for 100% human plasma (HP) as shown in figure 20. Mixing 10% mouse plasma and 
90% human plasma resulted in a clotting time of 112.3 seconds. These results are 
shown in figure 20. This mix provides enough rodent FVII for TF binding and a 
clotting time that is long enough to detect any significant changes with the additions 
of cells or agents. Hence this was the composition of the plasma used in all the 
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following plasma recalcifications assays applied to rodent cells.  
 
 
 
 
 
Figure 20: Titration assay to assess the contact activation clotting time of human vs. mouse plasma 
 
 
3.2.3 Tissue factor positive melanoma rat cell line as control cells for plasma 
recalcification assay 
I used TF positive (TF+) melanoma rat cells as control cells to confirm that both the 
triplicate plasma recalcification assay and the anti mouse/rat TF antibody are working 
appropriately and successfully. The plasma recalcification method used to assess 
clotting time (CT) in this experiment has been described in section 2.7 and the 
results are demonstrated in table 5 and figure 21. The data show significant 
reduction in CT in the presence of cells that express TF on their cell surface 
(p≤0.05). Pre-treatment of these cells with an inhibitory rabbit anti-mouse TF (mTF) 
antibody (Ab) partially corrected that effect when compared to treatment with an 
isotype control antibody but did not reach statistical significant (p=0.08). However, 
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the CT significantly increased with pre-conditioning these TF+ rat cells with either 
higher concentration of mTF antibody at 167μg/ml or the cytotopic agent PTL006 that 
binds to thrombin irreversibly (p≤0.05). Finally, the addition of cells into a solution 
containing PTL006, which having lost the tethering tail is essentially soluble hirulog, 
resulted in complete reversibility of the procoagulant effect of these cells. The CT 
was even greater than the spontaneous contact activation CT found for plasma in 
glass tube (p≤0.05). This perhaps reflects the undesirable systemic over anti-
coagulation observed when non-localised anti-thrombotic agents are applied. 
 
 
 Mean clotting time (seconds ± SE) 
No cells 122.7 ± 0.9 
Cells alone  50.0 ± 0.6 
Cells + rabbit IgG (isotype control) 55.0 ± 3.1 
Cells + rabbit anti mouse TF (16.7μg/L) 63.1 ± 5.5 
Cells + rabbit anti mouse TF (167μg/L) 75.0 ± 2.6 
Cells + PTL006 on cell surface 69.0 ± 3.4 
Cells + PTL006 in solution 190.6 ± 7.3 
 
Table 5: Clotting time in seconds ± standard error (SE) for in vitro plasma recalcification assays with no 
cells, with TF+ melanoma rat cells alone, with the addition of a isotype control antibody, rabbit anti 
mouse TF antibody or PTL006 on the cell surface or in solution 
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Figure 21: Plasma recalcification assay revealing in vitro prothrombotic effect of TF+ melanoma rat cells 
and the significant reversal of this property by pre-conditioning the cells with high concentration rabbit 
anti mTF, PTL006 tethered to the cell surface or in solution. The CT is on the y-axis is in seconds ± SE 
 
 
In summary, this experiment with TF+ control cells confirmed that the plasma 
recalcification assay is working appropriately and that a proportion of the clot 
formation within this assay was TF dependent. Although I did not confirm that the 
maximum concentration of anti-TF Ab used was fully saturating the TF on the cell 
surface of the melanoma cells, 167μl/L was the concentration of the same anti mTF 
Ab used for examining the coagulant properties of rat PDPCs. This experiment also 
demonstrated the anticoagulant effect of the cytotopic peptide PTL006. 
It is important to mention at this stage that there were no TF+ human cells available 
to be used as control cells for confirmation that anti human TF antibody are working 
appropriately and successfully.  
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3.2.4 In vitro examination of the coagulation properties of PDPCs and 
whether this property can be reversed with anti-thrombin cytotopic peptide. 
Having established that transplanted rat and human PDPCs successfully reverse the 
diabetic phenotype of STZ- treated animals, the next step was to assess if these 
cells lead to thrombosis in vitro as a potential mechanism for in vivo early cell loss 
post infusion.  
To examine if rat PDPCs resulted in coagulation, triplicate plasma recalcification 
assays were preformed as described in 2.7. The results of these experiments are 
shown in table 6 and figure 22. The data shows that in vitro CT was reduced 
significantly from 127 seconds to almost 40 seconds in the presence of PDPCs 
(p≤0.05). The CT for pre-conditioned cells with 167μl/L rabbit anti-mouse TF antibody 
was not significantly different to that of cells treated with isotype control antibody 
(p=0.24). However, the CT did significantly rise in the presence of pre-conditioned 
PDPCs with PTL006 or in the presence of these cells in solution with PTL006. It 
increased from 39.7 seconds to 57.3 and 174 seconds respectively (p≤0.05).  
 
 
 Mean clotting time (seconds ± SE) 
No cells 127.0 ± 2.6 
Cells alone 39.7 ± 2.4 
Cells + rabbit IgG (isotype control) 43.3 ± 1.8 
Cells + rabbit anti mouse TF 39.7 ± 2.0 
Cells + PTL006 on cell surface 57.3 ± 1.5 
Cells + PTL006 in solution 174 ± 4.1 
 
Table 6: Clotting time in seconds ± SE for in vitro plasma recalcification assays of PDPCs alone, with 
the addition of an isotype control antibody, rabbit anti mouse TF antibody, PTL006 tethered to the cell 
surface or cells with PTL006 in solution respectively  
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Figure 22: Plasma recalcification assays revealing the significant prothrombotic effect of PDPCs. It 
shows partial and complete reversal of this property by PTL006 when tethered to the cell surface and 
when present in solution respectively.  The pre-conditioning of PDPCs with the inhibitory anti mTF did 
not result in significantly changing the CT compared to cells pre-conditioned with isotype control 
antibody  
 
 
 
These results indicate that the PDPCs have a prothrombotic property that was not 
altered by inhibiting tissue factor with the highest concentration of rabbit anti-mouse 
TF antibody. Despite this apparent lack of TF involvement, the prothrombotic effect 
of these cells was partially mitigated by the tethered form of cytotopic peptide 
PTL006 and was reversed completely when this agent was added into the solution in 
which PDPCs were suspended. Similar to the findings of TF+ control cells 
experiment described in 3.2.3, CT for PDPCs in the presence of the soluble form of 
PTL006 exceeded that of the intrinsic contact activation CT of plasma alone. These 
results were reproducible on two other sets of rat PDPCs. Due to limited stem cell 
number, I did not have access to sufficient human PDPCs that would allow 
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examination of these cells to elucidate whether they exhibit the same effect as rat 
PDPCs on coagulation or not. 
In summary, these findings are consistent with the hypothesis that PDPCs are 
procoagulant in vitro and they suggest that the prothrombotic phenotype is possibly 
TF-independent. There are several possible explanations to the observations found 
in this experiment and will be discussed in 3.2.7.  
 
3.2.5 In vitro examination of the coagulation properties of day 7 human 
adherent CD34+ Omnicytes and whether this property can be reversed with 
anti-thrombin cytotopic peptide. 
To examine if Omnicytes resulted in thrombosis, triplicate plasma recalcification 
assays were preformed as described in 2.7. To assess reproducibility of the results, I 
repeated the same experiment with several different batches of day-7 human CD34+ 
Omnicytes on the same day and on separate days. Two important findings were 
consistent and reproducible in all these experiments. Firstly, similar to rat PDPCs, 
the data confirmed that day-7 adherent CD34+ Omnicytes were prothrombotic in 
vitro. They have a procoagulant property demonstrated by shortening of the CT when 
these cells are added to human plasma. Secondly, thrombin inhibition by the 
application of PTL006 locally on the cell surface or systemically in the solution 
resulted in the reversibility of coagulation caused by these cells. In all the 
experiments, pre-conditioning Omnicytes with anti-thrombin cytotopic PTL006 did 
significantly increase the CT back to spontaneous contact activation CT when 
compared to untreated cells. On the other hand, the addition of PTL006 into the 
solution in which the cells were suspended led to CT elevation beyond the observed 
baseline CT with plasma alone.  
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The next question of whether coagulation caused by Omnicytes was TF-dependent 
or TF-independent was more difficult to answer due to inconsistent results. There 
was variability in whether TF is functionally expressed on these cells or not. Only 
50% of the cell batches demonstrated significant partial reversibility of the coagulant 
effect by pre-treatment of the cells with sheep anti-human TF (hTF) antibody.  
Binding of the inhibitory sheep anti-hTF antibody to TF led to significantly longer CT 
compared to cells treated with isotype control antibody (p≤0.05). The results of one 
of these experiments are shown in table 8 and figure 21. These findings are 
suggestive of TF playing a pivotal role in thrombosis caused by these cells since 
inhibiting it partially mitigated the procoagulant effect. In contrast, the other 50% of 
the cell batches revealed no significant difference in the CT whether the cells were 
pre-conditioned with sheep anti-hTF antibody or isotype control antibody (p≥0.05). 
The results of one of these experiments are shown in table 7 and figure 23. This 
would indicate that inhibiting TF did not interfere with coagulation caused by these 
cells and in turn suggests that clot formation within the assay was TF-independent.  
 
 
 Mean clotting time (seconds ± SE) 
 
No cells (spontaneous) 192.3 ± 0.7 
Cells alone 89.0 ± 3.1 
Cells + sheep IgG (isotype control) 83.0 ± 2.6 
Cells + sheep anti human TF 108.7 ± 2.2 
Cells + PTL006 on cell surface 182.3 ± 12.0 
Cells + PTL006 in solution 293.3 ± 29.4 
 
Table 7: Clotting time in seconds ± SE for in vitro plasma recalcification assays of Omnicytes alone, 
Omnicytes with the addition of a isotype control antibody or sheep anti-human TF antibody, 
preconditioning the cells with PTL006 or the addition of PTL006 to the solution in which Omnicytes were 
suspended respectively 
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Figure 23: Clotting time in seconds ± SE of in vitro plasma recalcification assays for CD34+ Omnicytes. 
It reveals the procoagulant effects of these cells and reversibility of this effect by pre-treatment of the 
cells with sheep anti-hTF Ab, tethered PTL006 or in the presence of PTL006 in solution respectively 
 
 
 Mean clotting time (seconds ± SE) 
 
No cells 183 ± 12.7 
Cells alone 109.7 ± 3.5 
Cells + sheep IgG (isotype control) 122.3 ± 1.5 
Cells + sheep anti human TF 128.7 ±7.4 
No cells + FVII deficient plasma 162.0 ± 9.5 
Cells + FVII deficient plasma 142.3 ± 1.5 
Cells + PTL006 on cell surface 172.0 ± 3.0 
 
 
Table 8: Clotting time in seconds ± SE for in vitro plasma recalcification assays with no cells and in the 
presence of Omnicytes in normal plasma and in Factor VII (FVII) deficient plasma respectively. It also 
demonstrated the CT for pre-treated Omnicytes with a control antibody, sheep anti human TF (hTF) 
antibody or PTL006 
  
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
340
C
lo
tt
in
g
 t
im
e
 (
S
e
c
o
n
d
s
) 
p=0.011 
_________________________________________ 
 
p=6.6×10-4 
______________ 
 p=0.002 
____________ 
 
p=0.004 
______________ 
 
133 
 
 
 
 
Figure 24: Plasma recalcification assays revealing greater reduction of the CT in the presence of 
Omnicytes in normal plasma compared to Factor VII (FVII) deficient plasma. CT was unchanged with 
cells pre-treated with sheep anti human TF (hTF) antibody. The procoagulant effect was reversed when 
cells were pre-treated with PTL006 
 
 
 
However, it is important to highlight that on this occasion the plasma recalcification 
assay was performed on Omnicytes using normal plasma and factor VII deficient 
plasma respectively. As described earlier, the initiation phase of coagulation by the 
extrinsic system involves binding of TF to a small amount of circulating factor FVIIa 
(section 1.10.1). Using FVII deficient plasma would be expected to inhibit TF-
dependent coagulation from taking place and was used as another test for examining 
TF activity. As demonstrated in table 8 and figure 24, the addition of cells to normal 
plasma reduced the CT from 183 seconds to 109 seconds, which is a 40% reduction. 
Pre-treatment with anti-hTF antibody did not increase the CT. On repeating the 
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assay using FVII-deficient plasma, the addition of the cells did cause a statistically 
significant reduction in CT but the percentage change was very small. The CT 
decreased from 162 seconds to 142 seconds, which is only a 12% reduction. In this 
experiment, although inhibiting the TF pathway did not prevent the cells from causing 
significant clotting, it did result in a much smaller percentage reduction in the CT. 
This suggests that the absence of FVII did impair the clotting induced by the cells i.e. 
that TF is contributing little to the clotting here which is not consistent with the result 
of the inhibitory anti-TF antibody test. One possible explanation could be that the 
inhibitory anti-hTF antibody was either non-functional or used in too small 
concentration for saturation of TF expressed on surface of these Omnicytes in this 
experiment. However, they do suggest that for the 50% of omnicytes that presented 
this pattern in the clotting assays, TF contributed little to the prothrombotic tendency. 
In summary, these findings are consistent with the hypothesis that Omnicytes are 
prothrombotic in vitro and that this effect is reversed with the application of PTL006.  
It is however unclear if this prothrombotic phenotype is TF-dependent, TF-
independent or both. This has several potential explanations which will be discussed 
in 3.2.7 and certainly needs further investigations. 
 
3.2.6 Do “islet-equivalents” express tissue factor? 
Immunocytochemistry is a very well established method for detecting the presence of 
proteins or antigens on the cell surface. The key in this assessment is the primary 
antibody used to detect the protein, which is TF in this study. Hence, rabbit anti-
mouse TF and sheep anti- human TF antibody were selected for the examination of 
rat PDPCs and human Omnicytes respectively. 
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TF+ melanoma rat cells, from the same cell line used in 3.2.3, were tested as 
positive control cells for immunocytochemistry analysis. Rabbit anti-mouse TF 
primary antibody and goat anti-rabbit antibody IgG - FITC fluorescein conjugated 
secondary antibody were used in immunocytochemistry study as described in section 
2.5. Once the cells were dry and fixed, mounting medium with DAPI was added and 
then the slides were viewed under a fluorescence deconvolution microscope. Figure 
25 reveals the result of the analysis and demonstrates the absence of the expected 
FITC green fluorescein since these rat cells are known to express TF on their cell 
surface. I repeated this experiment on another occasion with the same cell line but 
obtained a similar negative outcome.  
 
      
Figure 25: Immunocytochemistry of TF+ melanoma rat cells. There is no evidence of the expected 
green fluorescein conjugated to the secondary antibody since these rat cells were known to express TF 
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These unexpected results could be explained by a problem in the cells themselves or 
in the experimental technique either due to human error in applying the method or 
due to non-functionality/low concentration of the antibody used. The same rat cells 
were positive for TF in the functional assays described in 3.2.3 indicating that they 
were not the source of the negative outcome. Additionally, the primary rabbit anti-
mouse TF antibody used here successfully inhibited TF appropriately in the 
functional assays in 3.2.3 and 3.2.5 and so this would go against it being the limiting 
step for the expected positive outcome. It is hence more likely that human error in the 
experimental technique have led to this negative result. Due to time limitation, I did 
not explore this likely occurrence. Ideally, I should have performed further analysis to 
identify the limiting step in the experimental method and in turn correct it to get the 
appropriate expected outcome prior to testing other cells. 
Despite unsuccessful outcome with the positive control rat cells and due to time 
constraint, I proceeded to perform further immunocytochemistry analysis to examine 
if TF expression on cell surface of rat CD90+ PDPCs and day-7 human adherent 
CD34+ Omnicytes is the possible trigger for initiating coagulation caused by these 
cells. In immunocytochemistry experiment of rat PDPCs, the same primary and 
secondary antibodies as in the study of rat TF+ melanoma cells described earlier 
were used. For immunohistochemistry assessment of Omnicytes, sheep anti-human 
TF primary antibody and donkey anti-sheep IgG - FITC fluorescein conjugated 
secondary antibody were used and applied as described in section 2.5.  
The results of these experiments demonstrated no apparent evidence for physical 
expression TF on the cell surface of neither rat PDPCs nor Omnicytes. Figures 26, 
27 and 28 show the lack of the green fluorochrome that would be expected to be 
observed in the presence of TF on the surface of these cells. The same negative 
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results were obtained on repeating these immnunocytochemistry studies on a 
different set of both rat PDPCs and Omnicytes at a different time point. In view of 
limited stem cell source, these analysis were not performed on rat CD90- PDPCs 
and human PDPCs. 
 
          
 
 
Figure 26: Immunocytochemistry analysis of rat PDPCs cells. There is no evidence of the green 
fluorescein conjugated secondary antibody possibly suggesting possible absence of TF on the cell 
surface these cells 
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Figure 27: Higher power of immunocytochemistry analysis of rat PDPCs cells 
         
 
 
 
          
 
Figure 28: Immunocytochemistry of day-7 human CD34+ Omnicytes. There is no evidence of the green 
fluorescein conjugated secondary antibody suggesting possible absence of TF on the cell surface of 
these cells 
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It is not possible to make any conclusions from these immunocytochemistry analyses 
since the same experiment on positive control cells did not give the expected 
affirmative outcome. Therefore, the absence of green fluorescein in this setting does 
not necessarily confirm the lack of TF expression on the cell surface of PDPCs and 
Omnicytes respectively. 
 
3.2.7 Conclusion of in vitro examination of “islet equivalents” 
Findings of in vitro assessment of PDPCs did support the hypothesis that these cells 
are prothrombotic and that this property can be reversed partially or completely by 
tethered and soluble form of PTL006 respectively. The data also suggested that the 
prothrombotic phenotype is possibly TF-independent.  
However, it is difficult to be certain and conclude that PDPCs do not express TF and 
that their procoagulant phenotype is TF-independent before investigating this further. 
One possible explanation for the results obtained is that insufficient TF inhibition 
occurred to demonstrate a significant effect on coagulation and in turn prolong CT.  
The highest concentration of rabbit anti-mTF antibody used in the plasma 
recalcification assays may have not saturated TF expressed on the surface of these 
PDPCs. Hence, prior to making any conclusion, it is essential to investigate this 
possibility by titrating increasing concentrations of anti-mTF antibody in the plasma 
recalcification assays and reassessing the functional expression of TF on PDPCs on 
each occasion. Additionally and in view of immunohistochemistry technique failure, 
other experimental methods, such as flow cytometry and RT-PCR, should also be 
applied to these cells to investigate whether TF is expressed on their surface or not. 
If these assessments confirm negative expression for TF, only then it can be 
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concluded that PDPCs do not express TF and can be speculated that they cause 
coagulation in vitro via a TF- independent mechanism. This second explanation is 
also possible but less likely. 
Although in most cases, coagulation in vivo is triggered by TF, there is published 
literature reporting the identification of an inducible prothrombinase that acts in a TF-
independent pathway, termed Fgl2/fibroleukin. It has been shown to contribute to 
immunologically mediated thrombosis in experimental and human viral hepatitis and 
in acute vascular xenograft and allograft rejection (Ghanekar 2004; Marsden 2003). 
Levy et al. demonstrated that the pathways by which vascular thromboses are 
elicited in viral hepatitis are mechanistically distinct from the classical pathways of 
coagulation induced by trauma or bacterial lipopolysaccharide (LPS). Activated 
endothelial cells and macrophages express distinct cell-surface procoagulants 
important for both the initiation and localisation of fibrin deposition in viral-induced 
liver disease. Fgl2/fibroleukin was initially identified as one of these procoagulants 
induced by murine hepatitis virus type-3 (MHV-3) infection (Parr 1995). The same 
group went on to successfully generate an fgl2/fibroleukin-deficient mouse. They did 
not demonstrate any baseline alterations in standard haematological and coagulation 
profiles or bleeding times between mice infected with the MHV-3 whether they were 
fgl2/fibroleukin-deficient or not.  They did however show that fibrin deposition and 
liver necrosis were markedly reduced and that survival was increased in 
fgl2/fibroleukin-deficient animals. There was failure of induction of fgl2/fibroleukin 
mRNA expression and lack of procoagulant activity in peritoneal machrophages 
isolated from these deficient mice. In contrast, the response to LPS, which induces 
TF/FVII-dependent procoagulant activity in peritoneal macrophages, was unaffected 
in fgl2/fribroleukin deficient mice compared to gfl2/fibroleukin positive mice (Marsden 
2003). In the same paper, they addressed the relevance of fgl2/fibroleukin in human 
viral hepatitis. They demonstrated the expression of Fgl2 mRNA in endothelial cells 
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and macrophages of liver from hepatitis patients. They also showed that expression 
of fg2l/fibroleukin mRNA and protein varies markedly in patients with marked chronic 
hepatitis B versus those with minimal chronic viral hepatitis B. Expression of 
f2gl/fibrleukin is highly associated with fibrin expression. 
In 2001, Levy et al. reported the isolation and functional expression of a distinct 
human prothrombinase termed Fgl2/fibroleukin. Human Fgl2-encoded protein is a 
serine protease that bypasses the TF/FVII extrinsic pathway and directly cleaves 
prothrombin to thrombin. Stimuli known to induce expression of the fgl2/fibroleukin 
mRNA and protein such as interferon gamma (INFγ) treatment, MHV-3 viral infection 
and xenotransplantation are distinct from those that elicit TF/FVII-dependent fibrin 
generation such as LPS. In contrast to FXa, the Fgl2/fibroleukin prothrombinase 
activity is not inhibited by anti-thrombin III and is not dependent on FVII. The function 
of constitutively expressed Fgl-2 remains to be conclusively determined and is the 
subject of ongoing studies (Levy 2000; Yuwaraj 2001). 
Grant et al. examined the role of fgl2 in acute vascular rejection (AVR) in xenografts. 
They reported that porcine kidney xenografts undergoing AVR showed induction of 
Fgl2 on graft vascular endothelial cells (Ghanekar 2004). They also demonstrated 
that deletion of Fgl-2 in the donor ameliorates AVR in a mouse-to-rat cardiac 
xenotransplantation model. Grafts from deficient mice had reduced fibrin deposition 
but developed cellular rejection. There was up-regulation of Fgl2- mRNA expression 
while TF mRNA levels declined in association with progression of AVR in donor 
grafts from wild type mice (Mendicino 2005). They explained that the diverging 
pattern of total graft mRNA TF and Fgl-2 expression during xenograft rejection 
suggests that these genes respond to different regulatory stimuli, consistent with in 
vitro studies that have shown that induction of TF expression on porcine EC by 
human serum is predominantly mediated by antibody and complement, whereas Fgl-
2 expression is not induced by media containing complement or isolectin B4 (a 
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substitute for anti-alpha-GAL-specific antibody) (Ghanekar 2004). They speculated 
that Fgl-2 may contribute to the previously described TF- independent coagulation 
activity of porcine endothelial cells, complete neutralization of which required the 
addition of hirudin, a thrombin inhibitor (Chen D 1999a).  
The same group also examined the role of this prothrombinase in allorejection. In a 
heterotopic cardiac transplant model, treatment of wild-type mice with neutralizing 
anti-Fgl2 antibody ameliorated histological evidence for allorejection and 
intravascular fibrin deposits and resulted in increased graft survival. They examined 
kidney biopsies from patients who had undergone renal transplantation. Human Fgl-2 
mRNA transcripts and proteins expression was in association with fibrin deposition 
location and correlated with the presence of rejection (Ning 2005). 
This prothrombinase Fgl2/fibroleukin could be a potential candidate for the trigger of 
the clotting effect of rat PDPCs in vitro via a TF-independent pathway by directly 
cleaving prothrombin and generating thrombin. This would also explain the 
discordant reversal of this effect by the hirulog-like cytotopic PTL006 as it binds 
thrombin irreversibly. However, Fgl-2 has been reported in the literature so far to be 
an inducible prothrombinase and its role in the absence of an inducible stimulus such 
as viral infection, rejection, or INFγ is not determined. In the in vitro studies, PDPCs 
were not stimulated with one of the known stimuli for Fgl-2/fibroleukin prior to the 
plasma recalcification assay but they have been in culture in the presence of added 
growth factors for a number of weeks. This could have been a trigger for the 
prothrombinase induction though unlikely. 
One can speculate that PDPCs may constitutively express Fgl-2 at low levels 
sufficient to result in coagulation in vitro but whether this effect is sustained and 
significant in vivo remains to be determined. This question can be answered firstly by 
investigating whether fg2l/fibroleukin mRNA and protein are expressed in PDPCs or 
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not and secondly by performing clotting studies of the animals in the immediate 
period after intravenous infusion of PDPCs to determine the level and in turn 
significance of coagulation activity as a result of this cellular therapy. These tests 
could include the extent of platelet consumption and the levels of fibrinogen and 
fibrinogen degradation products (FDP) which are indirect measure of thrombin 
generation. FDP are components of the blood produced by clot degeneration by the 
action of plasmin on deposited fibrin. The most notable subtype of FDP is D-dimer 
(section 1.10). If this effect does take place in vivo then PDPCs can potentially be 
lost through early thrombosis following transplantation into diabetic animals. 
Treatment of these ‘islet equivalent’ cells with anti-coagulation proteins, such as 
PTL006, prior to transplantation could reduce the degree of early cell destruction due 
to thrombosis. 
It has been shown that infused PDPCs do survive and reverse diabetic phenotype in 
STZ treated diabetic mice (section 3.1.2). This indirectly suggests that even if this 
thrombotic event takes place after transplantation of these cells, it does not lead to 
complete destruction of all the cells. Human PDPCs come from pancreatic tissue of 
biopsies or unsuitable transplant organs making the source of the cells limited to a 
certain extent. In turn, pre-treatment of the cells with anti-thrombin cytotopic agent 
such as PTL006 prior to infusion can be used as a way to optimise the number of 
cells required for reversing diabetes. 
Similar to PDPCs, findings of in vitro assessment of Omnicytes are consistent with 
the hypothesis that these cells are also prothrombotic and that this effect can be 
reversed with the application of PTL006.  It is however unclear if this prothrombotic 
phenotype is TF-independent, TF-independent or perhaps involving both 
mechanisms. The other question left unanswered is whether the prothrombotic 
phenotype and lack of efficacy at reversing diabetes in mice are connected. 
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The variability in the in vivo results with different batches of Omnicytes reported in 
3.1.2 parallels the variability observed in in vitro functional assays and so one 
possible explanation is the heterogeneity of phenotype between batches rather than 
inconsistencies with experimental technique. The inter-variability of different cell 
batches may have been influenced by the origin of the cells, which was diverse, and 
by the accurate reproducibility of the same end product (3.1.3). We know that 
Omnicytes have varying capacity to differentiate into insulin-secreting cells in culture, 
therefore it can be speculated that this cell inter-variability may have led to a varying 
extent of TF expression on the cell surface and hence the mixed results obtained. 
However, there are several findings of some of these experiments that introduces 
some doubt about the antibody used and suggest that the variable capability and 
efficacy of the anti-hTF antibody in inhibiting TF could be a more likely plausible 
explanation for the inconsistent results. One disadvantage and dissimilar to the anti-
mTF antibody, the human antibody was not tested on TF positive human control cell 
line prior to using it to assess Omnicytes in the plasma recalcification assays. This is 
due to the lack of such a cell line but the control experiment would have been useful 
in testing the anti-hTF antibody and reassuring if the results were as expected 
positive. Doubt about the antibody was confirmed using FVII deficient plasma in the 
clotting assay. It demonstrated that the absence of FVII did impair the clotting 
induced by the cells suggesting that TF might be involved, although only to a small 
extent.  
On the other hand, when used to assess Omnicytes, the anti-hTF antibody did not 
always result in a negative outcome. In fact, in 50% of the assays, the results were 
significantly positive and consistent with the antibody inhibiting TF. This points to 
functional anti-TF antibody but perhaps on occasions too small antibody 
concentration used to saturate the TF on the surface of Omnicytes which may well 
have differing degree of TF expression. Further experiments are needed with higher 
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concentrations of anti-hTF to determine if this is sufficient to unify and then 
reproduce the results and in turn support the conclusion that Omnicytes cause 
clotting via a TF-dependent pathway. 
In summary, for now it can be concluded that day-7 human adherent CD34+ 
Omnicytes have a universal procoagulant property but the universal functional 
expression of TF in these cells is not confirmed. There is however some evidence to 
suggest that TF-dependent mechanisms may be involved in thrombosis caused by 
these cells. Finally, this universal prothrombotic effect of Omnicytes was successfully 
mitigated by pre-treatment of the cells with anti-thrombin cytotopic agent. This leads 
to the potential use of this agent as a localised anti-thrombotic therapy to improve 
cell survival and performance post infusion. 
 
3.2.8 In vivo assessment of the coagulation properties of day 7 human 
adherent CD34+ Omnicytes 
Functional assays described earlier in 3.2.5 confirmed that Omnicytes are 
prothrombotic in vitro and that this effect can be reversed with the cytotopic agent 
PTL006. The next step was to assess if these cells cause coagulation in vivo and 
whether pre- treatment with this agent protects against this process. This was 
addressed by assessment of indirect evidence for coagulation in animals that have 
been infused with untreated and pre-treated Omnicytes respectively. 
3 groups of mice were made diabetic by STZ administration and on day 3 post STZ, 
the first group of 3 animals were infused with untreated Omnicytes and the second 
group received Omnicytes that had been pre- treated with the PTL006 as described 
in sections 2.2.2 and 2.2.3. The third group was a control group where the animals 
were injected with equal volumes of conditioned culture medium. Half an hour after 
146 
 
intravenous cell infusion, all animals were sacrificed. Immediate collection of mouse 
blood was performed via intra-cardiac aspiration. This blood was used to obtain 
plasma and evaluate platelet consumption as indirect evidence for coagulation 
following control or cellular therapy. Mean platelet count was calculated as described 
in section 2.5.2.  
The results are shown in table 9 and figure 29. Cellular infusion resulted in 43% 
reduction in mean platelet count from 1.04 x106 to 0.59 x106 indicating platelet 
consumption and in turn clotting but it did not reach statistical significant (p=0.07). On 
the other hand, infusion with Omnicytes pre-treated with anti-thrombin agent PTL006 
protected against this effect as demonstrated by preserved mean platelet count in 
this group of animals. This trend is very suggestive that the cellular treatment is a 
trigger of a coagulation leading to probable fibrin clot formation, thrombosis and 
resulting in a thrombocytopenia as platelets are sequestered in the clot. The results 
also suggest that this effect is preventable by the presence of PTL006 tethered to the 
surface of the cells infused. In vivo, this means that the agent will have a localised 
anti-thrombotic effect without the unwanted and undesirable side effects of systemic 
anticoagulation. Further experiments are needed to confirm the reproducibility of 
these results and to determine if this prothrombotic effect is significant and consistent 
with different batches of Omnicytes. 
 
 
  
Mean platelet count x10
6
/μL ± SE 
Control animals 
 
1.04 ± 0.29 
Animals injected with CD34+ Omnicytes 
 
0.59 ± 0.14 
Animals injected with pre-treated CD34+ 
Omnicytes with PTL006 
1.40 ± 0.15 
 
Table 9: Mean platelet count x10
6
/μL ± SE in control animals, animals treated with day-7 human 
adherent CD34+ Omnicytes and the same cells pre-treated with anti-thrombin PTL006  
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Figure 29: Mean platelet count x10
6
/μL ± SD in control animals, animals treated with day-7 human 
adherent CD34+ Omnicytes and the same cells pre-treated with anti-thrombin hirolug-like PTL006 
respectively. It shows platelet count reduction with cell infusion while this count is preserved when pre-
treated cells were infused 
 
 
 
I was unable to repeat this experiment to confirm my initial findings due to limited 
supply of Omnicytes. Additionally, due to restricted source of rat and human PDPCs, 
I did not get the opportunity to perform these experiments using PDPCs to assess in 
vivo procoagulant properties of these cells. Other assays that could also be used to 
detect coagulation activity are indirect measurements of in vivo thrombin generation 
in the plasma collected after stem cell infusion such as the levels of fibrin 
degradation products including d-dimers and the levels of activation peptides such as 
prothrombin fragment.   
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3.3 Phase I Safety and tolerability study following the infusion of 
autologous expanded progeny of an adult CD34+ stem cell subset 
(Insulincytes) to patients with type I diabetes Mellitus and a successful renal 
transplant 
Professor Charles Pusey was the Principal investigator of the trial. There were 5 co-
investigators: Prof Vassilios Papalois, Prof David Taube, Prof Jane Apperley, Dr Paul 
Tait and Prof Nagy Habib. The clinical trial monitor was Niekol Rombaut. I joined the 
team of the trial after the protocol has been established and the initial ethics approval 
was pending. Once part of the team, I was involved in every process related to the 
study from then onwards. This included several amendments of the protocol, 
applying for MHRA and ethics approvals for these amendments, consenting, 
screening and enrolling patients into the trial. Once a patient was recruited into the 
study, I was responsible for organising the various steps of the protocol by 
collaborating with the different departments (The haematology department, Imperial 
College Stem Cell Laboratory and John Goldman Centre for cellular therapy stem 
cell lab and the radiology department), assessing the patient at follow up visits and 
completing the Case Report Forms (CRF). I also worked closely with the study 
monitor at every stage to ensure all the necessary steps have been taken for a safe 
and successful clinical study. 
Details for the formal registration of the trial, MHRA approval and ethics approval 
were described earlier in section 2.6.1. 
 
 
3.3.1 Rationale to the study 
As reported earlier in section 2.1.2, the Habib’s group at Imperial College isolated a 
subpopulation of CD34+ cells as a separate putative stem cell source that they 
149 
 
termed “Omnicytes”. These isolated CD34+ Omnicytes are able to differentiate into 
multiple tissue types ex vivo including hepatocytes (Gordon 2006). In defined 
conditions in culture, up to 40% of the cells produce insulin and these Insulincytes 
have the ability to stabilise blood glucose levels in STZ-induced mice (section 3.1.2). 
The same group at Imperial College had already performed a phase I trial of stem 
cell administration to patients with liver insufficiency. Undifferentiated progeny of 
adherent CD34+ stem cell subset were injected into the portal vein or hepatic artery 
of five patients with liver disease. Each patient received up to 2x 109 of these cells. 
The procedure was well tolerated with no adverse events. There was no evidence of 
clinical benefit but moderate improvements in biochemical parameters were seen. 2 
patients had lower bilirubin levels, 1 patient had increased albumin level and 1 
patient had improved liver enzymes. None of the patients in the study experienced 
worsening of their liver function (Gordon 2006). 
Encouraged by the results of the in vitro and the limited in vivo Omnicyte 
experiments as well as the liver phase I trial, this study was set up to assess the 
safety and tolerability of the infusion of autologous expanded progeny of an adult 
CD34+ stem cell subset (Insulincytes) to patients with type I diabetes mellitus and a 
successful renal transplant. These cells had several advantages; they were 
haematopoietic in origin so easy to mobilize from bone marrow by G-CSF and to 
harvest peripherally by leukapheresis as explained in sections 2.6.2 and 2.6.3 
respectively. As they were adult stem cells, the ethics of embryonic stem cell therapy 
and the increased risk of malignant transformation were avoided. Finally, they were 
autologous in origin and hence escaped the need for enhanced immunosuppression. 
Patients included in the trial were diabetic patients who had received a successful 
kidney transplant and hence already on long-term immunosuppression. This had the 
additional benefit of minimising the chances of damage to the newly infused insulin-
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secreting cells by recurrence of the original destructive autoimmune process that 
resulted in developing diabetes in these patients.  
 
 
3.3.2 Objectives 
The primary end point of the study was to assess the safety and tolerability of 
expanded adult CD34+ stem cell infusion into the pancreas of a diabetic renal 
transplant recipient. 
The secondary end point was to assess the impact of this cellular therapy on the 
endocrine pancreatic function as measured by serial biochemical analysis and insulin 
requirements. 
 
3.3.3 Patient population 
The study was to include a total of maximum 10 patients who were type I diabetics 
with a functioning kidney transplant. These patients were to be under the care of 
Imperial College Kidney and Transplant Centre and were followed up at either 
St.Mary’s or Hammersmith transplant clinics. The study population was subsequently 
amended, with ethics approval, to include type II diabetic renal transplant recipients 
who were on insulin, had significant diabetic complications and were active on the 
pancreas transplant waiting list. Participation in the study did not preclude patients 
who were on the pancreas transplant waiting list from receiving a transplant and did 
not affect their position on the waiting list.  
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3.3.4 Consent and screening criteria 
Patients from the diabetic and transplant clinics who complied with the full inclusion 
criteria, as shown in table 10, were invited to enter the study and were asked to give 
their written consent.  With informed consent, these patients were then screened for 
suitability for trial enrolment. The screening process for these patients included full 
medical history and examination, a series of blood tests and a Magnetic Resonance 
Imaging (MRI) scan of the pancreas assessing volume and excluding any 
abnormality. The screening tests are summarised in table 11. The screening visit 
results were recorded in the CRF for each individual patient. 
 
 
Inclusion Criteria 
 
Exclusion Criteria 
Age16 to 65 years of age Age <16 or >65 years old. 
Type 1 or Type 2 diabetic with successful 
kidney transplant  
Chronic pancreatitis and poor exocrine 
pancreatic function 
Stable kidney graft function 
No previous rejection episodes 
No steroids as part of immunosuppression 
Follow up of > 1 year post kidney transplant 
Recent recurrent GI bleeding or 
spontaneous bacterial peritonitis  
WHO performance scores of less than 2 Pregnant or lactating women 
Life expectancy of at least 3 months HIV or life-threatening infection 
Ability to give informed consent Inability to give informed consent 
 Hypersensitivity to G-CSF 
 Patients who have been included in any 
other clinical trial within the previous month. 
 
Table 10: Inclusion and exclusion criteria for recruitment into the study 
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Screening tests 
 
  
Medical history 
 
  
Physical examination Weight, Height, WHO 
performance 
All systems – 
Cardiovascular, respiratory, 
Gastrointestinal, 
neurological, genitourinary 
as well examination of the 
eyes and skin 
Blood tests Haematology FBC, Clotting screen 
 Clinical chemistry Full renal profile, liver 
function test, amylase, LDH, 
CRP 
 Pancreatic endocrine 
function 
Fasting glucose, HbA1c, C-
peptide 
 Virology and microbiology HBV, HCV, HIV-1/2, HTLV-
1/2, HSV, CMV, EBV, 
syphilis and toxoplasmosis 
 Tissue typing 
 
ABOi 
Donor specific antibodies 
(DSA) 
Anti- ABOi titres* 
Radiology 
 
 MRI Pancreas 
 
* If the patient received an ABO - incompatible (ABOi) kidney transplant 
 
Table 11: screening tests for suitable patients who fulfilled the study inclusion criteria.  Haematology 
included full blood count (FBC) and clinical biochemistry included Lactate dehydrogenase (LDH), C-
reactive protein (CRP). Virology Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human 
immunodeficiency virus (HIV), Human T-lymphotrophic virus (HTLV), Herpes Simplex Virus (HSV), 
Cytomegalovirus (CMV) and Epstein Barr virus (EBV) 
 
 
 
 
3.3.5 Protocol summary 
Patients who had successful screening were entered into the study and underwent 
the trial protocol. This started with bone marrow progenitor cell mobilisation into the 
peripheral blood with daily subcutaneous G-CSF injection for 5 days to harvest 
CD34+ cells by leukapheresis on day 5. If the CD34+ product yield was low, the 
patient had a second leukapheresis on day 6 after another day of G-CSF as 
described in section 2.6.2 and 2.6.3 respectively. The second stage of the 
manufacture of the final stem cells product ‘Insulincyte’ entailed immunoselection 
and adherence selection of the CD34+ stem cells. This was performed under GMP 
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conditions at the Imperial College Stem Cell Laboratory and John Goldman Centre 
for cellular therapy at Hammersmith Hospital.  The final stage of product manufacture 
involved the expansion and differentiation of the immunoselected adherent CD34+ 
stem cells in cell factories with the addition of cell growth media supplemented with 
cell growth cytokines. The manufacturing method of the final cell product has been 
explained in sections 2.6.4 and 2.6.5. The process from harvest of the CD34+ cells 
until having the end stem cell product ‘Insulincyte’ ready for treatment use required 
21 days. On day 26 after the start of bone marrow mobilisation, autologous 
expanded progeny of an adult CD34+ stem cell subset were infused into the 
pancreas of the patient via selective catheterisation of the splenic artery under 
fluorescent guidance by an experienced radiologist as described in section 2.6.6. In 
order to avoid thromboembolic complications, the patient received subcutaneous 
injections of low molecular weight heparin (pre-filled syringes of 20mg Enoxaparin 
sodium, Clexane®, Sanofi) for a total of 5 days post stem cell infusion. The patient 
was followed up for total of 90 days from the start of the protocol. A schematic 
summary of the protocol is shown in figure 30. 
 
 
 
 
 
 
Figure 30: The timeline summary of the study protocol 
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During the process of bone marrow mobilisation, the patient was monitored on 
regular basis by hospital visits on days 0,1,3 and 4. During these visits, data were 
collected on symptoms, adverse events and toxicity. The outcome of all visits was 
documented in individual CRF of each trial patient. Additionally, during the first 4 
weeks of the study, and in keeping with the trial protocol, the patient was admitted 
twice. The first inpatient stay was on day 4 to allow for leukapheresis and CD34+ cell 
isolation on day 5 which maybe repeated on day 6. The second inpatient stay was on 
day 25 to allow for stem cell product infusion on day 26. In both occasions, the 
patient did not stay longer than 2 nights unless an adverse event or a complication 
had developed. 
 
 
3.3.6 Assessment of adverse events and endocrine pancreatic function  
After the stem cell infusion and during the study follow up period, patients attended 
the hospital for assessment at 6, 8 and 12 weeks after the start of bone marrow 
mobilisation and G-CSF administration (day 0). During these visits, data were 
collected on symptoms, adverse events and toxicity. The patient underwent physical 
examination which included weight and performance score. In addition, blood tests 
were also taken which included full blood count (FBC), clinical chemistry (full renal 
profile, liver function test, amylase, CRP), pancreatic endocrine function screen 
(random blood glucose, glycosylated haemoglobin (Hba1c) and C-peptide). DSA 
samples were collected at screening, prior to the stem cell infusion and week 12 at 
the end of the study. Similar to DSA, anti-ABO titres were also collected at the same 
time points in ABO incompatible renal transplant recipients. Table 12 summarises the 
protocol of the trial including the screening and follow up examination and tests 
performed at each visit. 
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 Baseline 
screen 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
26 
Day 
27 
Day 
28 
Wk 
6 
Wk 
8 
Wk 
12 
History 
and 
physical 
exam 
X X    X  X   X X X 
Weight X       X     X 
WHO 
performa
nce score 
X X      X   X X X 
Clinical 
chemistry 
X X  X  X X X X X X X X 
Haematol
ogy 
X X  X  X X X X X X X X 
Clotting 
screen 
X     X X X X X X X X 
Fasting or 
random 
glucose 
X X  X  X X X X X X X X 
Glycosyla
ted Hb 
X X    X  X   X X X 
Amylase X X  X  X X X X X X X X 
Insulin 
dose 
X X X X X X X X X X X X X 
Virology 
screen 
X             
G-CSF  X X X X X X       
Leukaphe
resis 
     X X       
Stem cell 
infusion 
        X     
MRI 
pancreas 
X             
Adverse 
event 
X X X X X X X X X X X X X 
 
Table 12: Summary of all the screening and follow up examination and tests performed according to the 
protocol throughout the study for each patient 
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3.3.7 Potential benefits and risks 
It was clearly explained to the patients that the primary aim of the study was to 
assess safety and tolerability of this cellular treatment and that the secondary aim 
was to assess for efficacy. Potential benefits of this treatment could include reducing 
the incidence of hypoglycaemic episodes, reducing the mean daily insulin 
requirements and improving diabetic control as would be illustrated with better 
Hba1c.  
Several potential risks were also explained to the patient. Firstly, published data has 
revealed that G-CSF-based PBSC mobilisation is generally safe, well tolerated and 
almost all donors complete the mobilisation and collection procedures. However, 
retrospective and prospective studies have identified transient, but not insignificant, 
morbidities experienced by G-CSF mobilised donors. In a retrospective analysis of 
41300 donors registered with the International Bone Marrow Transplant Registry 
(IBMTR) or European Blood and Marrow Transplant Group (EBMT), the rate of 
serious complications from G-CSF mobilization and PBSC collection was 1.1%. 
Many of these complications were associated with central venous catheters, which 
were inserted in 20% of donors (Cashen 2007). The most common symptoms were 
bone pain, headache, fatigue, and nausea. More serious side effects, although very 
rare, nonetheless can occur included transient splenomegaly, very rarely splenic 
rupture and potential toxicity related to procoagulant effects of G-CSF in high-risk 
individuals. In patients with underlying autoimmune disease, such as rheumatoid 
arthritis, systemic lupus erythromatosis (SLE) and multiple sclerosis, the use of G-
CSF to mobilise cells before planned autologous stem cell transplantation, has been 
associated with flares of the disease in these patients (Cashen 2007). In view of this 
last potential side effect and having kidney transplant recipients as trial participants, 
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one of the concerns in this study was possible graft dysfunction related to an 
alloimmune response triggered by G-CSF. However, there is sufficient evidence in 
the literature in solid organ transplant including kidney transplantation that this risk is 
minimal and the use of G-CSF in this population group was safe (Hurst 2011).  
Secondly, the potential small risk of possible malignant transformation of the stem 
cells. However, the stem cell product ‘insulincytes’ are adult differentiated stem cells 
and so have finite ability to proliferate making this transformation risk minimal. Lastly, 
the patients were informed of several possible serious but unlikely complications 
associated with the stem cell infusion procedure. These were arterial or venous 
complication including thrombosis during catheterisation or after cell infusion into the 
pancreas and the risk of pancreatitis. Low molecular weight heparin was 
administered for 5 days post infusion to reduce this thromboembolic risk. Infections 
might be introduced but were unlikely and if any infections did occur, appropriate 
antibiotic administration would be a very effective treatment. 
 
 
3.3.8 Patient Demographics 
Patients that met the inclusion criteria and had no exclusion criteria were 
approached. A total of 7 patients were consented and screened and all were 
successfully enrolled in the trial. Table 13 shows patient demographics. MRI of the 
pancreas in all of these patients revealed a similar result of an atrophic small native 
pancreas with no significant abnormality.  
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Gender Male 
Female 
5 
2 
Mean age at start of study 
(years) 
 54.6 ± 4.2 
Ethnicity Caucasian 
Indoasian 
6 
1 
DM Type I 
Type II 
5 
2 
Mean body mass index 
(BMI) at the start of study  
 29.6 ± 5.8  
Mean insulin requirement 
pre-treatment (iu/day) 
 61.7 ± 26.4  
Type of kidney transplant Live donor ABOc 
Live donor ABOi 
Deceased donor 
2 
2 
3 
Mean Creatinine (μmol/L) 
 
 127.4 ± 12.9 
 
Table 13: Demographics of the 7 patients enrolled in the study. ABO compatible (ABOc) and ABO 
incompatible (ABOi) 
 
 
 
 
3.3.9 Stem cell infusion 
Only 5 out of 7 patient had the stem cell product infusion. The bone marrow of 
patient study numbers 3 and 6 did not mobilise enough in response to G-CSF 
resulting in insufficient CD34+ cells to complete cell selection and expansion. These 
two patients had low CD34+ cell harvest yield of less than 0.01% of total cell number 
and hence did not complete the study. Table 14 shows the number of expanded 
progeny of adult CD34+ stem cell subset infused into patients who had successful 
bone marrow mobilisation with acceptable CD34+ cell yield.   
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Patient study 
number 
Peak total White 
cell count post 
G-CSF x10
3 
(WBC/μL) 
Day of peak 
WBC post G-
CSF 
Number of 
leukapheresis 
Expanded cell 
number 
received x10
6
 
1 35.7 3 2 153.8 
2 54.3 5 1 87.2 
3 34.1 5 1 Study 
discontinued 
4 32.3 4 1 70.0 
5 54.1 5 1 96.7 
6 37.3 3 2 Study 
discontinued 
7 49.3 5 2 84.6 
 
Table 14: The peak total white cell count after bone marrow mobilisation with G-CSF, the number of 
leukapheresis required for CD34+ harvest and the total number of expanded cells infused into the 
patients 
 
 
 
3.3.10 Outcome of the phase I study 
The primary end point of the study was achieved. Treatment protocol was tolerated 
well without any complications or major side effects related to the treatment. There 
were no adverse events in the short or medium- term follow up for all the patients 
until the end of the study. The only reported side effects were those of bone pain, 
fatigue, and nausea related to G-CSF administration which are common and very 
well recognized symptoms associated with G-CSF in the literature. One patient had a 
small haematoma at the site of the femoral vein catheter insertion as access for 
leukapheresis. This was managed conservatively with analgesia alone and resolved 
rapidly on follow up. 
PBSC mobilisation with G-CSF and the application of this cellular therapy were both 
safe and did not result in graft dysfunction or in any rejection episodes. Donor 
specific antibodies remained negative pre and post treatment. There was no change 
in anti- ABO titres pre and post procedure in 2 recipients who had received an ABOi 
kidney transplant. 
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In addition, there were no complications or adverse events associated with the stem 
cell infusion during or after the procedure. There was no intra-arterial or venous 
thrombosis and no episodes of pancreatitis. Table 15 demonstrates mean creatinine 
and mean amylase pre and post stem cell infusion (p≥0.05). In Imperial college 
Healthcare NHS trust biochemistry laboratory, the reference range for serum 
creatinine is 55-110 μmol/L and for serum amylase is 0-90 IU/L. 
 
 
Patient 
study 
number 
Mean creatinine 
(μmol/L) 
pre infusion 
Mean amylase 
(units/L) 
pre infusion 
Mean creatinine 
(μmol/L) 
post infusion 
Mean amylase 
(units/L) 
post infusion 
1 112.7 33.6 109.7 40.0 
2 122.8 106.3 124.0 140.2 
3 116.1 46.0 n/a* n/a* 
4 149.1 50.5 143.0 70.6 
5 125.6 44.0 115.2 56.5 
6 144.5 69.0 n/a* n/a* 
7 130.8 60.5 101.3 70.3 
* Study discontinued in patient 3 and patient 6 
 
Table 15: Mean creatinine in μmol/L and mean amylase units/L for the study patients before and after 
receiving expanded progeny of CD34+ stem cell infusion 
 
 
There were no convincing data to demonstrate the efficacy of this cellular therapy on 
diabetes in these patients and so the secondary end point was not achieved. In 4 out 
of 5 patients that completed the study, there was no significant change in their daily 
mean insulin requirement following the stem cell infusion and until the end of the 
study (p≥0.05). Hba1c and C-peptide were not significantly altered pre and post 
treatment (p≥0.05). These results are shown in table 16. In one type 2 diabetic 
patient, there was significant reduction in the mean daily insulin requirement post 
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stem cell treatment with sustained good glycaemic control as shown in table 16 
(p<0.05). There was a transient fall in this patient’s Hba1c which started prior to the 
stem cell infusion as shown in figure 31. It is worth noting that this patient had 2 kg 
weight loss during the 12-week study period. Since this patient is a type II diabetic 
with normal C-peptide, it can be speculated that the decrease in insulin dose may be 
related to the combination of the small weight loss along with the improved healthier 
lifestyle, which was reported by the patient throughout the trial. After the end of the 
study, routine blood tests performed in transplant clinic as part of the patient’s usual 
follow up visit assessment showed that this affect was not sustained. The patient 
gradually increased the insulin dose over the following weeks after the study due to 
suboptimal glycaemic control with increasing Hba1c. These results were not 
observed with the second type II diabetic included in the study. 
 
 
Patient 
study 
number 
Hba1c (%) 
pre 
infusion 
C-peptide 
(pmol/L) 
pre 
infusion 
Mean 
insulin 
dose 
(iu/day) 
pre 
infusion 
Hba1c 
post 
infusion 
C-peptide 
post 
infusion 
Mean 
insulin 
dose 
(iu/day) 
post 
infusion 
1 8.3 <33 31.5 ± 4.5 7.7 <33 32.2 ± 4.3 
2 5.4 2041 98.5 ± 7.5 5.6 2043 70.0 ± 7.6** 
3 7.7 <33 52.0 ± 3.7 n/a* n/a* n/a* 
4 8.5 186.5 71.5 ± 4.3 8.8 201 73.5 ± 3.5 
5 7.9 <33 30.5 ± 2.5 8.0 <33 32.1± 1.7 
6 10.0 <33 48 ± 5.2 n/a* n/a* n/a* 
7 5.9 491.5 65.0 ± 2.6 6.1 127.3 62.5 ± 3.7 
* Study discontinued in patient 3 and patient 6. ** p<0.05 for t-test insulin dose pre and post-infusion. 
 
Table 16:  Glycaemic control and insulin requirements for the study patients before and after receiving 
expanded progeny of CD34+ stem cell infusion 
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Figure 31: Glycaemic control in type II diabetic renal transplant recipient (patient 2) before and after 
receiving expanded progeny of CD34+ stem cell infusion  
 
 
 
 
3.3.11 Conclusion 
The findings of this phase I trial confirm that bone marrow mobilisation with G-CSF to 
manufacture an autologous haematopoietic adult stem cell product which can be 
delivered via intravenous catherisation and infusion into the pancreas of diabetic 
renal transplant recipient is a safe and well-tolerated process. It can be used as a 
method for delivering a potential cellular therapy. However, the trial was not 
successful in demonstrating efficacy of this stem cell product in improving diabetic 
control by reducing insulin requirements in the study patients. This maybe explained 
by several potential reasons affecting the various stages of the process. These 
include the number and variability of the cell source and in turn the quality of the end 
stem cell product, the method of delivery of this product resulting in possible early 
loss of the cells after infusion and finally probable inappropriate niche in the pancreas 
for cell engraftment, regeneration and repair. 
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In this trial, 2 patients were unable to complete the study due to low CD34+ cell yield 
despite 6 days of bone marrow mobilisation with G-CSF. As shown in table 15, this 
did not correlate with the peak white cell count reached in these patients which was 
not dissimilar to other patients that achieved an acceptable CD34+ cell yield. In the 
haematology literature, although many factors including the patient’s age, diagnosis 
and amount of prior therapy have been shown to predict the likelihood of collecting a 
sufficient number of autologous repopulating cells, factors affecting the capacity of 
normal donors to mobilise CD34+ cells following G-CSF are less well established. 
Reports have indicated in some cases wide inter-individual variation among normal 
subjects given G-CSF for PBSC mobilisation. In an IBMTR analysis, 60% of donors 
required more than one leukapheresis procedure to collect the target number of 
CD34+ cells, and 15% required three or more.  It has been shown that donor age, 
steady-state CD34 level, and both the total dose and schedule of G-CSF may impact 
CD34+ cell mobilisation in normal donors (Cashen 2007).  
The study patients did not have haematological disorders but were recipients of a 
kidney transplant and on long-term immunosuppression which may have affected 
their bone marrow and hence their response to G-CSF. So the lower yield of CD34+ 
cells in a couple of the patients can be explained by a similar observation of variable 
response to G-CSF in normal donors but this effect may have been exacerbated by 
maintenance immunosuppression. There is no published data that specifically 
addresses this hypothesis specifically with CD34+ stem cells but a recent study by 
Reinders et al examined bone marrow-derived MSC from patients with end-stage 
renal disease (ESRD) and found them to be phenotypically and functionally similar to 
healthy controls. They concluded that these cells would be suitable for autologous 
clinical applications in renal transplant recipients (Reinders 2013). However, MSCs 
are different from haematopoietic stem cells as described earlier in 1.9.2. They are 
CD34- and are usually isolated from bone marrow aspirate without mobilisation and 
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then expanded in culture (Reinders 2013). Nonetheless, the study does demonstrate 
that one type of bone marrow-derived stem cells of patients with ESRD is similar to 
the general population and this makes it more likely to extend to the other types of 
stem cells within the bone marrow. 
In their published paper, Gordon et al stated that 1-2 weeks of expansion and culture 
of CD34+ Omnicytes would provide 5-10 ×109 progeny cells for clinical applications 
(Gordon, 2006). Interestingly, 2x 109 (3 x 107cells/kg body weight) undifferentiated 
progeny of adherent CD34+ stem cell subset constituted the cellular therapy in phase 
I trial in five patients with liver disease led by the same group (Gordon, 2006). 
However, these undifferentiated cells were not used in this study. The cells remained 
in culture for 21 days in total to allow differentiation into Insulincytes prior to infusion. 
It is known that expansion of these cells in culture peaks between 7-10 days and that 
they have a finite ability to proliferate (personal communication with Gordon et al). 
Hence leaving cells in culture for longer period of time to allow differentiation is likely 
to result in a smaller number of cells at the end of the process. In this study, this 
prolonged period resulted in a mean of only 9.8 × 107 cells (1.2 x 106cells/kg body 
weight) available for infusion on day 26 of the study. In the largest published HSC 
trial to treat diabetes, the study design was very different to the protocol of this study 
but they used approximately 3x106cells/kg body weight as cellular therapy (Couri 
2009a; Voltarelli 2007). This is similar to the cell number used in our study but 
significantly less than the number of HSC used in the liver study by Gordon et al. 
The study design for this trial probably assumed that the effect of these cells is likely 
to be direct by cell engraftment into the damaged pancreas, secreting insulin and 
acting like an islet transplant. If this hypothesis were true, then it would be difficult to 
estimate the total number of Insulincytes required to confer the desired therapeutic 
effect in these diabetic patients. We know from the islet transplant literature that 
insulin independence might be achieved with approximately 8-10,000 islet 
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equivalents (IE)/kg body weight which is what is currently required in islet 
transplantation. A mass that usually demands two or more deceased donors 
(Kaufman, 2002). In addition, historical data in the Islet Transplant Registry (ITR) and 
published reports indicate that a minimum of 6,000 IE/kg need to be transplanted to 
increase the likelihood of a functional islet graft. However, there does not appear to 
be any conclusive data correlating the number of transplanted islet equivalents with 
those that actually engraft post-transplant 
(www.fda.gove/ohrms/dockets/ac/00/backgrd/3604b1b.doc). Stem cells used in 
cellular therapy for diabetes do not necessary form islet-like morphology and are in 
many cases transplanted prior to differentiation so it would be very difficult to 
estimate the number of stem cells required to give the same effect as 6,000 IE/Kg in 
islet transplantation. 
The quality of the stem cell end product as well as the quantity is an important factor 
that impacts on the outcome. We know from in vitro studies that Omnicytes are not 
homogenous despite universal expression of CD34 and adherence to plastic in 
culture. Although cell expansion was highly reliable and reproducible in in vitro 
experiments, only up to 40% of these cells differentiated into Insulincytes (Gordon, 
2006). This variable ability of these cells to differentiate into insulin-secreting cells in 
culture would in turn result in a variable end product after 21 days in the study. In 
vivo, only one experiment showed efficacy of day 7 Omnicytes in stabilising glucose 
levels in an animal diabetic model (section 3.1.3). 
In the trial, the composition of the expanded progeny of CD34+ stem cell product that 
was infused into the patient was not formally examined. On each occasion, the end 
product was sampled for total nucleated cell count and viability, sterility and freedom 
from mycoplasma contamination as quality control testing but not formally tested to 
confirm the proportion of Insulincytes in each batch. This would have been very 
informative and could have enabled a more accurate calculation of the true number 
of insulin-secreting cells infused per kg body weight into each patient. Assuming best 
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yield of 40% differentiation into insulin-secreting cells, this equates to a maximum 
mean of 4.8x 105 cells/kg body weight of Insulincytes administered to each patient in 
the study. This cell number is 10 times less than the average number of stem cells 
used as therapy in the stem cell literature. Hence, it can be proposed that actual 
number of Insulincytes infused and delivered to the pancreas in the study patients 
could have been insufficient to show any significant therapeutic effect and that the 
cell number required for such as effect is much larger. Delivering a larger number of 
autologous Insulincytes can test this proposal. This is however as described limited 
by several factors including the original number of CD34+ isolated, the differentiation 
capacity of the parent cell and the cultures and growth factors used in the expansion 
and differentiation process to obtain optimal results.  
The third potential hurdle that may have resulted in the lack of efficacy of the stem 
cell product in this phase I study could be due to early cell loss as a result of 
thrombosis as described in the islet allo and xeno-transplant literature (sections 
1.11.6 and 1.11.7). This potential problem is part of my overall study hypothesis and 
was partly assessed in vitro (section 3.2.5) and in vivo (section 3.2.8) during the 
study. I demonstrated in these experiments the procoagulant property of day-7 
CD34+ Omnicytes that are parent cells to the exact cells infused in the trial. 
However, if this property can be extrapolated to the progeny of Omnicytes, then 
Insulincytes can be assumed to be prothrombotic triggering coagulation and leading 
to cell destruction after delivery into the pancreas. Systemic prophylactic coagulation 
with LMWH was administered after the stem cell infusion but the timing of this may 
be too late to prevent the immediate cell loss from taking place. More experiments 
are needed to confirm that Insulincytes are prothrombotic in vitro and in vivo by 
demonstrating evidence of coagulation and examining the underlying mechanism for 
it in order to establish a better preventative strategy. 
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Finally, the niche where the Insulincytes were delivered i.e. pancreas may have been 
an unsuitable environment lacking the appropriate conditions and signals needed for 
cell engraftment, differentiation and repair. As described in section 1.9.2, many 
studies demonstrated that bone marrow derived stem cells are able to stimulate 
beta-cell regeneration in damaged pancreatic tissue by a variety of mechanisms 
(Ianus 2003). Choi et al showed that BMSC did not differentiate into pancreatic beta 
cells but they still have the potential for being host cells in beta-cell replacement 
therapy (Choi 2003) and Hess et al concluded from their studies that hyperglycaemia 
reduction in treated animals was attributable to a rapid rise in endogenous insulin 
stimulated by BMSC transplantation rather than differentiation of the BMSC into beta 
cells (Hess 2003). This is also consistent with the findings when PDPCs used as 
cellular therapy in the STZ-induced diabetic mice (Stevenson 2011). 
It is worth highlighting that in all of the animal studies, the injury to the pancreatic 
tissue was acute and probably reflected early changes in the diabetic disease model. 
If Insulincytes, which are haematopoietic in origin, have a similar effect to other 
BMSC reported in the literature then it can be proposed that they are likely to 
stimulate beta-cell repair and regeneration by another host cell via an indirect 
paracrine fashion rather than directly as assumed in the study design. This means 
that the damaged pancreas needs to have viable tissue including probably residual 
islets but more importantly other host cells in order to have the capacity for 
regeneration and repair.  Patients selected for this study were mainly type I diabetics 
who have had a long-standing diabetes and in turn extremely likely to have lost all 
their beta-cell mass in their early years of disease progression. All study patients, 
apart from one type II diabetic, had low or undetectable levels of C-peptide indicating 
lack of insulin production and therefore complete or almost complete destruction of 
beta cell mass. In addition, all MRI scans of the pancreas performed as part of the 
screening process for each study patient demonstrated atrophic pancreas, which is 
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again consistent with mostly scarred rather than viable pancreatic tissue. This 
reasoning probably explains the study design and timing of cellular therapy in the 
Brazilian stem cell study. The study had a 3-stage protocol aimed at the use of an 
immunomodulatory and regenerative strategy during the initial phase of the disease 
when the patient still has an important beta-cell reserve in an attempt to preserve 
and protect it (Couri 2009a; Voltarelli 2007). Patients that were enrolled in the study 
were within 6-week period of their diabetic disease presentation which is in contrast 
to the study patients in this trial. 
In summary, there are several possible explanations for the lack of efficacy of the 
cellular therapy in this phase I trial. Further experimental work is necessary to try and 
solve the main challenge to the success of the process. 
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4. DISCUSSION AND FUTURE WORK 
 
As highlighted in the introduction, type I diabetes mellitus is a metabolic disorder 
characterised by hyperglycaemia due to insulin deficiency. It is common and the 
incidence of TIDM has been increasing by about 3% per year (Aanstoot 2007). It is 
caused by autoimmune destruction of the insulin-producing beta cells in the 
pancreas. Despite insulin treatment, diabetes often results in metabolic defects 
leading to the development and progression of micro and macrovascular 
complications. Macrovascular disease leads to an increased prevalence of 
cardiovascular disease, while microvascular damage results in diabetic retinopathy, 
nephropathy and neuropathy. These late complications are associated with a high 
burden of morbidity and high rate of mortality. It has been shown that these diabetic 
complications are less common and less severe in patients with well-controlled blood 
glucose levels (Nathan 2005).  
Restoring euglycaemia by replacement of the destroyed insulin-producing tissue 
would be the gold standard treatment for these patients. As discussed in chapter 1, 
this can be achieved with pancreas transplantation but this is greatly limited by the 
shortage of deceased organ donors and by the high risk associated with this surgical 
procedure. Therefore this curative option is not available to all patients. Islets 
transplantation is a more recent treatment option performed by a relatively non-
invasive technique with a lower risk of immediate complications. Although it is a more 
attractive option, it is restricted by a variable success rates and by the limited number 
of organ donors particularly as 2-3 pancreata are required per recipient to achieve 
insulin independence. More importantly, a substantial percentage of islets are lost 
immediately post infusion into the portal vein through an inflammatory process 
termed the instant blood-mediated inflammatory reaction. It is well established that 
TF play a vital role in this process resulting in thrombosis and destruction of a 
significant proportion of the islet transplants. Xenotransplantation faces a similar 
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challenge to islet allotransplantation in addition to the specific immunological barrier 
associated with preformed xenoreactive natural antibodies. Both these processes 
contribute to the loss of the xenograft. There are also several technical and logistical 
obstacles for xenotransplantation. 
A promising and emerging treatment option for type I diabetes would be the use of 
stem cells as ‘islet equivalents’. Stem cells of various origins have been shown to 
have the ability to proliferate extensively and are able to differentiate into insulin-
secreting cells that can either function directly or act indirectly leading to islet repair 
and regeneration of new beta cells. Most of the evidence points to an indirect 
paracrine effect on existing beta cells rather than the direct differentiating of these 
stem cells into adequate numbers of insulin-secreting cells that can result in 
euglycaemia (section 1.9). This cellular therapy would mean unlimited source of cells 
that can be transplanted in a non-invasive method with low risk of complications. 
However, what is not known from the literature is whether stem cells result in 
triggering coagulation after intravenous infusion in a similar fashion to islet 
transplants resulting in stem cell thrombosis and destruction. 
This work has examined the efficacy of two sources of stem cells in restoring 
euglycaemia in an STZ-induced diabetic animal model. I demonstrated the success 
of specific population of pancreas derived progenitor cells in reversing this diabetic 
phenotype. The Shiel’s group in Glasgow performed subsequent analysis on the 
tissue harvested from the diabetic animals treated with this cellular therapy. They 
found evidence supporting the proposal that in this animal model, these PDPCs 
correct hyperglycaemia indirectly by triggering repair of existing islets and 
regeneration of new islets from the recipient’s own tissue rather than directly 
differentiating into sufficient number of insulin-secreting cells themselves (Stevenson 
2011). 
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More recently, the Shiel’s group in Glasgow has published a study that demonstrated 
that the presence of the same population of PDPCs from adult rat led to functional 
repair of renal damage in ischaemia reperfusion (I/R) injury model in mice. PDPC-
treated animals had superior renal function at day 14 after I/R injury, in comparison 
to saline-treated controls. Similar to the study in diabetic mice, FISH analysis 
demonstrated that the majority of repaired kidney tissue was mouse not rat in origin. 
Rat PDPCs were only detected at a frequency of 0.02%. The group concluded that 
PDPCs appear to again act indirectly in a paracrine way, stimulating host repair and 
regeneration rather than differentiating into renal tissue directly (McGlynn 2013). It is 
not published whether these researchers replicated the same results with human 
PDPCs. It would be exciting if this application could be extended to a different model 
of kidney injury or injury model of a different organ. Successful outcome would 
advocate the use of PDPCs as a cellular therapy to repair and regenerate damaged 
tissue irrespective of the tissue type. So far, this has been proven in vivo for the 
pancreas and the kidney. My and these experimental results would encourage 
testing these cells as therapy for diabetes and acute kidney injury in a phase I clinical 
trial respectively. 
In this work, I also demonstrated the lack of efficacy of day-7 human adherent 
CD34+ Omnicytes in reversing diabetes in the same mouse model. On one occasion, 
this cellular therapy resulted in stabilisation of blood glucose but this effect was not 
reproducible. Several explanations have been proposed to explain these findings 
including the possibility of early cell loss through thrombosis as observed after islet 
transplantation. 
As emphasized in the introduction, TF is thought to play a major role in initiating the 
IBMIR leading to significant early cell loss to thrombosis following allo and xeno islet 
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transplantation. I believe this work is the first to test the hypothesis of early cell 
destruction by a similar thrombotic process after cellular infusion of 2 different 
populations of stem cells: PDPCs and CD34+ Omnicytes. It examined the 
procoagulant properties of both stem cell types and attempted to establish whether 
these stem cells express tissue factor as a trigger for provoking coagulation by 
immunocytochemistry and functional plasma recalcification assays. 
The study demonstrated that both stem cell types are prothrombotic in vitro and that 
this effect can be mitigated by pre-treatment of these cells with the anti-thrombin 
cytotopic agent ‘PTL006’. One of the advantages of this agent is its local 
anticoagulant effect, shown by the limited rise in clotting time to equal or lower than 
the baseline contact activation clotting time when the cells were pre-conditioned with 
PTL006. This is compared to soluble hirulog that resulted in clotting time significantly 
exceeding the baseline clotting time. This would probably translate to local versus 
undesirable systemic effect in an in vivo setting and should be explored in future 
work. 
The in vivo work performed using Omnicytes is very suggestive that the infusion of 
this cellular treatment is a trigger for coagulation leading to probable fibrin clot 
formation and resulting in a thrombocytopenia as platelets are sequestered in the 
clot. The results also suggest that this effect is preventable by the presence of 
PTL006 tethered to the surface of the cells infused into these animals as 
demonstrated by the preserved platelet count at the end of the experiment. The 
outcome of this work points to a possible connection between the prothrombotic 
phenotype of Omnicytes and their lack of efficacy at reversing diabetes in mice. 
However, the work is incomplete and further investigations are necessary to firstly 
replicate the findings of this in vivo experiment using Omnicytes, secondly test the 
same hypothesis using PDPCs in vivo and finally extend the evidence for coagulation 
activity with other assays such as indirect measurements of thrombin generation in 
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the plasma collected after stem cell infusion. If these findings are found to be 
reproducible then the next step should be to re-examine the efficacy of untreated 
stem cells compared to PTL006-treated stem cells in reversing diabetic phenotype in 
STZ-induced animal model. Repeating the same work using different cell number 
infused would help to establish the minimal number of cells required for the desirable 
outcome. Based on the in vitro work, it would be expected to reveal that pre-
conditioning of the cells with anti-thrombin cytotopic agent improves the performance 
of the cells and reduces the necessary cell number to achieve normoglycaemia. 
This work is however inconclusive whether the procoagulant phenotype of PDPCs 
and Omnicytes is due to TF-dependent or TF-independent process. Although the 
data from plasma recalcification assays using PDPCs suggest that the prothrombotic 
effect is possibly TF-independent, it is not possible to make this conclusion before 
further experiments are carried out. Functional assays should be performed with 
higher concentration of anti-mTF antibody to ensure saturation and in turn complete 
inhibition of TF. The procoagulant property may be suppressed in an antibody 
concentration-dependent manner, which would support the involvement of TF. This 
has not been excluded in this study. Furthermore, TF expression on these cells 
should be examined again with improved successful immunocytochemistry as well as 
other experimental methods such as flow cytometry and RT-PCR. These 
assessments will help propose a more definitive mechanism for this prothrombotic 
property. If TF was found consistently not to play a role, then a possible explanation 
in that case could be the involvement of an inducible prothrombinase that acts in a 
TF-independent pathway, termed Fgl2/fibroleukin. It has been shown to contribute to 
immunologically mediated thrombosis in experimental and human viral hepatitis and 
in acute vascular xenograft as well as allograft rejection (Ghanekar 2004; Marsden 
2003). 
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The data resulting from plasma recalcification assays applied to Omnicytes did 
confirm generalised procoagulant property of these cells but it did not confirm 
universal functional expression of TF. However, there was some evidence to suggest 
that TF-dependent trigger may be involved in thrombosis caused by these cells. 
Some of the negative outcomes raised doubt about the anti-hTF antibody efficacy 
and concentration used especially in the absence of control TF+ human cells. For the 
above findings to become conclusive and similar to PDPCs, functional assays should 
be performed using Omnicytes with higher concentration of anti-hTF antibody to 
ensure saturation and in turn sufficient inhibition of TF as well as examining TF 
expression on these cells with various experimental techniques.  
Interesting, since the end of this study, recent evidence has been published 
investigating thromboembolism following mesenchymal stem cells transplantation 
and demonstrating TF as a trigger for procoagulation (Tatsumi 2013). The paper had 
several salient findings. It showed that within 24 hours of the intravenous 
administration of mouse adipose-derived MSCs (mADSCs), animal survival rate 
increased from 15% to 100% by reducing the number of cells infused from 1.5 x 105 
to 1.5 x 104 and was similar to infusing control PBS. Histological assessment of the 
mice demonstrated no evidence of systemic intravascular hypercoagulation but did 
reveal multiple fibrin clots formed in the right ventricle and the pulmonary arteries 
with mADSCs at the core of these fibrin clots. The researchers concluded that 
administered mADSCs triggered thrombus formation around the cells and initiated 
pulmonary embolism immediately after the administration (Tatsumi 2013).  
Tatsumi et al. investigated the procoagulant property of mADSC with clotting assays, 
and rotation thromboelastometry, They found that clotting times of plasma in the 
presence of mADSCs were shortened in a cell-number dependent manner and also 
depended on the length of incubation period as a single cell suspension. The clot 
formation time of whole blood was also shortened and was dependent on the 
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incubation period. In addition, the researchers showed that CT was similar using 
normal mouse plasma and FIX deficient plasma but significantly prolonged using 
FVII-deficient plasma suggesting that TF played a critical role in mADSCs-mediated 
coagulation. This suggestion was further strengthened by the demonstration that pre-
conditioning cells with several concentrations of anti-TF monoclonal antibody 
resulted in shortening of the CT in an antibody-dependent manner. They also 
showed that TF was strongly expressed on the cell surface of mADSCs using 
immunostaining, flow cytometry and by RT-PCR. Hence, their second conclusion 
was that mADSCs have a significant procoagulant property against plasma as well 
as whole blood, that this property was enhanced during cell suspension period and 
that the resultant clot formation was mediated by TF expressed on the cellular 
surface which accelerates the extrinsic blood coagulation pathway. The paper 
revealed similar findings in human MSC including adipose-derived (hADSC), bone 
marrow-derived and periodontal ligament-derived MSCs (Tatsumi 2013).  
The same group demonstrated the use of two strategies to minimise TF-triggered 
intravascular coagulation. Firstly, pre-treatment of hADSCs with recombinant human 
thrombomodulin which resulted in the suppression of coagulation in anticoagulant 
agent concentration-dependent manner and secondly, avoiding single cell 
suspension by in vitro use of uncultured hADSC which demonstrated almost no 
coagulant activity and minimal expression of TF on the cell surface. In vivo 
transplantation of 1.5 x 105 uncultured cells did not cause animal death and did not 
show any histological thrombotic changes in any organs. The paper’s final conclusion 
stated that TF has a critical role in promoting MSC-mediated coagulation in animal 
experiments and that its expression is likely to lead to thromboembolism. The 
authors proposed that extra interventions are required to weaken this procoagulant 
effect (Tatsumi 2013). The findings by Tatsumi et al. complements this study and 
supports the hypothesis that stem cells including bone marrow-derived stem cells 
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whether haematopoietic or mesenchymal have a universal procoagulant phenotype 
which results in thrombosis probably via a TF-dependent trigger leading to cell loss. 
This property clearly becomes very important when taking stem cell therapy forward 
to clinical practice. Considerations should be given to the stem cell number 
administered and to strategies for thromboembolic events avoidance in order to 
improve safety, tolerability and efficacy of these cellular therapies. 
Additionally, this work included the completion of a phase I clinical trial demonstrating 
the safety and tolerability of the infusion of autologous expanded progeny of an adult 
CD34+ stem cell subset to patients with type I diabetes mellitus and a successful 
renal transplant. The rationale of the study led to several unique points in the design 
of the trial which allowed assessment of different aspects of safety of this cellular 
therapy compared to previous trials. The cellular product here consisted of an 
expanded and differentiated progeny of CD34+ cell population as opposed to 
mobilised undifferentiated haematopoietic stem cells that are usually isolated and 
stored to be used at a later time point in other studies. The study population 
composed of long-standing diabetic patients with a functioning renal transplant 
contrasting the newly diagnosed diabetic patients with no previous history of end 
stage renal disease or of a kidney transplant enrolled in other studies. Finally, 
patients did not receive preconditioning treatment before administering the cellular 
therapy, which is usually the case in protocols of previous studies. 
This trial demonstrated the safety and tolerability of the use of G-CSF and bone 
marrow mobilisation in renal transplant recipients without initiating an alloimmune 
response or cause any harm to the kidney graft. It also revealed the safety and 
tolerability in using differentiated progeny of haematopoietic stem cells delivered as 
cellular therapy by selective catheterisation approach. There were no clinically 
observed thromboembolic events. The administration of LMWH after infusion of the 
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cell product may have contributed to this result but it is difficult to make any 
conclusion as the study was not designed to specifically address this possible hurdle.  
Despite achieving its primary end point, there was no convincing evidence in the 
phase I study to suggest efficacy of this cellular treatment in reducing insulin 
requirements of these patients. Several possible explanations have been proposed 
including the quantity and consistency of the cells delivered, early cell loss due to 
thrombosis which was not detectable clinically, unsuitability of the niche for cell 
engraftment and the lack of viable tissue for islet repair and regeneration.  
Since the efficacy of human PDPCs has been demonstrated in vivo, this cellular 
therapy would be a good candidate and a better alternative to be assessed in 
another phase I clinical trial for safety and efficacy. Using Omnicytes again as 
potential cellular therapy would certainly need further investigations to identify the 
limiting step and to unravel the reason(s) for lack of efficacy in the diabetic animal 
model and resolving these challenges prior to clinical practice. In addition, further in 
vivo work would help to determine the number of stem cells optimal for infusion to 
achieve efficacy safely and to support the clinical application of localised anti-
coagulant treatment such as an anti-thrombin cytotopic agent to prevent thrombosis 
and avoid potential harmful thromboembolic events. A final point, the published 
evidence favours an indirect effect of stem cell therapy for repair and regeneration of 
new islets and therefore the presence of viable pancreatic cells may be crucial. This 
could be in the form of patients with new diagnosis of TIDM or patients with type II 
diabetes where complete beta cell destruction has not taken place and where 
residual insulin/C-peptide is still being secreted. These patients may be a more 
suitable study population for inclusion in future trial.  
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In summary, this work provided increased insight to the widespread procoagulant 
phenotype of two different sources of stem cells that vary in origin and 
characteristics. It also provided evidence for potential localised treatment in the form 
of a cytotopic agent to minimise this effect in vitro and in limited in vivo experiments. 
TF was found to play a pivotal role in stem cell-mediated coagulation although the 
evidence is not conclusive and further work is necessary. This prothrombotic 
property will be very important when designing clinical trials of stem cell therapy. 
Finally, I demonstrated the safety and tolerability of the infusion of autologous 
expanded progeny of an adult CD34+ stem cell in a clinical phase I trial. There were 
several limitations to this study and future work is required which can build upon my 
work presented in this thesis to take this potential therapy forward. 
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